0000899749-18-000066.txt : 20181101 0000899749-18-000066.hdr.sgml : 20181101 20181101165404 ACCESSION NUMBER: 0000899749-18-000066 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 60 CONFORMED PERIOD OF REPORT: 20180930 FILED AS OF DATE: 20181101 DATE AS OF CHANGE: 20181101 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HEALTHCARE REALTY TRUST INC CENTRAL INDEX KEY: 0000899749 STANDARD INDUSTRIAL CLASSIFICATION: REAL ESTATE INVESTMENT TRUSTS [6798] IRS NUMBER: 621507028 STATE OF INCORPORATION: MD FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-11852 FILM NUMBER: 181154546 BUSINESS ADDRESS: STREET 1: 3310 WEST END AVE STREET 2: FOURTH FL SUITE 700 CITY: NASHVILLE STATE: TN ZIP: 37203 BUSINESS PHONE: 6152698175 MAIL ADDRESS: STREET 1: 3310 WEST END AVENUE, SUITE 700 CITY: NASHVILLE STATE: TN ZIP: 37203 10-Q 1 hr-2018930xsinglesourc.htm 10-Q Document
false--12-31Q320182018-09-300000899749falseLarge Accelerated Filerfalse0.900.010.013000000003000000001251320001252370001251320001252370000.01100.010.0150000000500000000000 0000899749 2018-01-01 2018-09-30 0000899749 2018-10-26 0000899749 2018-09-30 0000899749 2017-12-31 0000899749 2017-01-01 2017-09-30 0000899749 2018-07-01 2018-09-30 0000899749 2017-07-01 2017-09-30 0000899749 hr:CumulativeDividendsMember 2018-01-01 2018-09-30 0000899749 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-09-30 0000899749 hr:CumulativeDividendsMember 2018-09-30 0000899749 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000899749 hr:CumulativeNetIncomeMember 2018-09-30 0000899749 hr:CumulativeNetIncomeMember 2017-12-31 0000899749 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-09-30 0000899749 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0000899749 hr:CumulativeDividendsMember 2017-12-31 0000899749 us-gaap:CommonStockMember 2018-01-01 2018-09-30 0000899749 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0000899749 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-09-30 0000899749 us-gaap:CommonStockMember 2017-12-31 0000899749 hr:CumulativeNetIncomeMember 2018-01-01 2018-09-30 0000899749 us-gaap:CommonStockMember 2018-09-30 0000899749 2016-12-31 0000899749 2017-09-30 0000899749 hr:ParkingIncomeMember 2018-07-01 2018-09-30 0000899749 hr:MiscellaneousMember 2018-07-01 2018-09-30 0000899749 hr:RentalLeaseGuarantyMember 2018-01-01 2018-09-30 0000899749 hr:ParkingIncomeMember 2018-01-01 2018-09-30 0000899749 hr:ParkingIncomeMember 2017-01-01 2017-09-30 0000899749 hr:ManagementFeeIncomeMember 2017-07-01 2017-09-30 0000899749 hr:RentalLeaseGuarantyMember 2018-07-01 2018-09-30 0000899749 hr:RentalLeaseGuarantyMember 2017-07-01 2017-09-30 0000899749 hr:RentalLeaseGuarantyMember 2017-01-01 2017-09-30 0000899749 hr:MiscellaneousMember 2017-07-01 2017-09-30 0000899749 hr:ManagementFeeIncomeMember 2018-01-01 2018-09-30 0000899749 hr:MiscellaneousMember 2018-01-01 2018-09-30 0000899749 hr:MiscellaneousMember 2017-01-01 2017-09-30 0000899749 hr:ManagementFeeIncomeMember 2017-01-01 2017-09-30 0000899749 hr:ManagementFeeIncomeMember 2018-07-01 2018-09-30 0000899749 hr:ParkingIncomeMember 2017-07-01 2017-09-30 0000899749 srt:ScenarioPreviouslyReportedMember 2017-01-01 2017-09-30 0000899749 srt:ScenarioPreviouslyReportedMember 2017-07-01 2017-09-30 0000899749 2018-01-01 2018-03-31 0000899749 hr:RealEstateDispositionsMember naics:ZZ812930 2018-06-29 2018-06-29 0000899749 2018-04-26 2018-04-26 0000899749 hr:RealEstateAcquisitionsMember stpr:CO 2018-05-18 2018-05-18 0000899749 hr:RealEstateAcquisitionsMember 2018-01-01 2018-09-30 0000899749 hr:RealEstateAcquisitionsMember hr:LandHeldForDevelopmentMember 2018-06-29 0000899749 2018-06-27 2018-06-27 0000899749 hr:RealEstateDispositionsMember stpr:MI 2018-06-27 2018-06-27 0000899749 hr:RealEstateAcquisitionsMember hr:MedicalOfficeBuildingMember 2018-06-29 0000899749 hr:RealEstateDispositionsMember naics:ZZ812930 2018-06-29 0000899749 hr:RealEstateDispositionsMember stpr:MI 2018-06-27 0000899749 us-gaap:SegmentDiscontinuedOperationsMember 2018-09-30 0000899749 us-gaap:SegmentDiscontinuedOperationsMember 2017-12-31 0000899749 hr:RealEstateAcquisitionsMember stpr:WA 2018-05-03 2018-05-03 0000899749 hr:RealEstateAcquisitionsMember stpr:CO 2018-08-24 2018-08-24 0000899749 hr:RealEstateAcquisitionsMember stpr:CO 2018-05-18 0000899749 hr:RealEstateAcquisitionsMember stpr:WA 2018-06-29 0000899749 hr:RealEstateAcquisitionsMember stpr:OK 2018-05-21 2018-05-21 0000899749 hr:RealEstateAcquisitionsMember stpr:WA 2018-06-29 2018-06-29 0000899749 hr:RealEstateAcquisitionsMember 2018-09-30 0000899749 hr:RealEstateAcquisitionsMember stpr:WA 2018-05-03 0000899749 hr:RealEstateAcquisitionsMember stpr:OK 2018-05-21 0000899749 hr:RealEstateAcquisitionsMember stpr:CO 2018-08-24 0000899749 hr:RealEstateDispositionsMember stpr:VA 2018-04-26 0000899749 hr:RealEstateDispositionsMember stpr:MO 2018-08-30 2018-08-30 0000899749 hr:RealEstateDispositionsMember stpr:MO 2018-08-30 0000899749 hr:RealEstateDispositionsMember stpr:VA 2018-04-26 2018-04-26 0000899749 hr:RealEstateDispositionsMember 2018-09-30 0000899749 hr:RealEstateDispositionsMember 2018-01-01 2018-09-30 0000899749 hr:SeniorNotesdue2023Member us-gaap:SeniorNotesMember 2018-09-30 0000899749 hr:TermLoandue2022Member us-gaap:MediumTermNotesMember 2018-09-30 0000899749 hr:MortgageNotesPayableNetMember us-gaap:MortgagesMember 2017-12-31 0000899749 hr:SeniorNotesdue2025Member us-gaap:SeniorNotesMember 2018-09-30 0000899749 hr:SeniorNotesdue2028Member us-gaap:SeniorNotesMember 2018-09-30 0000899749 hr:TermLoandue2022Member us-gaap:MediumTermNotesMember 2017-12-31 0000899749 hr:MortgageNotesPayableNetMember us-gaap:MortgagesMember 2018-09-30 0000899749 hr:SeniorNotesdue2025Member us-gaap:SeniorNotesMember 2017-12-31 0000899749 hr:UnsecuredCreditFacilityDue2020Member us-gaap:LineOfCreditMember 2017-12-31 0000899749 hr:UnsecuredCreditFacilityDue2020Member us-gaap:LineOfCreditMember 2018-09-30 0000899749 hr:SeniorNotesdue2023Member us-gaap:SeniorNotesMember 2017-12-31 0000899749 hr:SeniorNotesdue2028Member us-gaap:SeniorNotesMember 2017-12-31 0000899749 hr:SeniorNotesdue2025Member us-gaap:InterestRateSwapMember us-gaap:SeniorNotesMember 2018-01-01 2018-09-30 0000899749 hr:TermLoandue2022Member us-gaap:InterestRateSwapMember us-gaap:MediumTermNotesMember 2018-09-30 0000899749 hr:TermLoandue2022Member us-gaap:MediumTermNotesMember 2018-01-01 2018-09-30 0000899749 us-gaap:OtherAssetsMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-09-30 0000899749 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-09-30 0000899749 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-09-30 0000899749 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2018-01-01 2018-09-30 0000899749 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-01-01 2018-09-30 0000899749 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2017-01-01 2017-09-30 0000899749 us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2017-01-01 2017-09-30 0000899749 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2018-01-01 2018-09-30 0000899749 us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-01-01 2018-09-30 0000899749 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-01-01 2018-09-30 0000899749 us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2018-01-01 2018-09-30 0000899749 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2017-01-01 2017-09-30 0000899749 hr:SettledInterestRateSwapMember 2018-09-30 0000899749 hr:ActiveInterestRateSwapsMember 2018-09-30 0000899749 hr:MedicalOfficeBuildingExpansionMember stpr:NC 2018-09-30 0000899749 hr:MedicalOfficeBuildingMember stpr:CO 2018-09-30 0000899749 hr:MedicalOfficeBuildingMember stpr:NC 2018-09-30 0000899749 us-gaap:EmployeeStockMember 2017-07-01 2017-09-30 0000899749 us-gaap:EmployeeStockMember 2018-01-01 2018-09-30 0000899749 us-gaap:EmployeeStockMember 2018-07-01 2018-09-30 0000899749 us-gaap:EmployeeStockMember 2016-12-31 0000899749 us-gaap:EmployeeStockMember 2017-01-01 2017-09-30 0000899749 us-gaap:EmployeeStockMember 2018-09-30 0000899749 us-gaap:EmployeeStockMember 2018-06-30 0000899749 us-gaap:EmployeeStockMember 2017-09-30 0000899749 us-gaap:EmployeeStockMember 2017-12-31 0000899749 us-gaap:EmployeeStockMember 2017-06-30 0000899749 hr:StockIncentivePlanMember 2018-09-30 0000899749 hr:StockIncentivePlanMember 2018-01-01 2018-09-30 0000899749 hr:StockIncentivePlanMember 2017-01-01 2017-09-30 0000899749 hr:StockIncentivePlanMember 2017-07-01 2017-09-30 0000899749 hr:StockIncentivePlanMember 2017-12-31 0000899749 hr:StockIncentivePlanMember 2017-09-30 0000899749 hr:StockIncentivePlanMember 2018-06-30 0000899749 hr:StockIncentivePlanMember 2018-07-01 2018-09-30 0000899749 hr:StockIncentivePlanMember 2016-12-31 0000899749 hr:StockIncentivePlanMember 2017-06-30 0000899749 us-gaap:RestrictedStockMember hr:StockIncentivePlanMember 2017-01-01 2017-09-30 0000899749 hr:AtTheMarketEquityOfferingProgramMember us-gaap:SubsequentEventMember 2018-10-26 0000899749 us-gaap:RestrictedStockMember hr:StockIncentivePlanMember 2018-01-01 2018-09-30 0000899749 us-gaap:SubsequentEventMember 2018-10-30 2018-10-30 0000899749 hr:AtTheMarketEquityOfferingProgramMember 2018-01-01 2018-09-30 0000899749 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-01-01 2018-09-30 0000899749 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2017-12-31 0000899749 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-09-30 0000899749 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2017-01-01 2017-09-30 0000899749 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2017-09-30 0000899749 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2016-12-31 0000899749 us-gaap:CommonStockMember 2017-01-01 2017-09-30 0000899749 us-gaap:CommonStockMember 2016-12-31 0000899749 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-09-30 0000899749 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember hr:AmountReclassifiedfromAOCIforSettledDerivativesAttributabletoParentMember 2018-01-01 2018-09-30 0000899749 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember hr:AmountReclassifiedfromAOCIforCurrentDerivativesAttributabletoParentMember 2018-01-01 2018-09-30 0000899749 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2017-12-31 0000899749 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2017-12-31 0000899749 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2018-09-30 0000899749 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-09-30 xbrli:pure hr:building iso4217:USD xbrli:shares xbrli:shares utreg:acre iso4217:USD utreg:sqft hr:state hr:property hr:swap_agreement

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________________________________________________
FORM 10-Q
____________________________________________________________
(Mark One)
x
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended: September 30, 2018
OR
o
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                     to                     
Commission File Number: 001-11852
____________________________________________________________
HEALTHCARE REALTY TRUST INCORPORATED
(Exact name of Registrant as specified in its charter) 
____________________________________________________________
Maryland
 
62 – 1507028
(State or other jurisdiction of
incorporation or organization)
 
(I.R.S. Employer
Identification No.)
 
3310 West End Avenue
 
 
Suite 700
 
 
Nashville, Tennessee 37203
 
 
(Address of principal executive offices)
 
 
 
 
 
(615) 269-8175
 
 
(Registrant’s telephone number, including area code)
 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  x    No  o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer x
Accelerated filer o
Non-accelerated filer o
Smaller reporting company o
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  o    No  x
 
As of October 26, 2018, the Registrant had 125,237,283 shares of Common Stock outstanding.
 



HEALTHCARE REALTY TRUST INCORPORATED
FORM 10-Q
September 30, 2018

TABLE OF CONTENTS
 



PART I. FINANCIAL INFORMATION

Item 1. Financial Statements
Healthcare Realty Trust Incorporated
Condensed Consolidated Balance Sheets
(Amounts in thousands, except per share data)
 
(Unaudited)
 
 
 
September 30,
2018
 
December 31,
2017
ASSETS
 
 
 
Real estate properties:
 
 
 
Land
$
217,322

 
$
201,283

Buildings, improvements and lease intangibles
3,669,852

 
3,601,460

Personal property
10,454

 
10,314

Construction in progress
26,960

 
5,458

Land held for development
24,645

 
20,123

 
3,949,233

 
3,838,638

Less accumulated depreciation and amortization
(989,585
)
 
(897,430
)
Total real estate properties, net
2,959,648

 
2,941,208

Cash and cash equivalents
10,027

 
6,215

Assets held for sale, net
8,826

 
33,147

Other assets, net
222,582

 
213,015

Total assets
$
3,201,083

 
$
3,193,585

LIABILITIES AND STOCKHOLDERS' EQUITY
 
 
 
Liabilities:
 
 
 
Notes and bonds payable
$
1,344,759

 
$
1,283,880

Accounts payable and accrued liabilities
72,927

 
70,995

Liabilities of properties held for sale
141

 
93

Other liabilities
43,004

 
48,734

Total liabilities
1,460,831

 
1,403,702

Commitments and contingencies


 


Stockholders' equity:
 
 
 
Preferred stock, $.01 par value per share; 50,000 shares authorized; none issued and outstanding

 

Common stock, $.01 par value per share; 300,000 shares authorized; 125,237 and 125,132 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively
1,252

 
1,251

Additional paid-in capital
3,181,263

 
3,173,429

Accumulated other comprehensive income (loss)
473

 
(1,299
)
Cumulative net income attributable to common stockholders
1,071,804

 
1,018,348

Cumulative dividends
(2,514,540
)
 
(2,401,846
)
Total stockholders' equity
1,740,252

 
1,789,883

Total liabilities and stockholders' equity
$
3,201,083

 
$
3,193,585


The accompanying notes, together with the Notes to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, are an integral part of these financial statements.

1



Healthcare Realty Trust Incorporated
Condensed Consolidated Statements of Income
For the Three and Nine Months Ended September 30, 2018 and 2017
(Amounts in thousands, except per share data)
(Unaudited)
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
REVENUES
 
 
 
 
 
 
 
Rental income
$
111,452

 
$
105,078

 
$
331,247

 
$
311,171

Other operating
2,010

 
1,947

 
5,973

 
5,816

 
113,462

 
107,025

 
337,220

 
316,987

EXPENSES
 
 
 
 
 
 
 
Property operating
44,135

 
40,628

 
127,691

 
116,663

General and administrative
8,504

 
8,021

 
25,977

 
24,720

Acquisition and pursuit costs
141

 
507

 
538

 
1,878

Depreciation and amortization
42,061

 
35,873

 
121,764

 
105,148

Bad debts, net of recoveries
(62
)
 
4

 
42

 
175

 
94,779

 
85,033

 
276,012

 
248,584

OTHER INCOME (EXPENSE)
 
 
 
 
 
 
 
Gain (loss) on sales of real estate assets
1,288

 
(7
)
 
30,879

 
39,525

Interest expense
(13,464
)
 
(14,107
)
 
(39,202
)
 
(42,694
)
Impairment of real estate assets

 
(5,059
)
 

 
(5,387
)
Interest and other income, net
41

 
354

 
571

 
396

 
(12,135
)
 
(18,819
)
 
(7,752
)
 
(8,160
)
NET INCOME
$
6,548

 
$
3,173

 
$
53,456

 
$
60,243

Basic earnings per common share
$
0.05

 
$
0.02

 
$
0.42

 
$
0.50

Diluted earnings per common share
$
0.05

 
$
0.02

 
$
0.42

 
$
0.50

Weighted average common shares outstanding - basic
123,300

 
119,098

 
123,281

 
116,181

Weighted average common shares outstanding - diluted
123,352

 
119,181

 
123,336

 
116,277

Dividends declared, per common share, during the period
$
0.30

 
$
0.30

 
$
0.90

 
$
0.90

The accompanying notes, together with the Notes to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, are an integral part of these financial statements.

2


Healthcare Realty Trust Incorporated
Condensed Consolidated Statements of Comprehensive Income
For the Three and Nine Months Ended September 30, 2018 and 2017
(Dollars in thousands)
(Unaudited)
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
NET INCOME
$
6,548

 
$
3,173

 
$
53,456

 
$
60,243

Other comprehensive income:
 
 
 
 
 
 
 
Interest rate swaps:
 
 
 
 
 
 
 
Reclassification adjustments for losses included in net income (interest expense)
95

 
43

 
369

 
127

Gains arising during the period on interest rate swaps
374

 

 
1,403

 

Total other comprehensive income
469

 
43

 
1,772

 
127

COMPREHENSIVE INCOME
$
7,017

 
$
3,216

 
$
55,228

 
$
60,370


The accompanying notes, together with the Notes to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, are an integral part of these financial statements.

3


Healthcare Realty Trust Incorporated
Condensed Consolidated Statement of Equity
For the Nine Months Ended September 30, 2018
(Dollars in thousands, except per share data)
(Unaudited)

 
Common
Stock
 
Additional
Paid-In
Capital
 
Accumulated
Other
Comprehensive
Income (Loss)
 
Cumulative
Net
Income
 
Cumulative
Dividends
 
Total
Stockholders’
Equity
Balance at December 31, 2017
$
1,251


$
3,173,429


$
(1,299
)
 
$
1,018,348

 
$
(2,401,846
)
 
$
1,789,883

Issuance of common stock

 
464

 

 

 

 
464

Common stock redemptions

 
(719
)
 

 

 

 
(719
)
Share-based compensation
1

 
8,089

 

 

 

 
8,090

Net income

 

 

 
53,456

 

 
53,456

Reclassification adjustments for losses included in net income (interest expense)


 

 
369

 

 

 
369

Gains arising during the period on interest rate swaps


 

 
1,403

 

 

 
1,403

Dividends to common stockholders ($0.90 per share)

 

 

 

 
(112,694
)
 
(112,694
)
Balance at September 30, 2018
$
1,252

 
$
3,181,263

 
$
473

 
$
1,071,804

 
$
(2,514,540
)
 
$
1,740,252

The accompanying notes, together with the Notes to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, are an integral part of these financial statements.


4


Healthcare Realty Trust Incorporated
Condensed Consolidated Statements of Cash Flows
For the Nine Months Ended September 30, 2018 and 2017
(Dollars in thousands)
(Unaudited)
 
Nine Months Ended September 30,
 
2018
 
2017
OPERATING ACTIVITIES
 
 
 
Net income
$
53,456

 
$
60,243

Adjustments to reconcile net income to net cash provided by operating activities:
 
 
 
Depreciation and amortization
121,764

 
105,148

Other amortization
2,113

 
3,056

Share-based compensation
8,090

 
7,496

Amortization of straight-line rent receivable
(3,599
)
 
(4,867
)
Amortization of straight-line rent liability
1,147

 
492

Gain on sales of real estate assets
(30,879
)
 
(39,525
)
Impairment of real estate assets

 
5,387

Equity from unconsolidated joint ventures (income)
(15
)
 

Distributions from unconsolidated joint ventures
182

 

Provision for bad debts, net
42

 
175

Changes in operating assets and liabilities:
 
 
 
Other assets
(6,891
)
 
(6,037
)
Accounts payable and accrued liabilities
5,908

 
(3,301
)
Other liabilities
(638
)
 
1,098

Net cash provided by operating activities
150,680

 
129,365

INVESTING ACTIVITIES
 
 
 
Acquisitions of real estate
(67,445
)
 
(72,934
)
Development of real estate
(21,059
)
 
(11,753
)
Additional long-lived assets
(59,802
)
 
(52,305
)
Proceeds from sales of real estate
64,271

 
119,425

Proceeds from notes receivable repayments
8

 
15

Net cash used in investing activities
(84,027
)
 
(17,552
)
FINANCING ACTIVITIES
 
 
 
Net borrowings (repayments) on unsecured credit facility
56,000

 
(107,000
)
Repayments of notes and bonds payable
(3,808
)
 
(4,654
)
Dividends paid
(112,694
)
 
(104,860
)
Net proceeds from issuance of common stock
459

 
248,384

Common stock redemptions
(2,673
)
 
(1,125
)
Debt issuance and assumption costs
(125
)
 
(84
)
Net cash (used in) provided by financing activities
(62,841
)
 
30,661

Increase in cash and cash equivalents
3,812

 
142,474

Cash and cash equivalents at beginning of period
6,215

 
54,507

Cash and cash equivalents at end of period
$
10,027

 
$
196,981

 
 
 
 
Supplemental Cash Flow Information:
 
 
 
Interest paid
$
30,463

 
$
42,136

Invoices accrued for construction, tenant improvements and other capitalized costs
$
5,680

 
$
6,842

Mortgage notes payable assumed upon acquisition (adjusted to fair value)
$
7,995

 
$
12,460

Capitalized interest
$
684

 
$
681

The accompanying notes, together with the Notes to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, are an integral part of these financial statements.

5

Healthcare Realty Trust Incorporated

Notes to the Condensed Consolidated Financial Statements
September 30, 2018
(Unaudited)

Note 1. Summary of Significant Accounting Policies
Business Overview
Healthcare Realty Trust Incorporated (the "Company") is a real estate investment trust ("REIT") that owns, leases, manages, acquires, finances, develops and redevelops income-producing real estate properties associated primarily with the delivery of outpatient healthcare services throughout the United States. As of September 30, 2018, the Company had gross investments of approximately $3.9 billion in 201 real estate properties located in 27 states totaling approximately 14.8 million square feet. The Company provided leasing and property management services to approximately 11.1 million square feet nationwide.

Basis of Presentation
The Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. They do not include all of the information and footnotes required by GAAP for complete financial statements. However, except as disclosed herein, management believes there has been no material change in the information disclosed in the Notes to the Consolidated Financial Statements included in the Annual Report on Form 10-K for the year ended December 31, 2017. All material intercompany transactions and balances have been eliminated in consolidation.

This interim financial information should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2017. Management believes that all adjustments of a normal, recurring nature considered necessary for a fair presentation have been included. In addition, the interim financial information does not necessarily represent or indicate what the operating results will be for the year ending December 31, 2018 for many reasons including, but not limited to, acquisitions, dispositions, capital financing transactions, changes in interest rates and the effects of other trends, risks and uncertainties.

Use of Estimates in the Condensed Consolidated Financial Statements
Preparation of the Condensed Consolidated Financial Statements in accordance with GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Actual results may differ from those estimates.
Revenue from Contracts with Customers (Topic 606)
The Company recognizes certain revenue under the core principle of Topic 606. This requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Lease revenue is not within the scope of Topic 606. To achieve the core principle, the Company applies the five step model specified in the guidance. See the New Accounting Pronouncements section below for additional information.

Revenue that is accounted for under Topic 606 is segregated on the Company’s Condensed Consolidated Statements of Income in the Other operating line item. This line item includes parking income, rental lease guaranty income, management fee income and other miscellaneous income. Below is a detail of the amounts by category:
(in thousands)
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
Type of Revenue
 
2018
 
2017
 
2018
 
2017
Parking income
 
$
1,752

 
$
1,669

 
$
5,197

 
$
4,907

Rental lease guaranty
 
168

 
168

 
488

 
545

Management fee income
 
68

 
70

 
205

 
237

Miscellaneous
 
22

 
40

 
83

 
127

 
 
$
2,010

 
$
1,947

 
$
5,973

 
$
5,816




6


The Company’s three major types of revenue that are accounted for under Topic 606 that are listed above are all accounted for as the performance obligation is satisfied. The performance obligations that are identified for each of these items are satisfied over time and the Company recognizes revenue monthly based on this principle.
Reclassifications
Condensed Consolidated Statements of Income
Certain reclassifications have been made on the Company's Condensed Consolidated Statements of Income. After the adoption of Accounting Standards Update ("ASU") 2014-08, "Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity," the Company's dispositions have not met the updated definition to be reported as discontinued operations. The Company had some residual impact from properties that were identified as discontinued operations prior to the adoption of ASU 2014-08. These amounts are considered immaterial and have been reclassified for the prior year presentation on the Company's Condensed Consolidated Statements of Income.
 
Three months ended September 30, 2017
 
Nine months ended September 30, 2017
(in thousands)
As Previously Reported
 
As Reclassified
 
As Previously Reported
 
As Reclassified
EXPENSES
 
 
 
 
 
 
 
Property operating expense
$
40,626

 
$
40,628

 
$
116,644

 
$
116,663

Bad debt, net
14

 
4

 
185

 
175

 
 
 
 
 
 
 
 
OTHER INCOME (EXPENSE)
 
 
 
 
 
 
 
Gain on sales of properties
(7
)
 
(7
)
 
39,519

 
39,525

 
 
 
 
 
 
 
 
INCOME FROM CONTINUING OPERATIONS
$
3,165

 
$
3,173

 
$
60,247

 
$
60,243

 
 
 
 
 
 
 
 
DISCONTINUED OPERATIONS
 
 
 
 
 
 
 
Income (loss) from discontinued operations
$
8

 
$

 
$
(9
)
 
$

Gain on sales of properties

 

 
5

 

INCOME (LOSS) FROM DISCONTINUED OPERATIONS
$
8

 
$

 
$
(4
)
 
$




New Accounting Pronouncements
Accounting Standards Update No. 2014-09 and No. 2015-14
In May 2014, the Financial Accounting Standards Board ("FASB") issued ASU No. 2014-09, "Revenue from Contracts with Customers," a comprehensive new revenue recognition standard that supersedes most existing revenue recognition guidance, including sales of real estate. This standard's core principle is that a company will recognize revenue when it transfers goods or services to customers in amounts that reflect the consideration to which the company expects to be entitled in exchange for those goods and services. However, leasing contracts, representing the major source of the Company's revenues, are not within the scope of the new standard and will continue to be accounted for under other standards.

In August 2015, the FASB issued ASU No. 2015-14, "Revenue from Contracts with Customers (Topic 606); Deferral of the Effective Date." This standard was effective for the Company for annual and interim periods beginning after December 15, 2017 with early adoption permitted only as of annual reporting periods beginning after December 15, 2016, including interim periods within that year.

The Company adopted this standard by using the full retrospective adoption method beginning on January 1, 2018. The Company's revenue-producing contracts are primarily leases that are not within the scope of this standard. As a result, the adoption of this standard did not have a material impact on the timing and measurement of the Company's leasing revenues. The Company has determined that parking income, rental lease guaranty income and management fee income are within the scope of Topic 606. However, these items were determined to have the same pattern of revenue recognition that the Company
had historically recognized. The Company reclassified these amounts along with all other items that are accounted for within the scope of Topic 606 into the Other operating line item on the Company's Condensed Consolidated Statements of Income. This line item historically contained the revenue associated with rental lease guaranty income, management fee income and other non-lease revenue. The Company reclassified parking income from rental income to other operating income.

7



The following table represents the impact of the adoption of this standard on the Company's Condensed Consolidated Statements of Income for the three and nine months ended September 30, 2017:

 
Three months ended September 30, 2017
 
Nine months ended September 30, 2017
(in thousands)
As Reported
 
As Reclassified
 
As Reported
 
As Reclassified
REVENUES
 
 
 
 
 
 
 
Rental income
$
106,561

 
$
105,078

 
$
315,519

 
$
311,171

Other operating
392

 
1,947

 
1,249

 
5,816

 
$
106,953

 
$
107,025

 
$
316,768

 
$
316,987

 
 
 
 
 
 
 
 
OTHER INCOME (EXPENSE)
 
 
 
 
 
 
 
Interest and other income, net
$
426

 
$
354

 
$
616

 
$
396

 
 
 
 
 
 
 
 
NET INCOME
$
3,173

 
$
3,173

 
$
60,243

 
$
60,243



Accounting Standards Update No. 2016-02, No. 2018-01 and No. 2018-11
In February 2016, the FASB issued ASU 2016-02, "Leases." In January 2018, the FASB issued ASU 2018-01, "Leases - Land Easement Practical Expedient for Transition to Topic 842," and in July 2018, the FASB issued ASU 2018-10, "Codification Improvements to Topic 842, Leases" and ASU 2018-11, "Leases - Targeted Improvements." These accounting standard updates are collectively referred to as "Topic 842."

Topic 842 provides several practical expedients that the Company expects to elect. These are (a) the package of practical expedients offered that allows an entity not to reassess upon adoption (i) whether an expired or existing contract contains a lease, (ii) lease classification related to expired or existing lease arrangements, and (iii) whether costs incurred on expired or existing leases qualify as initial direct costs, and (b) the practical expedient not to separate certain non-lease components, such as common area maintenance, from the lease component if (i) the timing and pattern of transfer are the same for the non-lease component and associated lease component, and (ii) the lease component would be classified as an operating lease if accounted for separately.

For lessees, the new standard establishes a right-of-use ("ROU") model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with the classification affecting the pattern of expense recognition in the income statement. The Company expects that most of the leases where the Company is the lessee will be recorded on the Company's balance sheet as operating leases. These leases are primarily ground leases, but also include the Company's corporate office lease, management office leases in third party buildings and certain copier and postage machine leases. The impact to the Company's Consolidated Balance Sheets has not yet been determined. The Company is in the process of working with consultants to determine the appropriate discount rate required to calculate the present value of the future lease payments for ground leases that have lease terms longer than typical secured financing allows.

For lessors, the new standard requires a lessor to classify leases as either sales-type, direct-financing or operating. A lease will be treated as a sale if it is considered to transfer control of the underlying asset, to the lessee. A lease will be classified as direct-financing if risks and rewards are conveyed without the transfer of control. Otherwise, the lease is treated as an operating lease. Lessor accounting remains largely unchanged with some exceptions including the concept of separating lease and nonlease components. Nonlease components, such as common area maintenance, will be accounted for under Topic 606 and separated from the lease payments. However, the Company will elect the lessor practical expedient allowing the Company to not separate these components when certain conditions are met. The Company does not expect a material impact from the adoption of Topic 842 related to leases where the Company is the lessor.

The new standard is effective for the Company on January 1, 2019. Topic 842 provides two transition alternatives. The Company expects to choose the optional transition method available to apply the guidance in Accounting Standards Codification Topic 840 in the comparative periods presented in the year Topic 842 is adopted. Topic 842 includes extensive quantitative and qualitative disclosures as compared to Topic 840, Leases, for both lessees and lessors. The Company is continuing to evaluate the impact from the adoption of this new standard on the Consolidated Financial Statements and related notes.


8


Accounting Standards Update No. 2016-13
In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." This update is intended to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. This update requires that financial statement assets measured at an amortized cost and certain other financial instruments be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. This standard is effective for annual and interim periods beginning after December 15, 2019 with early adoption permitted. The Company is in the initial stages of evaluating the impact from the adoption of this new standard on the Consolidated Financial Statements and related notes.

Accounting Standards Update No. 2017-04
In January 2017, the FASB issued ASU 2017-04, "Simplifying the Test for Goodwill Impairment." This update eliminates Step 2 of the goodwill impairment test. As such, an entity will perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize a goodwill impairment charge for the amount by which the reporting unit's carrying amount exceeds its fair value. This standard is effective for the Company for annual and interim periods beginning after December 15, 2019. The Company does not expect a material impact on the Consolidated Financial Statements and related notes from the adoption of this standard.

Accounting Standards Update No. 2017-05
In February 2017, the FASB issued ASU 2017-05, "Other Income - Gains and Losses from the Derecognition of Nonfinancial Assets." This update defines an in-substance nonfinancial asset, unifies guidance related to partial sales of nonfinancial assets, eliminates rules specifically addressing the sales of real estate, removes exceptions to the financial asset derecognition model and clarifies the accounting for contributions of nonfinancial assets to joint ventures. The Company adopted this standard as of January 1, 2018 on the full retrospective adoption method. The adoption of this standard did not have a material impact to the Consolidated Financial Statements and related notes.

Accounting Standards Update No. 2017-09
In May 2017, the FASB issued ASU 2017-09, "Compensation - Stock Compensation - Scope of Modification Accounting." This update provides guidance about which changes to the terms and conditions of share-based awards require an entity to apply modification accounting in Topic 718. The Company adopted this standard on January 1, 2018. The adoption of this standard did not have a material impact to the Consolidated Financial Statements and related notes.


9


Note 2. Real Estate Investments
2018 Acquisitions
The following table details the Company's acquisitions for the nine months ended September 30, 2018:
(Dollars in millions)
Type (1)
 
Date
Acquired
 
Purchase Price

 
Mortgage
Notes Payable Assumed
(2)

 
Cash
Consideration
(3)

 
Real
Estate

 
Other (4)

 
Square
Footage
(Unaudited)

Seattle, Washington
MOB
 
5/4/18
 
$
7.8

 
$

 
$
7.8

 
$
7.8

 
$

 
13,314

Denver, Colorado (5)
MOB, OFC
 
5/18/18
 
25.0

 
(8.0
)
 
16.6

 
25.1

 
(0.4
)
 
187,861

Oklahoma City, Oklahoma
MOB
 
5/21/18
 
11.4

 

 
11.4

 
11.5

 
(0.1
)
 
82,647

Seattle, Washington
MOB
 
6/29/18
 
26.2

 

 
26.2

 
26.7

 
(0.5
)
 
86,942

Denver, Colorado
MOB
 
8/24/18
 
4.1

 

 
4.2

 
4.2

 

 
17,084

 
 
 
 
 
$
74.5

 
$
(8.0
)
 
$
66.2

 
$
75.3

 
$
(1.0
)
 
387,848

______
(1)
MOB = medical office building; OFC = office
(2)
The mortgage note payable assumed in the acquisition does not reflect the fair value premium totaling $0.1 million recorded by the Company upon acquisition (included in Other).
(3)
Cash consideration excludes prorations of revenue and expense due to/from seller at the time of the acquisition.
(4)
Includes other assets acquired, liabilities assumed, intangibles recognized at acquisition and fair value adjustments on debt assumed.
(5)
Includes two properties.

2018 Dispositions
The following table details the Company's dispositions for the nine months ended September 30, 2018:
(Dollars in millions)
Type (1)
 
Date
Disposed
 
Sales Price
 
Closing Adjustments
 
Net
Proceeds
 
Net Real
Estate
Investment
 
Other (including receivables) (2)
 
Gain
 
Square
Footage
(
Unaudited)
Virginia (3) (4)
MOB, OFC
 
4/26/18
 
$
46.2

 
$

 
$
46.2

 
$
23.9

 
$

 
$
22.3

 
460,881

Michigan (3) (5)
SNF
 
6/27/18
 
9.5

 
(0.7
)
 
8.8

 
3.4

 

 
5.4

 
121,672

Missouri
MOB
 
8/30/18
 
9.8

 
(0.5
)
 
9.3

 
7.5

 
0.5

 
1.3

 
70,893

Total dispositions
 
$
65.5

 
$
(1.2
)
 
$
64.3

 
$
34.8

 
$
0.5

 
$
29.0

 
653,446

______
(1)
MOB = medical office building; OFC = office; SNF = skilled nursing facility
(2)
Includes straight-line rent receivables and leasing commissions.
(3)
Previously classified as held for sale.
(4)
Includes seven properties, comprised of five single-tenant net lease buildings and two multi-tenant buildings. These buildings were sold pursuant to the exercise of a fixed-price purchase option.
(5)
Includes five skilled nursing facilities. Sales price includes $0.5 million of forfeited earnest money from a prior terminated transaction.

Non-monetary Exchange
On June 29, 2018, the Company completed the swap of a non-revenue producing garage that was built by the Company in 2012 located in Denver, Colorado for 20.5 acres of land adjacent to the Catholic Health Initiative’s St. Anthony Hospital campus. A portion of this land, approximately 4.6 acres, has been allocated to an existing medical office building that was developed by the Company in 2017. This building is located on land previously ground leased from the hospital. The remaining land has been recorded in land held for development. The land acquired was appraised for $5.8 million. The Company had a net investment of $3.9 million in the parking garage and recognized a gain of $1.9 million in connection with this transaction.


10


Assets Held for Sale
As of December 31, 2017, the Company had eight properties classified as held for sale. The following changes to assets held for sale have occurred during 2018:

The Company reclassified five single-tenant net leased properties to held for sale as of March 31, 2018.

In April 2018, the Company sold seven properties, comprised of five single-tenant net leased properties and two multi-tenanted properties. The Company recognized a gain on disposition of approximately $22.3 million.

In June 2018, the Company sold five single-tenant net leased properties. The Company recognized a gain on disposition of approximately $5.4 million.

As of September 30, 2018, the Company had one property remaining classified as held for sale.

The table below reflects the assets and liabilities of the properties classified as held for sale as of September 30, 2018 and December 31, 2017:
(Dollars in thousands)
September 30,
2018
 
December 31,
2017
Balance Sheet data:
 
 
 
Land
$
1,125

 
$
4,636

Buildings, improvements and lease intangibles
18,231

 
63,654

Personal property

 
82

 
19,356

 
68,372

Accumulated depreciation
(10,657
)
 
(35,790
)
Real estate assets held for sale, net
8,699

 
32,582

Other assets, net
127

 
565

Assets held for sale, net
$
8,826

 
$
33,147

 
 
 
 
Accounts payable and accrued liabilities
$
119

 
$
38

Other liabilities
22

 
55

Liabilities of properties held for sale
$
141

 
$
93





11


Note 3. Notes and Bonds Payable
The table below details the Company’s notes and bonds payable. 
 
Maturity
Dates
 
Balance as of
 
Effective Interest Rate as of

(Dollars in thousands)
September 30, 2018

 
December 31, 2017

September 30, 2018

Unsecured Credit Facility
7/20
 
$
245,000

 
$
189,000

 
3.26
%
Unsecured Term Loan Facility, net of issuance costs (1)
12/22
 
149,132

 
148,994

 
3.41
%
Senior Notes due 2023, net of discount and issuance costs
4/23
 
248,013

 
247,703

 
3.95
%
Senior Notes due 2025, net of discount and issuance costs (2)
5/25
 
248,219

 
248,044

 
4.08
%
Senior Notes due 2028, net of discount and issuance costs
1/28
 
295,087

 
294,757

 
3.84
%
Mortgage notes payable, net of discounts and issuance costs and including premiums
12/18-5/40
 
159,308

 
155,382

 
4.83
%
 
 
 
$
1,344,759

 
$
1,283,880

 
 


______
(1)
The effective interest rate includes the impact of interest rate swaps on $25.0 million and $50.0 million of the outstanding balance at a rate of 2.18% and 2.46%, respectively (plus the applicable margin rate, currently 110 basis points).
(2)
The effective interest rate includes the impact of the $1.7 million settlement of a forward-starting interest rate swap that is included in Accumulated other comprehensive income (loss) on the Company's Condensed Consolidated Balance Sheets.



12


Note 4. Derivative Financial Instruments
Risk Management Objective of Using Derivatives
The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company principally manages its exposures to a wide variety of business and operational risks through management of its core business activities. The Company manages economic risks, including interest rate, liquidity, and credit risk, primarily by managing the amount, sources, and duration of its assets and liabilities and the use of derivative financial instruments. Specifically, the Company enters into derivative financial instruments to manage exposures that arise from business activities that result in the
receipt or payment of future known and uncertain cash amounts, the value of which are determined by interest rates. The Company’s derivative financial instruments are used to manage differences in the amount, timing, and duration of the Company’s known or expected cash receipts and its known or expected cash payments principally related to the Company’s borrowings.

Cash Flow Hedges of Interest Rate Risk
The Company’s objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish this objective, the Company primarily uses interest rate swaps as part of its interest rate risk management strategy. Interest rate swaps designated as cash flow hedges involve the receipt of variable amounts from a counterparty in exchange for the Company making fixed-rate payments over the life of the agreements without exchange of the underlying notional amount. Such derivatives were used to hedge the variable cash flows associated with existing variable-rate debt.

For derivatives designated and that qualify as cash flow hedges of interest rate risk, the gain or loss on the derivative is recorded in Accumulated other comprehensive income (loss) and subsequently reclassified into interest expense in the same period(s) during which the hedged transaction affects earnings. Amounts reported in Accumulated other comprehensive income (loss) related to derivatives will be reclassified to interest expense as interest payments are made on the Company’s variable-rate debt.

As of September 30, 2018, the Company had four outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk:
Derivative Instrument
 
Number of Instruments

 
Notional Amount
(in millions)
Interest rate swaps
 
4

 
$75.0


Tabular Disclosure of Fair Values of Derivative Instruments on the Balance Sheet
The table below presents the fair value of the Company's derivative financial instruments, as well as their classification on the Condensed Consolidated Balance Sheet as of September 30, 2018.
 
Asset Derivatives
 
Balance at September 30, 2018
(Dollars in thousands)
Balance Sheet Location
 
Fair Value

Derivatives designated as hedging instruments
 
 
 
Interest rate swaps
Other assets
 
$
1,579

Total derivatives designated as hedging instruments
 
 
$
1,579



Tabular Disclosure of the Effect of Cash Flow Hedge Accounting on Accumulated Other Comprehensive Income (Loss)
The table below presents the effect of cash flow hedge accounting on Accumulated Other Comprehensive Income (Loss) ("OCI") during the nine months ended September 30, 2018 and 2017 related to the Company's outstanding interest rate swaps.
 
Amount of Gain Recognized in OCI on Derivative
 
Amount of Loss Reclassified from OCI into Income
(Dollars in thousands)
2018

2018

 
2017

Interest rate products
$
1,403

Interest expense
$
243

 
$

Settled interest rate swaps

Interest expense
126

 
127

 
$
1,403

Total interest expense
$
369

 
$
127



13


Credit-risk-related Contingent Features
The Company's agreements with each of its derivative counterparties contain a cross-default provision under which the Company could be declared in default of its derivative obligations if repayment of the underlying indebtedness is accelerated by the lender due to the Company's default on the indebtedness.

The Company estimates that $0.2 million related to active interest rate swaps will be reclassified from OCI as a decrease to interest expense over the next 12 months, and that $0.2 million related to settled interest rate swaps will be amortized from OCI as an increase to interest expense over the next 12 months.

Note 5. Commitments and Contingencies
Legal Proceedings
The Company is, from time to time, involved in litigation arising in the ordinary course of business. The Company is not aware of any pending or threatened litigation that, if resolved against the Company, would have a material adverse effect on the Company’s consolidated financial position, results of operations or cash flows.

Redevelopment Activity
The Company is redeveloping a medical office building in Charlotte, North Carolina, which includes a 38,000 square foot vertical expansion. As of September 30, 2018, the Company has funded approximately $9.2 million on the redevelopment of this property. The project is expected to be completed in the first quarter of 2019.

Development Activity
The Company began the development of a 151,000 square foot medical office building in Seattle, Washington during 2017. As of September 30, 2018, the Company has funded approximately $18.0 million on the development. The Company expects the project to be completed in the second quarter of 2019.
Note 6. Stockholders' Equity

Common Stock    
The following table provides a reconciliation of the beginning and ending shares of common stock outstanding for the nine months ended September 30, 2018 and the year ended December 31, 2017:
 
September 30, 2018
 
December 31, 2017
Balance, beginning of period
125,131,593

 
116,416,900

Issuance of common stock
20,395

 
8,395,607

Nonvested share-based awards, net of withheld shares
85,196

 
319,086

Balance, end of period
125,237,184

 
125,131,593



At-The-Market Equity Offering Program
No shares were sold under the Company's At-the-Market Equity Offering Program during the nine months ended September 30, 2018. The Company had 5,868,697 authorized shares remaining available to be sold under the current sales agreements as of October 26, 2018.

Common Stock Dividends
During the nine months ended September 30, 2018, the Company declared and paid common stock dividends totaling $0.90 per share. On October 30, 2018, the Company declared a quarterly common stock dividend in the amount of $0.30 per share payable on November 30, 2018 to stockholders of record on November 15, 2018.

Accumulated Other Comprehensive Income (Loss)
As of September 30, 2018, the Company had four outstanding interest rate swaps to hedge the variable cash flows associated with existing variable-rate debt. The Company continues to amortize the 2015 settlement of forward-starting interest rate swaps that were entered into in connection with the issuance of the Company's Senior Notes due 2025. This amount will be reclassified out of OCI impacting net income over the 10-year term of the associated senior note issuance. See Note 4 for more information regarding the Company's derivative instruments.


14


The following table represents the changes in balances of each component and the amounts reclassified out of OCI related to the Company during the nine months ended September 30, 2018 and 2017:
 
Forward-starting Interest Rate Swaps
 
(Dollars in thousands)
2018
 
2017
 
Beginning balance
$
(1,299
)
 
$
(1,401
)
 
Gains arising during the period related to active interest rate swaps
1,403

 

 
Amounts reclassified from accumulated other comprehensive (income) loss
369

 
127

 
Net accumulated other comprehensive income
1,772

 
127

 
Ending balance
$
473

 
$
(1,274
)
 


The following table represents the details regarding the reclassifications from OCI during the nine months ended September 30, 2018:
Details about accumulated other comprehensive income (loss) components
 
Amount reclassified from accumulated other comprehensive income (loss)

 
Affected line item in the statement where net income is presented
(Dollars in thousands)
 
 
 
 
Amounts reclassified from accumulated other comprehensive income (loss) related to settled interest rate swaps
 
$
126

 
Interest Expense
Amounts reclassified from accumulated other comprehensive income (loss) related to current interest rate swaps
 
243

 
Interest Expense
 
 
$
369

 
 


Earnings Per Common Share
The Company uses the two-class method of computing net earnings per common shares. The Company's nonvested share-based awards are considered participating securities pursuant to the two-class method. The following table sets forth the computation of basic and diluted earnings per common share for the three and nine months ended September 30, 2018 and 2017.
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
(Dollars in thousands, except per share data)
2018
 
2017
 
2018
 
2017
Weighted average Common Shares outstanding
 
 
 
 
 
 
 
Weighted average Common Shares outstanding
125,233,462

 
120,895,835

 
125,206,342

 
117,981,159

Nonvested shares
(1,933,653
)
 
(1,797,686
)
 
(1,925,589
)
 
(1,800,180
)
Weighted average Common Shares outstanding—Basic
123,299,809

 
119,098,149

 
123,280,753

 
116,180,979

Weighted average Common Shares outstanding—Basic
123,299,809

 
119,098,149

 
123,280,753

 
116,180,979

Dilutive effect of employee stock purchase plan
52,147

 
83,242

 
54,763

 
96,260

Weighted average Common Shares outstanding—Diluted
123,351,956

 
119,181,391

 
123,335,516

 
116,277,239

Net Income
$
6,548

 
$
3,173

 
$
53,456

 
$
60,243

Dividends paid on nonvested share-based awards
(580
)
 
(538
)
 
(1,740
)
 
(1,609
)
Net income applicable to common stockholders
$
5,968

 
$
2,635

 
$
51,716

 
$
58,634

Basic earnings per common share - Net income
$
0.05

 
$
0.02

 
$
0.42

 
$
0.50

Diluted earnings per common share - Net income
$
0.05

 
$
0.02

 
$
0.42

 
$
0.50




15


Incentive Plans
A summary of the activity under the Company's share-based incentive plans for the three and nine months ended September 30, 2018 and 2017 is included in the table below.
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Share-based awards, beginning of period
1,938,100

 
1,797,686

 
1,907,645

 
1,786,497

Granted

 

 
107,751

 
103,615

Vested
(5,051
)
 

 
(82,347
)
 
(92,426
)
Share-based awards, end of period
1,933,049

 
1,797,686

 
1,933,049

 
1,797,686



During the nine months ended September 30, 2018 and 2017, the Company withheld 22,555 and 16,581 shares of common stock, respectively, from participants to pay estimated withholding taxes related to shares that vested.

In addition to the share-based incentive plans, the Company maintains the 2000 Employee Stock Purchase Plan (the "Purchase Plan"). A summary of the activity under the Purchase Plan for the three and nine months ended September 30, 2018 and 2017 is included in the table below.
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Outstanding and exercisable, beginning of period
350,535

 
344,572

 
318,100

 
316,321

Granted

 

 
203,836

 
206,824

Exercised
(2,531
)
 
(5,452
)
 
(13,236
)
 
(24,482
)
Forfeited
(9,583
)
 
(9,291
)
 
(34,489
)
 
(36,524
)
Expired

 

 
(135,790
)
 
(132,310
)
Outstanding and exercisable, end of period
338,421

 
329,829

 
338,421

 
329,829



Note 7. Fair Value of Financial Instruments
The following methods and assumptions were used to estimate the fair value of each class of financial instrument for which it is practical to estimate that value.

Cash and cash equivalents - The carrying amount approximates fair value due to the short term maturity of these investments.

Borrowings under the unsecured credit facility due 2020 and unsecured term loan facility due 2022 - The carrying amount approximates fair value because the borrowings are based on variable market interest rates.

Senior Notes and Mortgage Notes payable - The fair value of notes and bonds payable is estimated using cash flow analyses, based on the Company’s current interest rates for similar types of borrowing arrangements.

Interest rate swap agreements - Interest rate swap agreements are recorded in other liabilities on the Company's Consolidated Balance Sheets at fair value. Fair value is estimated by utilizing pricing models that consider forward yield curves and discount rates.

The table below details the fair values and carrying values for notes and bonds payable at September 30, 2018 and December 31, 2017.
 
September 30, 2018
 
December 31, 2017
(Dollars in millions)
Carrying Value
 
Fair Value
 
Carrying Value
 
Fair Value
Notes and bonds payable (1)
$
1,344.8

 
$
1,300.2

 
$
1,283.9

 
$
1,269.7


______
(1)
Level 2 – model-derived valuations in which significant inputs and significant value drivers are observable in active markets.



16


Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Disclosure Regarding Forward-Looking Statements
This report and other materials the Company has filed or may file with the Securities and Exchange Commission, as well as information included in oral statements or other written statements made, or to be made, by management of the Company, contain, or will contain, disclosures that are “forward-looking statements.” Forward-looking statements include all statements that do not relate solely to historical or current facts and can be identified by the use of words such as “may,” “will,” “expect,” “believe,” “anticipate,” “target,” “intend,” “plan,” “estimate,” “project,” “continue,” “should,” “could," "budget" and other comparable terms. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of risks and uncertainties, including the risks described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, that could significantly affect the Company’s current plans and expectations and future financial condition and results.

The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Stockholders and investors are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in the Company’s filings and reports, including, without limitation, estimates and projections regarding the performance of development projects the Company is pursuing.

For a detailed discussion of the Company’s risk factors, please refer to the Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2017.

Liquidity and Capital Resources
Sources and Uses of Cash
The Company’s primary sources of cash include rent receipts from its real estate portfolio based on contractual arrangements with its tenants and sponsors, borrowings under the Company's unsecured credit facility due 2020, proceeds from the sales of real estate properties and proceeds from public or private debt or equity offerings.

The Company expects to continue to meet its liquidity needs, including funding additional investments, paying dividends, and funding debt service, through cash on hand, cash flows from operations, and the cash flow sources described above. The Company had unencumbered real estate assets with a gross book value of approximately $3.5 billion at September 30, 2018, of which a portion could serve as collateral for secured mortgage financing. The Company believes that its liquidity and sources of capital are adequate to satisfy its cash requirements. The Company cannot, however, be certain that these sources of funds will be available at a time and upon terms acceptable to the Company in sufficient amounts to meet its liquidity needs.

Investing Activities
Cash flows used in investing activities for the nine months ended September 30, 2018 were approximately $84.0 million. Below is a summary of significant investing activities.
2018 Acquisitions
The following table details the Company's acquisitions for the nine months ended September 30, 2018:
(Dollars in millions)
 
Health System Affiliation
 
Date
Acquired
 
Purchase Price

 
Mortgage
Notes Payable Assumed

 
Square
Footage

 
Cap Rate

 
Hospital Campus Location (1)
Seattle, Washington
 
Overlake Health
 
5/4/18
 
$
7.8

 
$

 
13,314

 
5.0
%
 
ADJ
Denver, Colorado (2)
 
CHI
 
5/18/18
 
25.0

 
(8.0
)
 
187,861

 
6.4
%
 
ADJ
Oklahoma City, Oklahoma
 
Integris Health
 
5/21/18
 
11.4

 

 
82,647

 
5.9
%
 
ADJ
Seattle, Washington
 
MultiCare Health
 
6/29/18
 
26.2

 

 
86,942

 
5.7
%
 
On
Denver, Colorado
 
CHI
 
8/24/18
 
4.1

 

 
17,084

 
6.0
%
 
ADJ
 
 
 
 
 
 
$
74.5

 
$
(8.0
)
 
387,848

 
5.9
%
 
 
______
(1)
On = Located on a hospital campus; ADJ = adjacent to a hospital campus. The Company defines an adjacent property as being no more than 0.25 miles from a hospital campus.
(2)
Includes two properties (a medical office building and an office building).


17


Capital Funding
The following table details the Company's capital funding for the nine months ended September 30, 2018:
(Dollars in millions)
 
Nine Months Ended September 30, 2018

Redevelopment and development
 
$
28.7

1st generation tenant improvements & planned capital expenditures for acquisitions
 
9.7

2nd generation tenant improvements
 
20.6

Capital expenditures
 
17.5

Total capital funding
 
$
76.5


2018 Dispositions
The Company disposed of 13 properties during the nine months ended September 30, 2018 for a total sales price of $65.5 million, including cash proceeds of $64.3 million and $1.2 million of closing costs and related adjustments. The following table details these dispositions for the nine months ended September 30, 2018:
(Dollars in millions)
 
Date Disposed
 
Sales Price
 
Square Footage
 
3Q 2018 NOI
 
Disposition Cap Rate
 
Property Type (1)
Virginia (2)
 
4/26/18
 
$
46.2

 
460,881

 
$

 
13.3
%
 
MOB, OFC
Michigan (3)
 
6/27/18
 
9.5

 
121,672

 

 
25.5
%
 
SNF
Missouri
 
8/30/18
 
9.8

 
70,893

 
0.1

 
4.3
%
 
MOB
Total dispositions
 
$
65.5

 
653,446

 
$
0.1

 
13.7
%
 
 
______
(1)
MOB = medical office building; OFC = office; SNF = skilled nursing facility
(2)
Includes seven properties, comprised of five single-tenant net lease buildings and two multi-tenant buildings. These buildings were sold pursuant to the exercise of a fixed-price purchase option.
(3)
Includes five skilled nursing facilities. Sales price includes $0.5 million of forfeited earnest money from a prior terminated transaction.

Financing Activities
Cash flows used in financing activities for the nine months ended September 30, 2018 were approximately $62.8 million. Inflows from equity related to the Company's common stock issuances, dividend reinvestment program, and employee stock purchase plan and net borrowings totaled $56.5 million, net of issuance costs incurred. Aggregate cash outflows totaled approximately $119.3 million primarily associated with dividends paid to common stockholders. See Notes 3 and 6 to the Condensed Consolidated Financial Statements for more information about capital markets and financing activities.

Operating Activities
Cash flows provided by operating activities increased from $129.4 million for the nine months ended September 30, 2017 to $150.7 million for the nine months ended September 30, 2018. Items impacting cash flows from operations include, but are not limited to, cash generated from property operations, interest payments and the timing related to the payment of invoices and other expenses and receipts of tenant rent.
The Company may, from time to time, sell additional properties and redeploy cash from property sales into new investments. To the extent revenues related to the properties being sold exceed income from these new investments, the Company's results of operations and cash flows could be adversely affected.

Off-Balance Sheet Arrangements
The Company has no off-balance sheet arrangements that are reasonably likely to have a current or future material effect on the Company’s financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

New Accounting Pronouncements
See Note 1 to the Company's Condensed Consolidated Financial Statements accompanying this report for information on new accounting standards.


18


Trends and Matters Impacting Operating Results
Management monitors factors and trends important to the Company and the REIT industry to gauge the potential impact on the operations of the Company. In addition to the matters discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, below are some of the factors and trends that management believes may impact future operations of the Company.

Expiring Leases
The Company expects that approximately 15% to 20% of the leases in its multi-tenanted portfolio will expire each year in the ordinary course of business. There are 195 leases totaling 0.6 million square feet in the Company's multi-tenant portfolio that will expire during the remainder of 2018. Approximately 92% of the leases expiring in 2018 are located in buildings on or adjacent to hospital campuses, are distributed throughout the portfolio, and are not concentrated with any one tenant, health system or market area. The Company typically expects to retain 75% to 90% of multi-tenant property tenants upon expiration, and the retention ratio for the first nine months of the year has been within this range.

The Company has two single-tenant net leased, on-campus inpatient rehabilitation facilities with lease terms scheduled to expire in the third quarter of 2019.  The Company expects that the lessee will exercise its third renewal option related to one of the leases, representing 0.9% of the total cash NOI for the trailing twelve months ended September 30, 2018.  The other lease, representing 0.8% of total cash NOI for the same period, is not expected to renew; however, the Company expects that the hospital ground lessor will either exercise its option to purchase the building at fair market value, or if not, the Company will exercise its option to purchase the land at fair market value.
Property Operating Agreement Expirations
One of the Company’s owned real estate properties as of September 30, 2018 was covered under a property operating agreement between the Company and a sponsoring health system. This agreement contractually obligates the sponsoring health system to provide to the Company a minimum return on the Company’s investment in the property in exchange for the right to be involved in the operating decisions of the property, including tenancy. If the minimum return is not achieved through normal operations of the property, the Company calculates and accrues to property lease guaranty revenue, each quarter, any shortfalls due from the sponsoring health systems under the terms of the property operating agreement. This agreement expires in February 2019. The Company recognized $0.2 million in property operating guaranty revenue during the third quarter of 2018 related to this agreement. See Note 1 to the Company's Condensed Consolidated Financial Statements accompanying this report for additional information on rental lease guaranty income.

Operating Expenses
The Company has historically experienced increases in property taxes throughout its portfolio as a result of increasing assessments and tax rates levied across the country. The Company continues its efforts to appeal property tax increases and manage the impact of the increases. In addition, the Company has historically incurred variability in portfolio utilities expense based on seasonality, with the first and third quarters usually reflecting greater amounts. The effects of these operating expense increases are mitigated in leases that have provisions for operating expense reimbursement. As of September 30, 2018, leases for 87% of the Company's multi-tenant leased square footage allow for some recovery of operating expenses, with 32% having modified gross lease structures and 55% having net lease structures.

19


Purchase Options
Information about the Company's unexercised purchase options and the amount and basis for determination of the purchase price is detailed in the table below (dollars in thousands):
 
 
 
 
Gross Real Estate Investment as of September 30, 2018
Year Exercisable
 
Number of Properties
 
Fair Market Value Method (1)

 
Non Fair Market Value Method (2)

 
Total

Current
 
4

 
$
95,569

 
$

 
$
95,569

2019
 
1

 
21,355

 

 
21,355

2020
 

 

 

 

2021
 
1

 

 
14,984

 
14,984

2022
 

 

 

 

2023
 

 

 

 

2024
 

 

 

 

2025
 
5

 
19,760

 
221,929

 
241,689

2026
 

 

 

 

2027
 

 

 

 

2028 and thereafter
 
4

 
119,165

 

 
119,165

Total
 
15

 
$
255,849

 
$
236,913

 
$
492,762

_____
(1)
The purchase option price includes a fair market value component that is determined by an appraisal process.
(2)
Includes properties with stated purchase prices or prices based on fixed capitalization rates. These properties have purchase prices that are on average 17% greater than the Company's current gross investment.

Non-GAAP Financial Measures and Key Performance Indicators
Management believes that net income, as defined by GAAP, is the most appropriate earnings measurement. However, management considers certain non-GAAP financial measures and key performance indicators to be useful supplemental measures of the Company's operating performance. A non-GAAP financial measure is generally defined as one that purports to measure historical or future financial performance, financial position or cash flows, but excludes or includes amounts that would not be so adjusted in the most comparable GAAP measure. Set forth below are descriptions of the non-GAAP financial measures and key performance indicators management considers relevant to the Company's business and useful to investors, as well as reconciliations of these measures to the most directly comparable GAAP financial measures.

The non-GAAP financial measures and key performance indicators presented herein are not necessarily identical to those presented by other real estate companies due to the fact that not all real estate companies use the same definitions. These measures should not be considered as alternatives to net income (determined in accordance with GAAP), as indicators of the Company's financial performance, or as alternatives to cash flow from operating activities (determined in accordance with GAAP) as measures of the Company's liquidity, nor are these measures necessarily indicative of sufficient cash flow to fund all of the Company's needs. Management believes that in order to facilitate a clear understanding of the Company's consolidated historical operating results, these measures should be examined in conjunction with net income as presented in the Condensed Consolidated Financial Statements and other financial data included elsewhere in this report.

Funds from Operations ("FFO"), Normalized FFO and Funds Available for Distribution ("FAD")
FFO and FFO per share are operating performance measures adopted by the National Association of Real Estate Investment Trusts (“NAREIT”). NAREIT defines FFO as the most commonly accepted and reported measure of a REIT’s operating performance equal to “net income (computed in accordance with GAAP), excluding gains (or losses) from sales of property, plus depreciation and amortization related to real estate properties, leasing commission amortization and after adjustments for unconsolidated partnerships and joint ventures.” The Company follows the NAREIT definition in calculating and presenting FFO and FFO per share.


20


Management believes FFO and FFO per share to be supplemental measures of a REIT’s performance because they provide an understanding of the operating performance of the Company’s properties without giving effect to certain significant non-cash items, primarily depreciation and amortization expense. Historical cost accounting for real estate assets in accordance with GAAP assumes that the value of real estate assets diminishes predictably over time. However, real estate values instead have historically risen or fallen with market conditions. The Company believes that by excluding the effect of depreciation, amortization and gains or losses from sales of real estate, all of which are based on historical costs and which may be of limited relevance in evaluating current performance, FFO and FFO per share can facilitate comparisons of operating performance between periods. The Company reports FFO and FFO per share because these measures are observed by management to also be the predominant measures used by the REIT industry and by industry analysts to evaluate REITs and because FFO per share is consistently reported, discussed, and compared by research analysts in their notes and publications about REITs. For these reasons, management has deemed it appropriate to disclose and discuss FFO and FFO per share. However, FFO does not represent cash generated from operating activities determined in accordance with GAAP and is not necessarily indicative of cash available to fund cash needs. FFO should not be considered as an alternative to net income attributable to common stockholders as an indicator of the Company’s operating performance or as an alternative to cash flow from operating activities as a measure of liquidity.
In addition to FFO and FFO per share, the Company presents Normalized FFO, Normalized FFO per share, and FAD. Normalized FFO is presented by adding to FFO acquisition-related costs, acceleration of deferred financing costs, debt extinguishment costs and other Company-defined normalizing items to evaluate operating performance. FAD is presented by adding to Normalized FFO non-real estate depreciation and amortization, deferred financing fees amortization, share-based compensation expense and provision for bad debts, net; and subtracting maintenance capital expenditures, including second generation tenant improvements and leasing commissions paid and straight-line rent income, net of expense. The Company's definition of these terms may not be comparable to that of other real estate companies as they may have different methodologies for computing these amounts. Normalized FFO and FAD should not be considered as an alternative to net income as an indicator of the Company's financial performance or to cash flow from operating activities as an indicator of the Company's liquidity. Normalized FFO and FAD should be reviewed in connection with GAAP financial measures.


21


The table below reconciles net income to FFO, Normalized FFO and FAD for the three and nine months ended September 30, 2018 and 2017:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
(Amounts in thousands, except per share data)
2018
 
2017
 
2018
 
2017
Net Income
$
6,548

 
$
3,173

 
$
53,456

 
$
60,243

(Gain) loss on sales of real estate assets
(1,288
)
 
7

 
(30,879
)
 
(39,525
)
Impairment of real estate assets

 
5,059

 

 
5,387

Real estate depreciation and amortization
42,723

 
36,478

 
123,475

 
107,453

Total adjustments
41,435

 
41,544

 
92,596

 
73,315

FFO Attributable to Common Stockholders
$
47,983

 
$
44,717

 
$
146,052

 
$
133,558

Acquisition and pursuit costs (1)
141

 
507

 
538

 
1,878

Revaluation of awards upon retirement
70

 

 
70

 

Forfeited earnest money received

 

 
(466
)
 

Normalized FFO Attributable to Common Stockholders
$
48,194

 
$
45,224

 
$
146,194

 
$
135,436

Non-real estate depreciation and amortization
1,506

 
1,388

 
4,453

 
4,112

Provision for bad debt, net
(62
)
 
4

 
42

 
175

Straight-line rent, net
(413
)
 
(1,156
)
 
(2,426
)
 
(4,374
)
Stock-based compensation
2,605

 
2,429

 
8,020

 
7,496

Total non-cash items
3,636

 
2,665

 
10,089

 
7,409

2nd generation TI
(6,950
)
 
(4,481
)
 
(20,572
)
 
(13,438
)
Leasing commissions paid
(1,139
)
 
(1,826
)
 
(4,937
)
 
(4,394
)
Capital additions
(6,229
)
 
(4,203
)
 
(17,530
)
 
(12,390
)
FAD
$
37,512

 
$
37,379

 
$
113,244

 
$
112,623

FFO per Common Share—Diluted
$
0.39

 
$
0.37

 
$
1.18

 
$
1.14

Normalized FFO per Common Share—Diluted
$
0.39

 
$
0.38

 
$
1.18

 
$
1.16

FFO weighted average common shares outstanding - Diluted (2)
124,192

 
120,081

 
124,051

 
117,109

_____
(1)
Acquisition and pursuit costs include third party and travel costs related to the pursuit of acquisitions and developments.
(2)
Diluted weighted average common shares outstanding for the three and nine months ended September 30, 2018 includes the dilutive effect of nonvested share-based awards outstanding of 839,990 and 715,562, respectively.


Cash Net Operating Income ("NOI") and Same Store Cash NOI
Cash NOI and Same Store Cash NOI are key performance indicators. Management considers these to be supplemental measures that allow investors, analysts and Company management to measure unlevered property-level operating results. The Company defines Cash NOI as rental income and property lease guaranty income less property operating expenses. Cash NOI excludes non-cash items such as above and below market lease intangibles, straight-line rent, lease inducements, lease terminations, tenant improvement amortization and leasing commission amortization. Cash NOI is historical and not necessarily indicative of future results.

Same Store Cash NOI compares Cash NOI for stabilized properties. Stabilized properties are properties that have been included in operations for the duration of the year-over-year comparison period presented and include redevelopment projects. Accordingly, stabilized properties exclude properties that were recently acquired or disposed of, properties classified as held for sale, and development conversions. In addition, the Company excludes properties that meet any of the following Company-defined criteria to be included in the reposition property group:

Properties having less than 60% occupancy that is expected to last at least two quarters;
Properties that experience a loss of occupancy over 30% in a single quarter; or
Properties with negative net operating income that is expected to last at least two quarters.

Any recently acquired property will be included in the same store pool once the Company has owned the property for eight full quarters. Development properties will be included in the same store pool eight full quarters after substantial completion. Any additional square footage created by redevelopment projects at a same store property is included in the same store pool

22


immediately upon completion. Any property included in the reposition property group will be included in the same store analysis once occupancy has increased to 60% or greater with positive net operating income and has remained at that level for eight full quarters.

The following table reflects the Company's same store cash NOI for the three months ended September 30, 2018 and 2017.
 
 
 
 
 
Same Store Cash NOI for the
 
 
 
 
 
Three Months Ended September 30,
(Dollars in thousands)
Number of Properties 
 
Gross Investment at September 30, 2018
 
2018
 
2017
Multi-tenant Properties
145

 
$
2,833,607

 
$
51,508

 
$
49,995

Single-tenant Net Lease Properties
15

 
482,727

 
10,967

 
10,578

Total
160

 
$
3,316,334

 
$
62,475

 
$
60,573


The following tables reconcile net income to same store NOI and the same store property count to the total owned real estate portfolio for the three months ended September 30, 2018 and 2017:
Reconciliation of Same Store Cash NOI:
 
Three Months Ended September 30,
(Dollars in thousands)
2018
 
2017
Net income
$
6,548

 
$
3,173

Other (income) expense
12,135

 
18,819

General and administrative expense
8,504

 
8,021

Depreciation and amortization expense
42,061

 
35,873

Other expenses (1)
1,855

 
1,922

Straight-line rent revenue
(802
)
 
(1,332
)
Other revenue (2)
(1,173
)
 
(1,327
)
Cash NOI
69,128

 
65,149

Cash NOI not included in same store
(6,653
)
 
(4,576
)
Same store cash NOI
$
62,475

 
$
60,573

_____
(1)
Includes acquisition and pursuit costs, bad debt, above and below market ground lease intangible amortization, leasing commission amortization and ground lease straight-line rent expense.
(2)
Includes management fee income, interest, mortgage interest income, above and below market lease intangible amortization, lease inducement amortization, lease terminations and tenant improvement overage amortization.
Reconciliation of Same Store Property Count:
 
Property Count as of September 30, 2018
Same Store Properties
160

Acquisitions
26

Development Conversion
1

Reposition
14

Total Owned Real Estate Properties
201



23


Results of Operations
Three Months Ended September 30, 2018 Compared to Three Months Ended September 30, 2017
The Company’s results of operations for the three months ended September 30, 2018 compared to the same period in 2017 were impacted by acquisitions, developments, dispositions, gains, impairments recorded and capital markets transactions.

Revenues
Total revenues increased $6.4 million, or 6.0%, to approximately $113.5 million for the three months ended September 30, 2018 compared to $107.0 million in the prior year period. This increase is comprised of the following:
 
Three Months Ended September 30,
 
Change
(Dollars in thousands)
2018
 
2017
 
$
 
%
Property operating
$
99,367

 
$
90,935

 
$
8,432

 
9.3
 %
Single-tenant net lease
11,283

 
12,811

 
(1,528
)
 
(11.9
)%
Straight-line rent
802

 
1,332

 
(530
)
 
(39.8
)%
Rental income
111,452

 
105,078

 
6,374

 
6.1
 %
Other operating
2,010

 
1,947

 
63

 
3.2
 %
Total Revenues
$
113,462

 
$
107,025

 
$
6,437

 
6.0
 %

Property operating revenue increased $8.4 million, or 9.3%, from the prior year period primarily as a result of the following activity:

Acquisitions and developments in 2017 and 2018 contributed $7.3 million.
Leasing activity, including contractual rent increases, contributed $1.7 million.
The conversion of one property to single-tenant net lease resulted in a decrease of $0.2 million.
Dispositions in 2017 and 2018 resulted in a decrease of $0.4 million.

Single-tenant net lease revenue decreased $1.5 million, or 11.9%, from the prior year period primarily as a result of the following activity:

Dispositions in 2018 resulted in a decrease of $2.1 million.
Leasing activity including contractual rent increases contributed $0.4 million.
An acquisition in 2017 resulted in an increase of $0.1 million.
The conversion of one property from multi-tenant resulted in an increase of $0.1 million.

Straight-line rent revenue decreased $0.5 million, or 39.8%, from the prior year period primarily as a result of net leasing activity and contractual rent increases of $0.7 million, partially offset by an increase from acquisitions and developments in 2017 and 2018 of $0.2 million.
    
Expenses
Property operating expenses increased $3.5 million, or 8.6%, for the three months ended September 30, 2018 compared to the prior year period primarily as a result of the following activity:

Acquisitions and developments in 2017 and 2018 resulted in an increase of $3.0 million.
Portfolio property tax increases of $0.5 million.
Compensation expense increased $0.3 million.
Dispositions in 2017 and 2018 and resulted in a decrease of $0.3 million.

General and administrative expenses increased approximately $0.5 million, or 6.0%, for the three months ended September 30, 2018 compared to the prior year period primarily as a result of increases in payroll compensation expense of $0.3 million and performance-based compensation expense of $0.2 million.

24


Depreciation and amortization expense increased $6.2 million, or 17.2%, for the three months ended September 30, 2018 compared to the prior year period primarily as a result of the following activity:
Acquisitions and developments in 2017 and 2018 resulted in an increase of $5.2 million.
Various building and tenant improvement expenditures resulted in an increase of $3.0 million.
Dispositions in 2017 and 2018 resulted in a decrease of $0.6 million.
Assets that became fully depreciated resulted in a decrease of $1.4 million.

Other income (expense)
In the third quarter of 2018, the Company recorded a gain of approximately $1.3 million on the sale of a property.
Interest expense decreased $0.6 million, or 4.6%, for the three months ended September 30, 2018 compared to the prior year period. The components of interest expense are as follows:
 
Three Months Ended September 30,
 
Change
(Dollars in thousands)
2018
 
2017
 
$
 
%
Contractual interest
$
13,016

 
$
13,603

 
$
(587
)
 
(4.3
)%
Net discount/premium accretion
8

 
44

 
(36
)
 
(81.8
)%
Deferred financing costs amortization
611

 
615

 
(4
)
 
(0.7
)%
Interest rate swap amortization
42

 
42

 

 
 %
Interest cost capitalization
(213
)
 
(197
)
 
(16
)
 
8.1
 %
Total interest expense
$
13,464

 
$
14,107

 
$
(643
)
 
(4.6
)%

Contractual interest expense decreased $0.6 million, or 4.3%, primarily due to the following activity:
The Company's unsecured senior notes due 2021 ("Senior Notes due 2021") were repaid in the fourth quarter of 2017 and accounted for a decrease of $5.8 million.
The Company's unsecured senior notes due 2028 ("Senior Notes due 2028") were issued in the fourth quarter of 2017 and accounted for an increase of $2.7 million.
The Unsecured Credit Facility balance and interest rate increases accounted for an increase of approximately $1.8 million.
The Company's unsecured term loan due 2022 (the "Unsecured Term Loan") interest rate increase accounted for an increase of $0.3 million.
Mortgage notes assumed upon acquisition of real properties accounted for an increase of $0.4 million.




25


Results of Operations
Nine Months Ended September 30, 2018 Compared to Nine Months Ended September 30, 2017
The Company’s results of operations for the nine months ended September 30, 2018 compared to the same period in 2017 were impacted by acquisitions, developments, dispositions, gains, impairments recorded and capital markets transactions.

Revenues
Total revenues increased $20.2 million, or 6.4%, to approximately $337.2 million for the nine months ended September 30, 2018 compared to $317.0 million in the prior year period. This increase is comprised of the following:
 
Nine Months Ended September 30,
 
Change
(Dollars in thousands)
2018
 
2017
 
$
 
%
Property operating
$
291,079

 
$
266,485

 
$
24,594

 
9.2
 %
Single-tenant net lease
36,569

 
39,819

 
(3,250
)
 
(8.2
)%
Straight-line rent
3,599

 
4,867

 
(1,268
)
 
(26.1
)%
Rental income
331,247

 
311,171

 
20,076

 
6.5
 %
Other operating
5,973

 
5,816

 
157

 
2.7
 %
Total Revenues
$
337,220

 
$
316,987

 
$
20,233

 
6.4
 %

Property operating revenue increased $24.6 million, or 9.2%, from the prior year period primarily as a result of the following activity:

Acquisitions and developments in 2017 and 2018 contributed $20.9 million.
Leasing activity, including contractual rent increases, contributed $5.9 million.
Dispositions in 2017 and 2018 resulted in a decrease of $1.9 million.
The conversion of one property to single-tenant net lease resulted in a decrease of $0.3 million.

Single-tenant net lease revenue decreased $3.3 million, or 8.2%, from the prior year period primarily as a result of the following activity:

Dispositions in 2017 and 2018 resulted in a decrease of $5.1 million.
Acquisitions in 2017 resulted in an increase of $0.5 million.
Leasing activity, including contractual rent increases, contributed $1.1 million.
The conversion of one property from multi-tenant resulted in an increase of $0.2 million.

Straight-line rent revenue decreased $1.3 million, or 26.1%, from the prior year period primarily as a result of the following activity:

Net leasing activity, including contractual rent increases, resulted in a decrease of $1.7 million.
Dispositions in 2017 and 2018 resulted in a decrease of $0.3 million.
Acquisitions and developments in 2017 and 2018 resulted in an increase of $0.7 million.
    
Expenses
Property operating expenses increased $11.0 million, or 9.5%, for the nine months ended September 30, 2018 compared to the prior year period primarily as a result of the following activity:

Acquisitions and developments in 2017 and 2018 resulted in an increase of $8.8 million.
Increases in portfolio operating expenses as follows:
property tax of approximately $1.4 million;
maintenance and repair expense of approximately $0.3 million;
janitorial expense of approximately $0.3 million;

26


compensation-related expenses of approximately $1.0 million; and
other expenses of $0.3 million.
Dispositions in 2017 and 2018 resulted in a decrease of $0.9 million.
Utilities expense decreased $0.2 million.

General and administrative expenses increased approximately $1.3 million, or 5.1%, for the nine months ended September 30, 2018 compared to the prior year period primarily as a result of increases in compensation and other administrative costs.
Depreciation and amortization expense increased $16.6 million, or 15.8%, for the nine months ended September 30, 2018 compared to the prior year period primarily as a result of the following activity:
Acquisitions and developments in 2017 and 2018 resulted in an increase of $14.6 million.
Various building and tenant improvement expenditures resulted in an increase of $8.8 million.
Dispositions in 2017 and 2018 resulted in a decrease of $2.7 million.
Assets that became fully depreciated resulted in a decrease of $4.1 million.

Other income (expense)
For the nine months ended September 30, 2018 the Company recorded gains of approximately $30.9 million on the sale of 13 properties including a gain recognized on the non-monetary exchange in the second quarter of 2018. See Note 2 to the Condensed Consolidated Financial Statements for additional information regarding the non-monetary exchange. For the nine months ended September 30, 2017, the Company recorded gains of approximately $39.5 million on the sale of eight properties and impairment charges of approximately $5.4 million on two properties.
In the first quarter of 2018, the Company recorded $0.5 million of other income related to the termination fee of a purchase and sale agreement. The third quarter of 2017 includes approximately $0.2 million of interest income for restricted cash.
Interest expense decreased $3.5 million, or 8.2%, for the nine months ended September 30, 2018 compared to the prior year period. The components of interest expense are as follows:
 
Nine Months Ended September 30,
 
Change
(Dollars in thousands)
2018
 
2017
 
$
 
%
Contractual interest
$
37,927

 
$
41,259

 
$
(3,332
)
 
(8.1
)%
Net discount/premium accretion
10

 
149

 
(139
)
 
(93.3
)%
Deferred financing costs amortization
1,823

 
1,840

 
(17
)
 
(0.9
)%
Interest rate swap amortization
126

 
127

 
(1
)
 
(0.8
)%
Interest cost capitalization
(684
)
 
(681
)
 
(3
)
 
0.4
 %
Total interest expense
$
39,202

 
$
42,694

 
$
(3,492
)
 
(8.2
)%

Contractual interest expense decreased $3.3 million, or 8.1%, primarily due to the following activity:
The Senior Notes due 2021 were repaid in the fourth quarter of 2017 and accounted for a decrease of $17.3 million.
The Senior Notes due 2028 were issued in the fourth quarter of 2017 and accounted for an increase of $8.2 million.
Unsecured Credit Facility balance and interest rate increases accounted for an increase of approximately $3.6 million.
Unsecured Term Loan interest rate increase accounted for an increase of $1.1 million.
Mortgage notes assumed upon acquisition of real properties accounted for an increase of $1.3 million, offset by Mortgage notes repayments decrease of approximately $0.2 million.



27


Item 3. Quantitative and Qualitative Disclosures about Market Risk
The Company is exposed to market risk in the form of changing interest rates on its debt and mortgage notes. Management uses regular monitoring of market conditions and analysis techniques to manage this risk. During the nine months ended September 30, 2018, there were no material changes in the quantitative and qualitative disclosures about market risks presented in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.

Item 4. Controls and Procedures
Disclosure Controls and Procedures
The Company’s management, with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company’s disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), as of the end of the period covered by this report. Based on this evaluation, the Company’s Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of such period, the Company’s disclosure controls and procedures were effective in recording, processing, summarizing and reporting, on a timely basis, information required to be disclosed by the Company in the reports it files or submits under the Exchange Act.
Changes in Internal Control over Financial Reporting
There have not been any changes in the Company’s internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the fiscal quarter to which this report relates that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.


28


PART II—OTHER INFORMATION

Item 1. Legal Proceedings
The Company is, from time to time, involved in litigation arising in the ordinary course of business. The Company is not aware of any pending or threatened litigation that, if resolved against the Company, would have a material adverse effect on the Company’s consolidated financial position, results of operations or cash flows.

Item 1A. Risk Factors
In addition to the other information set forth in this report, an investor should carefully consider the factors discussed in Part I, “Item 1A. Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, which could materially affect the Company’s business, financial condition or future results. The risks, as described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, are not the only risks facing the Company. Additional risks and uncertainties not currently known to management or that management currently deems immaterial also may materially, adversely affect the Company’s business, financial condition, operating results or cash flows.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

During the three months ended September 30, 2018, the Company withheld shares of Company common stock to satisfy employee tax withholding obligations payable upon the vesting of nonvested stock, as follows:
Period
Total Number of Shares Purchased
Average Price Paid per Share
Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs
Maximum Number of Shares that May Yet Be Purchased Under the Plans or Programs
July 1 - July 31
1,359

$
29.04



August 1 - August 31




September 1 - September 30




Total
1,359

 
 
 

Authorized Repurchases of Equity Securities by the Issuer
On May 1, 2018, the Company’s Board of Directors authorized the repurchase of up to $50 million of outstanding shares of the Company’s common stock either in the open market or through privately negotiated transactions, subject to market conditions, regulatory constraints, and other customary conditions. The Company is not obligated under this authorization to repurchase any specific number of shares. As of the date of this report, the Company has not repurchased any shares of its common stock under this authorization.


29


Item 6. Exhibits
Exhibit
 
Description
 
 
 
 
 
 
 
 
Exhibit 4.1
 
Specimen Stock Certificate (3)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Exhibit 101.INS
 
The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.
 
 
 
Exhibit 101.SCH
 
XBRL Taxonomy Extension Schema Document (furnished electronically herewith)
 
 
 
Exhibit 101.CAL
 
XBRL Taxonomy Extension Calculation Linkbase Document (furnished electronically herewith)
 
 
 
Exhibit 101.LAB
 
XBRL Taxonomy Extension Labels Linkbase Document (furnished electronically herewith)
 
 
 
Exhibit 101.DEF
 
XBRL Taxonomy Extension Definition Linkbase Document (furnished electronically herewith)
 
 
 
Exhibit 101.PRE
 
XBRL Taxonomy Extension Presentation Linkbase Document (furnished electronically herewith)
_______________
(1)
Filed as an exhibit to the Company's Form 8-K filed May 5, 2017 and hereby incorporated by reference.
(2)
Filed as an exhibit to the Company's Form 10-Q for the quarter ended June 30, 2015 and hereby incorporated by reference.
(3)
Filed as an exhibit to the Company’s Registration Statement on Form S-11 (Registration No. 33-60506) filed April 2, 1993 and hereby incorporated by reference.
(4)
Filed as an exhibit to the Company's Form 8-K filed May 17, 2001 and hereby incorporated as reference.
(5)
Filed as an exhibit to the Company's Form 8-K filed March 26, 2013 and hereby incorporated by reference.
(6)
Filed as an exhibit to the Company's Form 8-K filed April 24, 2015 and hereby incorporated by reference.
(7)
Filed as an exhibit to the Company’s Form 8-K filed December 11, 2017 and hereby incorporated by reference.




30



SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
 
HEALTHCARE REALTY TRUST INCORPORATED
 
 
 
 
 
 
By:
/s/ J. CHRISTOPHER DOUGLAS
 
 
 
J. Christopher Douglas
Executive Vice President and Chief Financial Officer
 
 
 
 
Date:
November 1, 2018
 
 



31
EX-31.1 2 hr-2018930xex311.htm EXHIBIT 31.1 Exhibit


CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302

Exhibit 31.1
Healthcare Realty Trust Incorporated
Quarterly Certification
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Todd J. Meredith, certify that:
1.
I have reviewed this quarterly report on Form 10-Q of Healthcare Realty Trust Incorporated;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date:
November 1, 2018
 
 
 
/s/ TODD J. MEREDITH
 
 
Todd J. Meredith
 
 
President and Chief Executive Officer



EX-31.2 3 hr-2018930xex312.htm EXHIBIT 31.2 Exhibit


CERTIFICATION OF THE CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302
Exhibit 31.2
Healthcare Realty Trust Incorporated
Quarterly Certification
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
I, J. Christopher Douglas, certify that:
1.
I have reviewed this quarterly report on Form 10-Q of Healthcare Realty Trust Incorporated;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


 

Date:
November 1, 2018
 
 
 
/s/ J. CHRISTOPHER DOUGLAS
 
 
J. Christopher Douglas
 
 
Executive Vice President and Chief Financial Officer



EX-32 4 hr-2018930xex32.htm EXHIBIT 32 Exhibit


CERTIFICATIONS PURSUANT TO 18 U.S.C. SECTION 1350 SECTION 906
Exhibit 32
Healthcare Realty Trust Incorporated
Certification Pursuant to
18 U.S.C. Section 1350,
as Adopted Pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report of Healthcare Realty Trust Incorporated (the “Company”) on Form 10-Q for the quarter ended September 30, 2018, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Todd J. Meredith, President and Chief Executive Officer of the Company, and I, J. Christopher Douglas, Executive Vice President and Chief Financial Officer of the Company, each certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
1.
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.
Information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



Date:
November 1, 2018
 
 
 
/s/ TODD J. MEREDITH
 
 
Todd J. Meredith
 
 
President and Chief Executive Officer
 
 
 
 
 
/s/ J. CHRISTOPHER DOUGLAS
 
 
J. Christopher Douglas
 
 
Executive Vice President and Chief Financial Officer



EX-101.SCH 5 hr-20180930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2105100 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2405401 - Disclosure - Commitments and Contingencies - Construction Activity (Details) link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1004001 - Statement - Condensed Consolidated Statement of Equity (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Condensed Consolidated Statement of Equity (Unaudited) Statement link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Condensed Consolidated Statements of Income (Unaudited) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Derivative Financial Instruments link:presentationLink link:calculationLink link:definitionLink 2404405 - Disclosure - Derivative Financial Instruments - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - Derivative Financial Instruments - Derivative Instruments Designated as Cash Flow Hedges (Details) link:presentationLink link:calculationLink link:definitionLink 2404404 - Disclosure - Derivative Financial Instruments - Effect of Cash Flow Hedging on AOCI (Details) link:presentationLink link:calculationLink link:definitionLink 2404403 - Disclosure - Derivative Financial Instruments - Fair Value of Derivative Instruments on the Balance Sheet (Details) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Derivative Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Fair Value of Financial Instruments link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - Fair Value of Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - Fair Value of Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - Notes and Bonds Payable link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - Notes and Bonds Payable (Details) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - Notes and Bonds Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Real Estate Investments link:presentationLink link:calculationLink link:definitionLink 2402402 - Disclosure - Real Estate Investments - Acquisitions (Details) link:presentationLink link:calculationLink link:definitionLink 2402404 - Disclosure - Real Estate Investments - Assets Held for Sale (Details) link:presentationLink link:calculationLink link:definitionLink 2402405 - Disclosure - Real Estate Investments - Discontinued Operations and Assets Held for Sale - Balance Sheet (Details) link:presentationLink link:calculationLink link:definitionLink 2402403 - Disclosure - Real Estate Investments - Dispositions (Details) link:presentationLink link:calculationLink link:definitionLink 2302301 - Disclosure - Real Estate Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 2406404 - Disclosure - Stockholders' Equity - Changes in accumulated other comprehensive income (Details) link:presentationLink link:calculationLink link:definitionLink 2406406 - Disclosure - Stockholders' Equity - Computation of basic and diluted earnings (loss) per common share (Details) link:presentationLink link:calculationLink link:definitionLink 2406405 - Disclosure - Stockholders' Equity - Reclassifications out of AOCI (Details) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Stockholders' Equity - Reconciliation of beginning and ending common stock outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - Stockholders' Equity (Stock Transactions - Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2406408 - Disclosure - Stockholders' Equity - Summary of activity under Employee Stock Purchase Plan (Details) link:presentationLink link:calculationLink link:definitionLink 2406407 - Disclosure - Stockholders' Equity - Summary of activity under stock-based incentive plans (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2401403 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 2401406 - Disclosure - Summary of Significant Accounting Policies - Impact of Adoption of New Accounting Standard (Details) link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2401405 - Disclosure - Summary of Significant Accounting Policies - Reclassifications (Details) link:presentationLink link:calculationLink link:definitionLink 2401404 - Disclosure - Summary of Significant Accounting Policies - Revenue Recognition (Details) link:presentationLink link:calculationLink link:definitionLink 2301302 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 hr-20180930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 hr-20180930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 hr-20180930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Derivative Instrument [Axis] Derivative Instrument [Axis] Derivative Contract [Domain] Derivative Contract [Domain] Active Interest Rate Swap Active Interest Rate Swaps [Member] Active Interest Rate Swaps [Member] Settled Interest Rate Swap Settled Interest Rate Swap [Member] Settled Interest Rate Swap [Member] Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Interest rate cash flow hedge gain (loss) to be reclassified to interest expense during the next 12 months Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Equity [Abstract] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Stock Issuance Program [Axis] Stock Issuance Program [Axis] Stock Issuance Program [Axis] Stock Issuance Program [Domain] Stock Issuance Program [Domain] [Domain] for Stock Issuance Program [Axis] At The Market Equity Offering Program At The Market Equity Offering Program [Member] At The Market Equity Offering Program [Member] Class of Stock [Line Items] Class of Stock [Line Items] Issuance of common stock (shares) Stock Issued During Period, Shares, New Issues Number of authorized shares remaining under offering program (shares) Number of Authorized Shares Remaining Under Offering Program Number of Authorized Shares Remaining Under Offering Program Dividends declared per common share, during the period (in dollars per share) Common Stock, Dividends, Per Share, Declared Income Statement [Abstract] REVENUES Revenues [Abstract] Rental income Operating Leases, Income Statement, Lease Revenue Other operating Revenue from Contract with Customer, Excluding Assessed Tax Revenues Revenues EXPENSES Operating Expenses [Abstract] Property operating Direct Costs of Leased and Rented Property or Equipment General and administrative General and Administrative Expense Acquisition and pursuit costs Acquisition Costs, Period Cost Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Bad debts, net of recoveries Provision for Loan and Lease Losses Total Expenses Operating Expenses OTHER INCOME (EXPENSE) Nonoperating Income (Expense) [Abstract] Gain (loss) on sales of real estate assets Gains (Losses) on Sales of Investment Real Estate Interest expense Interest Expense Impairment of real estate assets Impairment of Real Estate Interest and other income, net Other Nonoperating Income Total other income (expense) Nonoperating Income (Expense) NET INCOME Net Income (Loss) Attributable to Parent Basic earnings per common share (in dollars per share) Earnings Per Share, Basic Diluted earnings per common share (in dollars per share) Earnings Per Share, Diluted Weighted average common shares outstanding - basic (in shares) Weighted Average Number of Shares Outstanding, Basic Weighted average common shares outstanding - diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Dividends declared, per common share, during the period (in dollars per share) Business Combinations [Abstract] Number of properties held for sale Number of Properties Held for Sale Number of properties held for sale. Number of properties reclassified to held for sale Number of Properties Reclassified to Held for Sale Number of Properties Reclassified to Held for Sale Gain on disposition of property Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property Number of properties exercising purchase option Number of Properties Exercising Purchase Option Number of Properties Exercising Purchase Option Number of single-tenant net leased buildings Number of Single-tenant Net Leased Buildings Number of Single-tenant Net Leased Buildings Number of multi-tenant buildings Number of Multi-tenant Buildings Number of Multi-tenant Buildings Accounting Policies [Abstract] Schedule of Error Corrections and Prior Period Adjustment Restatement [Table] Schedule of Error Corrections and Prior Period Adjustment Restatement [Table] Restatement [Axis] Restatement [Axis] Restatement [Domain] Restatement [Domain] As Previously Reported Previously Reported [Member] Reclassifications [Line Items] Error Corrections and Prior Period Adjustments Restatement [Line Items] Property operating expense Gain on sales of properties INCOME FROM CONTINUING OPERATIONS Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent Income (loss) from discontinued operations Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of Tax Gain on sales of properties Gain (Loss) on Disposition of Real Estate, Discontinued Operations INCOME (LOSS) FROM DISCONTINUED OPERATIONS Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent Statement of Financial Position [Abstract] Preferred stock, par value (dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, authorized shares Preferred Stock, Shares Authorized Preferred stock, issued shares Preferred Stock, Shares Issued Preferred stock, outstanding shares Preferred Stock, Shares Outstanding Common stock, par value (dollars per share) Common Stock, Par or Stated Value Per Share Common stock, authorized shares Common Stock, Shares Authorized Common stock, issued shares Common Stock, Shares, Issued Common stock, outstanding shares Common Stock, Shares, Outstanding Statement of Cash Flows [Abstract] OPERATING ACTIVITIES Net Cash Provided by (Used in) Operating Activities [Abstract] Net income Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization Other amortization Amortization of Other Deferred Charges Share-based compensation Share-based Compensation Amortization of straight-line rent receivable Straight-line Rent Receivable Straight-line rent receivable. Amortization of straight-line rent liability Straight-line Rent Liability Straight-line rent liability. Gain on sales of real estate assets Gains (Losses) on Sales of Investment Real Estate, Including Discontinued Operation Gains (Losses) on Sales of Investment Real Estate, Including Discontinued Operation Impairment of real estate assets Impairment of Real Estate, Continuing and Discontinued Operations Impairment of Real Estate, Continuing and Discontinued Operations Equity from unconsolidated joint ventures (income) Income (Loss) from Equity Method Investments Distributions from unconsolidated joint ventures Proceeds from Equity Method Investment, Distribution Provision for bad debts, net Provision for Doubtful Accounts Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Other assets Increase (Decrease) in Other Operating Assets Accounts payable and accrued liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Other liabilities Increase (Decrease) in Other Operating Liabilities Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities INVESTING ACTIVITIES Net Cash Provided by (Used in) Investing Activities [Abstract] Acquisitions of real estate Payments to Acquire Real Estate Development of real estate Payments to Develop Real Estate Assets Additional long-lived assets Payments for Capital Improvements Proceeds from sales of real estate Proceeds from Sale of Property Held-for-sale Proceeds from notes receivable repayments Proceeds from Sale and Collection of Notes Receivable Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities FINANCING ACTIVITIES Net Cash Provided by (Used in) Financing Activities [Abstract] Net borrowings (repayments) on unsecured credit facility Proceeds from (Repayments of) Lines of Credit Repayments on notes and bonds payable Repayments of Debt Dividends paid Payments of Ordinary Dividends, Common Stock Net proceeds from issuance of common stock Proceeds from Issuance of Common Stock Common stock redemptions Payments for Repurchase of Common Stock Debt issuance and assumption costs Payments of Debt Issuance Costs Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities Increase in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Cash and cash equivalents at beginning of period Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents at end of period Supplemental Cash Flow Information: Supplemental Cash Flow Information [Abstract] Interest paid Interest Paid, Including Capitalized Interest, Operating and Investing Activities Invoices accrued for construction, tenant improvements and other capitalized costs Capital Expenditures Incurred but Not yet Paid Mortgage notes payable assumed upon acquisition (adjusted to fair value) Notes Assumed Capitalized interest Interest Paid, Capitalized, Investing Activities Debt Disclosure [Abstract] Notes and Bonds Payable Debt Disclosure [Text Block] Fair Value Disclosures [Abstract] Derivative [Table] Derivative [Table] Measurement Basis [Axis] Measurement Basis [Axis] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Portion at Fair Value Measurement [Member] Portion at Fair Value Measurement [Member] Carrying Value Reported Value Measurement [Member] Fair Value Estimate of Fair Value Measurement [Member] Derivative [Line Items] Derivative [Line Items] Notes and bonds payable Debt Instrument, Fair Value Disclosure Disaggregation of revenue Disaggregation of Revenue [Table Text Block] Schedule of reclassifications Schedule of Reclassifications [Table Text Block] Schedule of Reclassifications [Table Text Block] Impact of Adoption of New Accounting Standard Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Interest Expense Interest Expense [Member] Hedging Relationship [Axis] Hedging Relationship [Axis] Hedging Relationship [Domain] Hedging Relationship [Domain] Cash Flow Hedging Cash Flow Hedging [Member] Hedging Designation [Axis] Hedging Designation [Axis] Hedging Designation [Domain] Hedging Designation [Domain] Designated as Hedging Instrument Designated as Hedging Instrument [Member] Interest Rate Products Interest Rate Contract [Member] Settled Interest Rate Swaps Interest Rate Swap [Member] Amount of Gain Recognized in OCI on Derivative Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax Amount of Loss Reclassified from OCI into Income Derivative Instruments, Loss Reclassified from Accumulated OCI into Income, Effective Portion Schedule of Debt Schedule of Debt [Table Text Block] Real Estate Investments Acquisitions and Dispositions [Text Block] Acquisitions and dispositions. Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Interest Rate Swap Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Forward-starting Interest Rate Swaps Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Number of instruments Number of Interest Rate Derivatives Held Period for reclassification out of AOCI Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimate of Time to Transfer Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward] AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] Beginning balance Stockholders' Equity Attributable to Parent Gains arising during the period related to active interest rate swaps OCI, before Reclassifications, Net of Tax, Attributable to Parent Amounts reclassified from accumulated other comprehensive (income) loss Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent Total other comprehensive income Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Ending balance Statement of Comprehensive Income [Abstract] NET INCOME Other comprehensive income: Other Comprehensive Income (Loss), Net of Tax [Abstract] Interest rate swaps: Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax [Abstract] Reclassification adjustments for losses included in net income (interest expense) Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Net of Tax Gains arising during the period on interest rate swaps Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Net of Tax COMPREHENSIVE INCOME Comprehensive Income (Loss), Net of Tax, Attributable to Parent Notional amount Derivative, Notional Amount Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Operating Activities [Axis] Operating Activities [Axis] Operating Activities [Domain] Operating Activities [Domain] Discontinued Operations Discontinued Operations [Member] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Asset Dispositions and Potential Dispositions Assets and Liabilities Related to Held for Sale and Discontinued Operations [Abstract] Assets and liabilities related to held for sale and discontinued operations. Balance Sheet data (as of the period ended): Land Land Buildings, improvements and lease intangibles Investment Building and Building Improvements Personal property Personal Property Personal property. Real estate properties, Total Real Estate Investment Property, at Cost Accumulated depreciation Real Estate Investment Property, Accumulated Depreciation Total real estate properties, net Real Estate Investment Property, Net Other assets, net Other Assets Assets held for sale, net Assets Held-for-sale and Discontinued Operations Net Assets held for sale and discontinued operations, net. Accounts payable and accrued liabilities Disposal Group, Including Discontinued Operation, Accounts Payable and Accrued Liabilities Other liabilities Disposal Group, Including Discontinued Operation, Other Liabilities Liabilities of properties held for sale Disposal Group, Including Discontinued Operation, Liabilities Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block] Schedule of Derivative Instruments in Statement of Financial Position, Fair Value Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss) Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss) [Table Text Block] Derivative Financial Instruments Derivative Instruments and Hedging Activities Disclosure [Text Block] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Common Stock Common Stock [Member] Reconciliation of the beginning and ending common stock outstanding Reconciliation of Beginning and Ending Common Stock Outstanding [Roll Forward] Reconciliation of the beginning and ending common stock outstanding. Balance, beginning of period Issuance of common stock Nonvested share-based awards, net of withheld shares Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Balance, end of period Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] ASSETS Assets [Abstract] Real estate properties: Real Estate Investment Property, Net [Abstract] Construction in progress Development in Process Land held for development Land Available for Development Less accumulated depreciation and amortization Cash and cash equivalents Assets held for sale, net Other assets, net Total assets Assets LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] Liabilities: Liabilities [Abstract] Notes and bonds payable Long-term Debt Accounts payable and accrued liabilities Accounts Payable and Accrued Liabilities Liabilities of properties held for sale Other liabilities Other Liabilities Total liabilities Liabilities Commitments and contingencies Commitments and Contingencies Stockholders' equity: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Preferred stock, $.01 par value per share; 50,000 shares authorized; none issued and outstanding Preferred Stock, Value, Issued Common stock, $.01 par value per share; 300,000 shares authorized; 125,237 and 125,132 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital, Common Stock Accumulated other comprehensive income (loss) Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax Cumulative net income attributable to common stockholders Cumulative Net Income Attributable to Common Stockholders Cumulative net income attributable to common stockholders. Cumulative dividends Cumulative Dividends Total stockholders' equity Total liabilities and stockholders' equity Liabilities and Equity Schedule of Real Estate Dispositions [Table] Schedule of Real Estate Dispositions [Table] Schedule of real estate dispositions. Real Estate Acquisitions and Mortgage Note Financing [Axis] Real Estate Acquisitions and Mortgage Note Financing [Axis] Real Estate Acquisitions and Mortgage Note Financing. Real Estate Acquisitions and Mortgage Note Financing [Domain] Real Estate Acquisitions and Mortgage Note Financing [Domain] Real Estate Acquisitions and Mortgage Note Financing. Real Estate Acquisition Real Estate Acquisitions [Member] Real estate acquisitions. Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Land Held for Development Land Held for Development [Member] Land Held for Development [Member] Real Estate, Type of Property [Axis] Real Estate, Type of Property [Axis] Real Estate [Domain] Real Estate [Domain] Medical Office Building Medical Office Building [Member] Medical Office Building [Member] Garage 812930 Parking Lots and Garages [Member] Real Estate Dispositions and Mortgage Note Repayments [Axis] Real Estate Dispositions and Mortgage Note Repayments [Axis] Real Estate Dispositions and Mortgage Note Repayments [Axis] Real Estate Dispositions and Mortgage Note Repayments [Domain] Real Estate Dispositions and Mortgage Note Repayments [Domain] Real Estate Dispositions and Mortgage Note Repayments [Domain] Real Estate Dispositions Real Estate Dispositions [Member] Real Estate Dispositions [Member] Geographical [Axis] Geographical [Axis] Geographical [Domain] Geographical [Domain] VIRGINIA VIRGINIA MICHIGAN MICHIGAN MISSOURI MISSOURI Real Estate Dispositions [Line Items] Real Estate Dispositions [Line Items] Real estate dispositions. Disposal Date Disposal Date Sales price Disposition Sales Price Disposition Sales Price Net Proceeds Proceeds from Sale of Real Estate Held-for-investment Closing Adjustments Closing Adjustments Disposed Entity Closing Adjustments Disposed Entity, including closing costs and other adjustments to the sales price. Net Real Estate Investment Real Estate Investment Net Disposed of During Period Real estate investment net disposed of during the Period. Real Estate Other Real Estate Other Real estate other. Appraised value of land Appraised Value of Land Appraised Value of Land Gain/(Impairment) Area of land acquired Area of Land Square footage Area Covered Under Real Estate Investment Sold in Measurement Units Area covered under real estate investment sold in measurement units. Forfeited earnest money Earnest Money Deposits Business Overview Nature of Operations [Policy Text Block] Nature Of Operations Policy. Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Use of Estimates in the Condensed Consolidated Financial Statements Use of Estimates, Policy [Policy Text Block] Revenue from Contracts with Customers (Topic 606) Revenue from Contract with Customer [Text Block] New Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Business Overview: Business Overview [Abstract] Business Overview [Abstract] Gross investment amount, total Investment in Real Estate Properties and Mortgage Notes Investment in real estate properties and mortgage notes. Number of real estate properties Number of Real Estate Investments Number of real estate investments. Number of states that the Company owns real estate in, whole units Real Estate Investments Property Owned in Number of States Real estate investments property owned in number of states. Square footage of owned real estate properties Area of Real Estate Property Approximate square feet for which Nationwide property management services provided by company Approximate Square Feet Provided by Company Approximate square feet for which Nationwide property management services provided by company Other assets Other Assets [Member] Asset derivatives Derivative Asset, Fair Value, Gross Asset Statement of Stockholders' Equity [Abstract] Dividend per share to common Stockholders (in dollars per share) Common Stock, Dividends, Per Share, Cash Paid Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Line of Credit Line of Credit [Member] Medium-term Notes Medium-term Notes [Member] Senior Notes Senior Notes [Member] Mortgages Mortgages [Member] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Unsecured Credit Facility Unsecured Credit Facility Due 2020 [Member] Unsecured Credit Facility Due 2020 [Member] Unsecured Term Loan Facility, net of issuance costs (1) Term Loan due 2022 [Member] Term Loan due 2022 [Member] Senior Notes due 2023, net of discount and issuance costs Senior Notes due 2023 [Member] Senior Notes due 2023 [Member] Senior Notes due 2025, net of discount and issuance costs (2) Senior Notes due 2025 [Member] Senior Notes due 2025 [Member] Senior Notes due 2028, net of discount and issuance costs Senior Notes due 2028 [Member] Senior Notes due 2028 [Member] Mortgage notes payable, net of discounts and issuance costs and including premiums Mortgage Notes Payable, Net [Member] Mortgage Notes Payable, Net [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Effective interest rate (percent) Debt Instrument, Interest Rate, Effective Percentage Derivative, fixed interest rate (percent) Derivative, Fixed Interest Rate Basis spread on variable rate (percent) Debt Instrument, Basis Spread on Variable Rate Loss on forward starting interest rate swap agreement recognized in OCI Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, before Tax Reclassification out of Accumulated Other Comprehensive Income [Table] Reclassification out of Accumulated Other Comprehensive Income [Table] Amounts reclassified from accumulated other comprehensive income (loss) related to settled interest rate swaps Amount Reclassified from AOCI for Settled Derivatives Attributable to Parent [Member] Amount Reclassified from AOCI for Settled Derivatives Attributable to Parent [Member] Amounts reclassified from accumulated other comprehensive income (loss) related to current interest rate swaps Amount Reclassified from AOCI for Current Derivatives Attributable to Parent [Member] Amount Reclassified from AOCI for Current Derivatives Attributable to Parent [Member] Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income [Member] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Interest Expense Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Product and Service [Axis] Product and Service [Axis] Product and Service [Domain] Product and Service [Domain] Parking Income Parking Income [Member] Parking Income [Member] Rental Lease Guaranty Rental Lease Guaranty [Member] Rental Lease Guaranty [Member] Management Fee Income Management Fee Income [Member] Management Fee Income [Member] Miscellaneous Miscellaneous [Member] Miscellaneous [Member] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] Stock Incentive Plan Stock Incentive Plan [Member] Stock Incentive Plan [Member] Award Type [Axis] Award Type [Axis] Award Type [Domain] Equity Award [Domain] Restricted Stock Restricted Stock [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Summary of the activity under the incentive plans Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Share-based awards, beginning of period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Granted (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Vested (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Share-based awards, end of period Shares withheld to pay estimated withholding taxes Shares Paid for Tax Withholding for Share Based Compensation Reconciliation of beginning and ending common stock outstanding Reconciliation of Beginning and Ending Common Stock Outstanding [Table Text Block] Reconciliation of beginning and ending common stock outstanding. Schedule of accumulated other comprehensive income (loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Reclassification out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] Earnings (loss) per share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Summary of the activity under the Incentive Plan Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block] Summary of employee stock purchase plan activity Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block] Employee Stock Purchase Plan Employee Stock [Member] Summary of the Employee Stock Purchase Plan activity Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Outstanding and exercisable, beginning of period (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Granted (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Exercised (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Forfeited (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Expired (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Outstanding and exercisable, end of period (shares) Fair value and carrying values for notes and bonds payable, mortgage notes receivable, and notes receivable Fair Value, by Balance Sheet Grouping [Table Text Block] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] WASHINGTON WASHINGTON COLORADO COLORADO OKLAHOMA OKLAHOMA Business Acquisition [Line Items] Business Acquisition [Line Items] Date Acquired Business Acquisition, Effective Date of Acquisition Purchase price Business Combination, Consideration Transferred Mortgage Note Payable Assumed Business Combination, Consideration Transferred, Liabilities Incurred Cash consideration Payments to Acquire Businesses, Gross Real Estate Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Real Property Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Real Property Other Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Fair Value Adjustments and Other Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Fair Value Adjustments and Other Square footage Business Acquisition Purchase Price Allocation Square Footage Business Acquisition Purchase Price Allocation Square Footage. Fair value adjustments Notes Assumed, Unamortized Premium Notes Assumed, Unamortized Premium Number of properties acquired Number of Properties Acquired Number of Properties Acquired Statement [Table] Statement [Table] Additional Paid-in Capital Additional Paid-in Capital [Member] Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Cumulative Net Income Cumulative Net Income [Member] Cumulative Net Income [Member]. Cumulative Dividends Cumulative Dividends [Member] Cumulative Dividends [Member]. Statement [Line Items] Statement [Line Items] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Issuance of common stock Stock Issued During Period, Value, New Issues Common stock redemptions Stock Repurchased and Retired During Period, Value Share-based compensation Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Dividends to common stockholders ($0.90 per share) Dividends, Common Stock, Cash New Accounting Pronouncements or Change in Accounting Principle [Table] New Accounting Pronouncements or Change in Accounting Principle [Table] As Reported New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Revenues Fair Value of Financial Instruments Fair Value Disclosures [Text Block] Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Weighted average Common Shares outstanding Weighted Average Number of Shares Outstanding, Diluted [Abstract] Weighted average Common Shares outstanding Weighted Average Number of Shares Issued, Basic Nonvested shares Weighted Average Number of Shares, Restricted Stock Weighted average Common Shares—Basic Dilutive effect of employee stock purchase plan Incremental Common Shares Attributable to Dilutive Effect of Employee Stock Purchase Plan Incremental common shares attributable to dilutive effect of employee stock purchase plan. Weighted average Common Shares outstanding—Diluted Net Income Dividends paid on nonvested share-based awards Dividends, Share-based Compensation Net income applicable to common stockholders Net Income (Loss) from Continuing Operations Available to Common Stockholders, Basic Net Income (Loss) from Continuing Operations Available to Common Stockholders, Basic Summary of acquisitions Schedule of Business Acquisitions, by Acquisition [Table Text Block] Summary of dispositions Asset Dispositions [Table Text Block] Asset Dispositions. Assets held for sale Disposal Groups, Including Discontinued Operations [Table Text Block] Document and Entity Information [Abstract] Document and Entity Information. Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Document Type Document Type Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Emerging Growth Company Entity Emerging Growth Company Entity Small Business Entity Small Business Other Commitments [Table] Other Commitments [Table] Medical Office Building Expansion Medical Office Building Expansion [Member] Medical Office Building Expansion [Member] NORTH CAROLINA NORTH CAROLINA Other Commitments [Line Items] Other Commitments [Line Items] Approximate Square Feet Total amount funded Construction Activity, Total Amount Funded Construction Activity, Total Amount Funded EX-101.PRE 9 hr-20180930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 10 hr-2018930xsinglesourc_htm.xml IDEA: XBRL DOCUMENT 0000899749 2018-01-01 2018-09-30 0000899749 hr:CumulativeDividendsMember 2018-09-30 0000899749 hr:ActiveInterestRateSwapsMember 2018-09-30 0000899749 hr:MedicalOfficeBuildingExpansionMember stpr:NC 2018-09-30 0000899749 hr:MedicalOfficeBuildingMember stpr:CO 2018-09-30 0000899749 hr:MedicalOfficeBuildingMember stpr:NC 2018-09-30 0000899749 us-gaap:EmployeeStockMember 2017-07-01 2017-09-30 0000899749 us-gaap:EmployeeStockMember 2018-01-01 2018-09-30 0000899749 us-gaap:EmployeeStockMember 2018-07-01 2018-09-30 0000899749 us-gaap:EmployeeStockMember 2016-12-31 0000899749 us-gaap:EmployeeStockMember 2017-01-01 2017-09-30 0000899749 us-gaap:EmployeeStockMember 2018-09-30 0000899749 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000899749 us-gaap:EmployeeStockMember 2018-06-30 0000899749 us-gaap:EmployeeStockMember 2017-09-30 0000899749 us-gaap:EmployeeStockMember 2017-12-31 0000899749 us-gaap:EmployeeStockMember 2017-06-30 0000899749 hr:StockIncentivePlanMember 2018-09-30 0000899749 hr:StockIncentivePlanMember 2018-01-01 2018-09-30 0000899749 hr:StockIncentivePlanMember 2017-01-01 2017-09-30 0000899749 hr:StockIncentivePlanMember 2017-07-01 2017-09-30 0000899749 hr:StockIncentivePlanMember 2017-12-31 0000899749 hr:StockIncentivePlanMember 2017-09-30 0000899749 hr:CumulativeNetIncomeMember 2018-09-30 0000899749 hr:StockIncentivePlanMember 2018-06-30 0000899749 hr:StockIncentivePlanMember 2018-07-01 2018-09-30 0000899749 hr:StockIncentivePlanMember 2016-12-31 0000899749 hr:StockIncentivePlanMember 2017-06-30 0000899749 us-gaap:RestrictedStockMember hr:StockIncentivePlanMember 2017-01-01 2017-09-30 0000899749 us-gaap:SubsequentEventMember hr:AtTheMarketEquityOfferingProgramMember 2018-10-26 0000899749 us-gaap:RestrictedStockMember hr:StockIncentivePlanMember 2018-01-01 2018-09-30 0000899749 us-gaap:SubsequentEventMember 2018-10-30 2018-10-30 0000899749 hr:AtTheMarketEquityOfferingProgramMember 2018-01-01 2018-09-30 0000899749 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-01-01 2018-09-30 0000899749 hr:CumulativeNetIncomeMember 2017-12-31 0000899749 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2017-12-31 0000899749 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-09-30 0000899749 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2017-01-01 2017-09-30 0000899749 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2017-09-30 0000899749 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2016-12-31 0000899749 us-gaap:CommonStockMember 2017-01-01 2017-09-30 0000899749 us-gaap:CommonStockMember 2016-12-31 0000899749 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-09-30 0000899749 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember hr:AmountReclassifiedfromAOCIforSettledDerivativesAttributabletoParentMember 2018-01-01 2018-09-30 0000899749 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember hr:AmountReclassifiedfromAOCIforCurrentDerivativesAttributabletoParentMember 2018-01-01 2018-09-30 0000899749 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-09-30 0000899749 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2017-12-31 0000899749 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2017-12-31 0000899749 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2018-09-30 0000899749 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-09-30 0000899749 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0000899749 hr:CumulativeDividendsMember 2017-12-31 0000899749 us-gaap:CommonStockMember 2018-01-01 2018-09-30 0000899749 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0000899749 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-09-30 0000899749 2018-10-26 0000899749 us-gaap:CommonStockMember 2017-12-31 0000899749 hr:CumulativeNetIncomeMember 2018-01-01 2018-09-30 0000899749 us-gaap:CommonStockMember 2018-09-30 0000899749 2016-12-31 0000899749 2017-09-30 0000899749 hr:ParkingIncomeMember 2018-07-01 2018-09-30 0000899749 hr:MiscellaneousMember 2018-07-01 2018-09-30 0000899749 hr:RentalLeaseGuarantyMember 2018-01-01 2018-09-30 0000899749 hr:ParkingIncomeMember 2018-01-01 2018-09-30 0000899749 hr:ParkingIncomeMember 2017-01-01 2017-09-30 0000899749 2018-09-30 0000899749 hr:ManagementFeeIncomeMember 2017-07-01 2017-09-30 0000899749 hr:RentalLeaseGuarantyMember 2018-07-01 2018-09-30 0000899749 hr:RentalLeaseGuarantyMember 2017-07-01 2017-09-30 0000899749 hr:RentalLeaseGuarantyMember 2017-01-01 2017-09-30 0000899749 hr:MiscellaneousMember 2017-07-01 2017-09-30 0000899749 hr:ManagementFeeIncomeMember 2018-01-01 2018-09-30 0000899749 hr:MiscellaneousMember 2018-01-01 2018-09-30 0000899749 hr:MiscellaneousMember 2017-01-01 2017-09-30 0000899749 hr:ManagementFeeIncomeMember 2017-01-01 2017-09-30 0000899749 hr:ManagementFeeIncomeMember 2018-07-01 2018-09-30 0000899749 2017-12-31 0000899749 hr:ParkingIncomeMember 2017-07-01 2017-09-30 0000899749 srt:ScenarioPreviouslyReportedMember 2017-01-01 2017-09-30 0000899749 srt:ScenarioPreviouslyReportedMember 2017-07-01 2017-09-30 0000899749 2018-01-01 2018-03-31 0000899749 naics:ZZ812930 hr:RealEstateDispositionsMember 2018-06-29 2018-06-29 0000899749 2018-04-26 2018-04-26 0000899749 stpr:CO hr:RealEstateAcquisitionsMember 2018-05-18 2018-05-18 0000899749 hr:RealEstateAcquisitionsMember 2018-01-01 2018-09-30 0000899749 hr:LandHeldForDevelopmentMember hr:RealEstateAcquisitionsMember 2018-06-29 0000899749 2018-06-27 2018-06-27 0000899749 2017-01-01 2017-09-30 0000899749 stpr:MI hr:RealEstateDispositionsMember 2018-06-27 2018-06-27 0000899749 hr:MedicalOfficeBuildingMember hr:RealEstateAcquisitionsMember 2018-06-29 0000899749 naics:ZZ812930 hr:RealEstateDispositionsMember 2018-06-29 0000899749 stpr:MI hr:RealEstateDispositionsMember 2018-06-27 0000899749 us-gaap:SegmentDiscontinuedOperationsMember 2018-09-30 0000899749 us-gaap:SegmentDiscontinuedOperationsMember 2017-12-31 0000899749 stpr:WA hr:RealEstateAcquisitionsMember 2018-05-03 2018-05-03 0000899749 stpr:CO hr:RealEstateAcquisitionsMember 2018-08-24 2018-08-24 0000899749 stpr:CO hr:RealEstateAcquisitionsMember 2018-05-18 0000899749 stpr:WA hr:RealEstateAcquisitionsMember 2018-06-29 0000899749 2018-07-01 2018-09-30 0000899749 stpr:OK hr:RealEstateAcquisitionsMember 2018-05-21 2018-05-21 0000899749 stpr:WA hr:RealEstateAcquisitionsMember 2018-06-29 2018-06-29 0000899749 hr:RealEstateAcquisitionsMember 2018-09-30 0000899749 stpr:WA hr:RealEstateAcquisitionsMember 2018-05-03 0000899749 stpr:OK hr:RealEstateAcquisitionsMember 2018-05-21 0000899749 stpr:CO hr:RealEstateAcquisitionsMember 2018-08-24 0000899749 stpr:VA hr:RealEstateDispositionsMember 2018-04-26 0000899749 stpr:MO hr:RealEstateDispositionsMember 2018-08-30 2018-08-30 0000899749 stpr:MO hr:RealEstateDispositionsMember 2018-08-30 0000899749 stpr:VA hr:RealEstateDispositionsMember 2018-04-26 2018-04-26 0000899749 2017-07-01 2017-09-30 0000899749 hr:RealEstateDispositionsMember 2018-09-30 0000899749 hr:RealEstateDispositionsMember 2018-01-01 2018-09-30 0000899749 hr:SeniorNotesdue2023Member us-gaap:SeniorNotesMember 2018-09-30 0000899749 hr:TermLoandue2022Member us-gaap:MediumTermNotesMember 2018-09-30 0000899749 hr:MortgageNotesPayableNetMember us-gaap:MortgagesMember 2017-12-31 0000899749 hr:SeniorNotesdue2025Member us-gaap:SeniorNotesMember 2018-09-30 0000899749 hr:SeniorNotesdue2028Member us-gaap:SeniorNotesMember 2018-09-30 0000899749 hr:TermLoandue2022Member us-gaap:MediumTermNotesMember 2017-12-31 0000899749 hr:MortgageNotesPayableNetMember us-gaap:MortgagesMember 2018-09-30 0000899749 hr:SeniorNotesdue2025Member us-gaap:SeniorNotesMember 2017-12-31 0000899749 hr:CumulativeDividendsMember 2018-01-01 2018-09-30 0000899749 hr:UnsecuredCreditFacilityDue2020Member us-gaap:LineOfCreditMember 2017-12-31 0000899749 hr:UnsecuredCreditFacilityDue2020Member us-gaap:LineOfCreditMember 2018-09-30 0000899749 hr:SeniorNotesdue2023Member us-gaap:SeniorNotesMember 2017-12-31 0000899749 hr:SeniorNotesdue2028Member us-gaap:SeniorNotesMember 2017-12-31 0000899749 hr:SeniorNotesdue2025Member us-gaap:InterestRateSwapMember us-gaap:SeniorNotesMember 2018-01-01 2018-09-30 0000899749 hr:TermLoandue2022Member us-gaap:InterestRateSwapMember us-gaap:MediumTermNotesMember 2018-09-30 0000899749 hr:TermLoandue2022Member us-gaap:MediumTermNotesMember 2018-01-01 2018-09-30 0000899749 us-gaap:OtherAssetsMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-09-30 0000899749 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-09-30 0000899749 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-09-30 0000899749 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-09-30 0000899749 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2018-01-01 2018-09-30 0000899749 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-01-01 2018-09-30 0000899749 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2017-01-01 2017-09-30 0000899749 us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2017-01-01 2017-09-30 0000899749 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2018-01-01 2018-09-30 0000899749 us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-01-01 2018-09-30 0000899749 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-01-01 2018-09-30 0000899749 us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2018-01-01 2018-09-30 0000899749 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2017-01-01 2017-09-30 0000899749 hr:SettledInterestRateSwapMember 2018-09-30 pure hr:building iso4217:USD shares shares utreg:acre iso4217:USD utreg:sqft hr:state hr:property hr:swap_agreement false --12-31 Q3 2018 2018-09-30 0000899749 false Large Accelerated Filer false 0.90 0.01 0.01 300000000 300000000 125132000 125237000 125132000 125237000 0.0110 0.01 0.01 50000000 50000000 0 0 0 0 10-Q HEALTHCARE REALTY TRUST INCORPORATED 125237283 217322000 201283000 3669852000 3601460000 10454000 10314000 26960000 5458000 24645000 20123000 3949233000 3838638000 989585000 897430000 2959648000 2941208000 10027000 6215000 8826000 33147000 222582000 213015000 3201083000 3193585000 1344759000 1283880000 72927000 70995000 141000 93000 43004000 48734000 1460831000 1403702000 0 0 1252000 1251000 3181263000 3173429000 -473000 1299000 1071804000 1018348000 2514540000 2401846000 1740252000 1789883000 3201083000 3193585000 111452000 105078000 331247000 311171000 2010000 1947000 5973000 5816000 113462000 107025000 337220000 316987000 44135000 40628000 127691000 116663000 8504000 8021000 25977000 24720000 141000 507000 538000 1878000 42061000 35873000 121764000 105148000 -62000 4000 42000 175000 94779000 85033000 276012000 248584000 1288000 -7000 30879000 39525000 13464000 14107000 39202000 42694000 0 5059000 5387000 41000 354000 571000 396000 -12135000 -18819000 -7752000 -8160000 6548000 3173000 53456000 60243000 0.05 0.02 0.42 0.50 0.05 0.02 0.42 0.50 123300000 119098000 123281000 116181000 123352000 119181000 123336000 116277000 0.30 0.30 0.90 0.90 6548000 3173000 53456000 60243000 -95000 -43000 -369000 -127000 374000 1403000 469000 43000 1772000 127000 7017000 3216000 55228000 60370000 1251000 3173429000 -1299000 1018348000 -2401846000 1789883000 464000 464000 719000 719000 1000 8089000 8090000 53456000 53456000 -369000 -369000 1403000 1403000 112694000 112694000 1252000 3181263000 473000 1071804000 -2514540000 1740252000 53456000 60243000 121764000 105148000 2113000 3056000 8090000 7496000 3599000 4867000 1147000 492000 30879000 39525000 5387000 15000 182000 42000 175000 6891000 6037000 5908000 -3301000 -638000 1098000 150680000 129365000 67445000 72934000 21059000 11753000 59802000 52305000 64271000 119425000 8000 15000 -84027000 -17552000 56000000 -107000000 3808000 4654000 112694000 104860000 459000 248384000 2673000 1125000 125000 84000 -62841000 30661000 3812000 142474000 6215000 54507000 10027000 196981000 30463000 42136000 5680000 6842000 7995000 12460000 684000 681000 Business Overview<span style="font-family:inherit;font-size:10pt;">Healthcare Realty Trust Incorporated (the "Company") is a real estate investment trust ("REIT") that owns, leases, manages, acquires, finances, develops and redevelops income-producing real estate properties associated primarily with the delivery of outpatient healthcare services throughout the United States. As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company had gross investments of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$3.9 billion</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;"><span>201</span></span><span style="font-family:inherit;font-size:10pt;"> real estate properties located in </span><span style="font-family:inherit;font-size:10pt;"><span>27</span></span><span style="font-family:inherit;font-size:10pt;"> states totaling approximately </span><span style="font-family:inherit;font-size:10pt;"><span>14.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> square feet. The Company provided leasing and property management services to approximately </span><span style="font-family:inherit;font-size:10pt;"><span>11.1 million</span></span> square feet nationwide. Business Overview<div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Healthcare Realty Trust Incorporated (the "Company") is a real estate investment trust ("REIT") that owns, leases, manages, acquires, finances, develops and redevelops income-producing real estate properties associated primarily with the delivery of outpatient healthcare services throughout the United States. As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company had gross investments of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$3.9 billion</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;"><span>201</span></span><span style="font-family:inherit;font-size:10pt;"> real estate properties located in </span><span style="font-family:inherit;font-size:10pt;"><span>27</span></span><span style="font-family:inherit;font-size:10pt;"> states totaling approximately </span><span style="font-family:inherit;font-size:10pt;"><span>14.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> square feet. The Company provided leasing and property management services to approximately </span><span style="font-family:inherit;font-size:10pt;"><span>11.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> square feet nationwide.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Basis of Presentation</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. They do not include all of the information and footnotes required by GAAP for complete financial statements. However, except as disclosed herein, management believes there has been no material change in the information disclosed in the Notes to the Consolidated Financial Statements included in the Annual Report on Form 10-K for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2017</span><span style="font-family:inherit;font-size:10pt;">. All material intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">This interim financial information should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2017</span><span style="font-family:inherit;font-size:10pt;">. Management believes that all adjustments of a normal, recurring nature considered necessary for a fair presentation have been included. In addition, the interim financial information does not necessarily represent or indicate what the operating results will be for the year ending </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> for many reasons including, but not limited to, acquisitions, dispositions, capital financing transactions, changes in interest rates and the effects of other trends, risks and uncertainties.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Use of Estimates in the Condensed Consolidated Financial Statements</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Preparation of the Condensed Consolidated Financial Statements in accordance with GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Actual results may differ from those estimates.</span></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Revenue from Contracts with Customers (Topic 606)</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recognizes certain revenue under the core principle of Topic 606. This requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Lease revenue is not within the scope of Topic 606. To achieve the core principle, the Company applies the five step model specified in the guidance. See the New Accounting Pronouncements section below for additional information.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue that is accounted for under Topic 606 is segregated on the Company’s Condensed Consolidated Statements of Income in the Other operating line item. This line item includes parking income, rental lease guaranty income, management fee income and other miscellaneous income. Below is a detail of the amounts by category:</span></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Type of Revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Parking income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,752</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,669</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,197</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,907</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Rental lease guaranty</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>168</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>168</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>488</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>545</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Management fee income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>68</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>70</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>205</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>237</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Miscellaneous</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>40</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>83</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>127</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,010</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,947</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,973</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,816</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s three major types of revenue that are accounted for under Topic 606 that are listed above are all accounted for as the performance obligation is satisfied. The performance obligations that are identified for each of these items are satisfied over time and the Company recognizes revenue monthly based on this principle. </span></div><div style="line-height:120%;padding-top:12px;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Reclassifications</span></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;font-size:8pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:8pt;font-style:italic;font-weight:bold;">Condensed Consolidated Statements of Income</span></div><div style="line-height:120%;padding-bottom:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain reclassifications have been made on the Company's Condensed Consolidated Statements of Income. After the adoption of Accounting Standards Update ("ASU") 2014-08, "Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity," the Company's dispositions have not met the updated definition to be reported as discontinued operations. The Company had some residual impact from properties that were identified as discontinued operations prior to the adoption of ASU 2014-08. These amounts are considered immaterial and have been reclassified for the prior year presentation on the Company's Condensed Consolidated Statements of Income.</span></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:39%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Three months ended September 30, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Nine months ended September 30, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">As Previously Reported</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">As Reclassified</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">As Previously Reported</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">As Reclassified</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">EXPENSES</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Property operating expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>40,626</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>40,628</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>116,644</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>116,663</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Bad debt, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>185</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>175</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">OTHER INCOME (EXPENSE)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Gain on sales of properties</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>39,519</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>39,525</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">INCOME FROM CONTINUING OPERATIONS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,165</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,173</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>60,247</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>60,243</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">DISCONTINUED OPERATIONS</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Income (loss) from discontinued operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Gain on sales of properties</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">INCOME (LOSS) FROM DISCONTINUED OPERATIONS</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">New Accounting Pronouncements</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:8pt;font-style:italic;font-weight:bold;">Accounting Standards Update No. 2014-09 and No. 2015-14</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2014, the Financial Accounting Standards Board ("FASB") issued ASU No. 2014-09, "Revenue from Contracts with Customers," a comprehensive new revenue recognition standard that supersedes most existing revenue recognition guidance, including sales of real estate. This standard's core principle is that a company will recognize revenue when it transfers goods or services to customers in amounts that reflect the consideration to which the company expects to be entitled in exchange for those goods and services. However, leasing contracts, representing the major source of the Company's revenues, are not within the scope of the new standard and will continue to be accounted for under other standards.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2015, the FASB issued ASU No. 2015-14, "Revenue from Contracts with Customers (Topic 606); Deferral of the Effective Date." This standard was effective for the Company for annual and interim periods beginning after December 15, 2017 with early adoption permitted only as of annual reporting periods beginning after December 15, 2016, including interim periods within that year. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company adopted this standard by using the full retrospective adoption method beginning on January 1, 2018. The Company's revenue-producing contracts are primarily leases that are not within the scope of this standard. As a result, the adoption of this standard did not have a material impact on the timing and measurement of the Company's leasing revenues. The Company has determined that parking income, rental lease guaranty income and management fee income are within the scope of Topic 606. However, these items were determined to have the same pattern of revenue recognition that the Company</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">had historically recognized. The Company reclassified these amounts along with all other items that are accounted for within the scope of Topic 606 into the Other operating line item on the Company's Condensed Consolidated Statements of Income. This line item historically contained the revenue associated with rental lease guaranty income, management fee income and other non-lease revenue. The Company reclassified parking income from rental income to other operating income.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table represents the impact of the adoption of this standard on the Company's Condensed Consolidated Statements of Income for the three and </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2017</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:97.65625%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:39%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Three months ended September 30, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Nine months ended September 30, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-style:italic;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">As Reported</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">As Reclassified</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">As Reported</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">As Reclassified</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">REVENUES</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Rental income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>106,561</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>105,078</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>315,519</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>311,171</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other operating</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>392</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,947</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,249</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,816</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>106,953</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>107,025</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>316,768</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>316,987</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">OTHER INCOME (EXPENSE)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest and other income, net</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>426</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>354</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>616</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>396</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">NET INCOME</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,173</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,173</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>60,243</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>60,243</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:8pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:8pt;font-style:italic;font-weight:bold;">Accounting Standards Update No. 2016-02, No. 2018-01 and No. 2018-11</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02, "Leases." In January 2018, the FASB issued ASU 2018-01, "Leases - Land Easement Practical Expedient for Transition to Topic 842," and in July 2018, the FASB issued ASU 2018-10, "Codification Improvements to Topic 842, Leases" and ASU 2018-11, "Leases - Targeted Improvements." These accounting standard updates are collectively referred to as "Topic 842." </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Topic 842 provides several practical expedients that the Company expects to elect. These are (a) the package of practical expedients offered that allows an entity not to reassess upon adoption (i) whether an expired or existing contract contains a lease, (ii) lease classification related to expired or existing lease arrangements, and (iii) whether costs incurred on expired or existing leases qualify as initial direct costs, and (b) the practical expedient not to separate certain non-lease components, such as common area maintenance, from the lease component if (i) the timing and pattern of transfer are the same for the non-lease component and associated lease component, and (ii) the lease component would be classified as an operating lease if accounted for separately.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For lessees, the new standard establishes a right-of-use ("ROU") model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with the classification affecting the pattern of expense recognition in the income statement. The Company expects that most of the leases where the Company is the lessee will be recorded on the Company's balance sheet as operating leases. These leases are primarily ground leases, but also include the Company's corporate office lease, management office leases in third party buildings and certain copier and postage machine leases. The impact to the Company's Consolidated Balance Sheets has not yet been determined. The Company is in the process of working with consultants to determine the appropriate discount rate required to calculate the present value of the future lease payments for ground leases that have lease terms longer than typical secured financing allows.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For lessors, the new standard requires a lessor to classify leases as either sales-type, direct-financing or operating. A lease will be treated as a sale if it is considered to transfer control of the underlying asset, to the lessee. A lease will be classified as direct-financing if risks and rewards are conveyed without the transfer of control. Otherwise, the lease is treated as an operating lease. Lessor accounting remains largely unchanged with some exceptions including the concept of separating lease and nonlease components. Nonlease components, such as common area maintenance, will be accounted for under Topic 606 and separated from the lease payments. However, the Company will elect the lessor practical expedient allowing the Company to not separate these components when certain conditions are met. The Company does not expect a material impact from the adoption of Topic 842 related to leases where the Company is the lessor.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The new standard is effective for the Company on January 1, 2019. Topic 842 provides two transition alternatives. The Company expects to choose the optional transition method available to apply the guidance in Accounting Standards Codification Topic 840 in the comparative periods presented in the year Topic 842 is adopted. Topic 842 includes extensive quantitative and qualitative disclosures as compared to Topic 840, Leases, for both lessees and lessors. The Company is continuing to evaluate the impact from the adoption of this new standard on the Consolidated Financial Statements and related notes.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:8pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:8pt;font-style:italic;font-weight:bold;">Accounting Standards Update No. 2016-13</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." This update is intended to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. This update requires that financial statement assets measured at an amortized cost and certain other financial instruments be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. This standard is effective for annual and interim periods beginning after December 15, 2019 with early adoption permitted. The Company is in the initial stages of evaluating the impact from the adoption of this new standard on the Consolidated Financial Statements and related notes.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:8pt;font-style:italic;font-weight:bold;">Accounting Standards Update No. 2017-04</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued ASU 2017-04, "Simplifying the Test for Goodwill Impairment." This update eliminates Step 2 of the goodwill impairment test. As such, an entity will perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize a goodwill impairment charge for the amount by which the reporting unit's carrying amount exceeds its fair value. This standard is effective for the Company for annual and interim periods beginning after December 15, 2019. The Company does not expect a material impact on the Consolidated Financial Statements and related notes from the adoption of this standard.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:8pt;font-style:italic;font-weight:bold;">Accounting Standards Update No. 2017-05</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2017, the FASB issued ASU 2017-05, "Other Income - Gains and Losses from the Derecognition of Nonfinancial Assets." This update defines an in-substance nonfinancial asset, unifies guidance related to partial sales of nonfinancial assets, eliminates rules specifically addressing the sales of real estate, removes exceptions to the financial asset derecognition model and clarifies the accounting for contributions of nonfinancial assets to joint ventures. The Company adopted this standard as of January 1, 2018 on the full retrospective adoption method. The adoption of this standard did not have a material impact to the Consolidated Financial Statements and related notes.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:8pt;font-style:italic;font-weight:bold;">Accounting Standards Update No. 2017-09</span></div>In May 2017, the FASB issued ASU 2017-09, "Compensation - Stock Compensation - Scope of Modification Accounting." This update provides guidance about which changes to the terms and conditions of share-based awards require an entity to apply modification accounting in Topic 718. The Company adopted this standard on January 1, 2018. The adoption of this standard did not have a material impact to the Consolidated Financial Statements and related notes. 3900000000 201 27 14800000 11100000 Basis of Presentation<div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. They do not include all of the information and footnotes required by GAAP for complete financial statements. However, except as disclosed herein, management believes there has been no material change in the information disclosed in the Notes to the Consolidated Financial Statements included in the Annual Report on Form 10-K for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2017</span><span style="font-family:inherit;font-size:10pt;">. All material intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">This interim financial information should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2017</span><span style="font-family:inherit;font-size:10pt;">. Management believes that all adjustments of a normal, recurring nature considered necessary for a fair presentation have been included. In addition, the interim financial information does not necessarily represent or indicate what the operating results will be for the year ending </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span> for many reasons including, but not limited to, acquisitions, dispositions, capital financing transactions, changes in interest rates and the effects of other trends, risks and uncertainties. Use of Estimates in the Condensed Consolidated Financial StatementsPreparation of the Condensed Consolidated Financial Statements in accordance with GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Actual results may differ from those estimates. Revenue from Contracts with Customers (Topic 606)<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recognizes certain revenue under the core principle of Topic 606. This requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Lease revenue is not within the scope of Topic 606. To achieve the core principle, the Company applies the five step model specified in the guidance. See the New Accounting Pronouncements section below for additional information.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue that is accounted for under Topic 606 is segregated on the Company’s Condensed Consolidated Statements of Income in the Other operating line item. This line item includes parking income, rental lease guaranty income, management fee income and other miscellaneous income. Below is a detail of the amounts by category:</span></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Type of Revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Parking income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,752</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,669</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,197</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,907</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Rental lease guaranty</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>168</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>168</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>488</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>545</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Management fee income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>68</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>70</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>205</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>237</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Miscellaneous</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>40</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>83</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>127</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,010</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,947</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,973</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,816</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>The Company’s three major types of revenue that are accounted for under Topic 606 that are listed above are all accounted for as the performance obligation is satisfied. The performance obligations that are identified for each of these items are satisfied over time and the Company recognizes revenue monthly based on this principle. Below is a detail of the amounts by category:<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Type of Revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Parking income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,752</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,669</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,197</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,907</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Rental lease guaranty</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>168</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>168</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>488</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>545</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Management fee income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>68</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>70</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>205</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>237</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Miscellaneous</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>40</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>83</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>127</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,010</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,947</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,973</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,816</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 1752000 1669000 5197000 4907000 168000 168000 488000 545000 68000 70000 205000 237000 22000 40000 83000 127000 2010000 1947000 5973000 5816000 These amounts are considered immaterial and have been reclassified for the prior year presentation on the Company's Condensed Consolidated Statements of Income.<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:39%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Three months ended September 30, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Nine months ended September 30, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">As Previously Reported</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">As Reclassified</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">As Previously Reported</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">As Reclassified</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">EXPENSES</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Property operating expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>40,626</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>40,628</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>116,644</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>116,663</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Bad debt, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>185</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>175</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">OTHER INCOME (EXPENSE)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Gain on sales of properties</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>39,519</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>39,525</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">INCOME FROM CONTINUING OPERATIONS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,165</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,173</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>60,247</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>60,243</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">DISCONTINUED OPERATIONS</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Income (loss) from discontinued operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Gain on sales of properties</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">INCOME (LOSS) FROM DISCONTINUED OPERATIONS</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 40626000 40628000 116644000 116663000 14000 4000 185000 175000 -7000 -7000 39519000 39525000 3165000 3173000 60247000 60243000 8000 0 -9000 0 0 0 5000 0 8000 0 -4000 0 New Accounting Pronouncements<div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:8pt;font-style:italic;font-weight:bold;">Accounting Standards Update No. 2014-09 and No. 2015-14</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2014, the Financial Accounting Standards Board ("FASB") issued ASU No. 2014-09, "Revenue from Contracts with Customers," a comprehensive new revenue recognition standard that supersedes most existing revenue recognition guidance, including sales of real estate. This standard's core principle is that a company will recognize revenue when it transfers goods or services to customers in amounts that reflect the consideration to which the company expects to be entitled in exchange for those goods and services. However, leasing contracts, representing the major source of the Company's revenues, are not within the scope of the new standard and will continue to be accounted for under other standards.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2015, the FASB issued ASU No. 2015-14, "Revenue from Contracts with Customers (Topic 606); Deferral of the Effective Date." This standard was effective for the Company for annual and interim periods beginning after December 15, 2017 with early adoption permitted only as of annual reporting periods beginning after December 15, 2016, including interim periods within that year. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company adopted this standard by using the full retrospective adoption method beginning on January 1, 2018. The Company's revenue-producing contracts are primarily leases that are not within the scope of this standard. As a result, the adoption of this standard did not have a material impact on the timing and measurement of the Company's leasing revenues. The Company has determined that parking income, rental lease guaranty income and management fee income are within the scope of Topic 606. However, these items were determined to have the same pattern of revenue recognition that the Company</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">had historically recognized. The Company reclassified these amounts along with all other items that are accounted for within the scope of Topic 606 into the Other operating line item on the Company's Condensed Consolidated Statements of Income. This line item historically contained the revenue associated with rental lease guaranty income, management fee income and other non-lease revenue. The Company reclassified parking income from rental income to other operating income.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table represents the impact of the adoption of this standard on the Company's Condensed Consolidated Statements of Income for the three and </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2017</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:97.65625%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:39%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Three months ended September 30, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Nine months ended September 30, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-style:italic;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">As Reported</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">As Reclassified</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">As Reported</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">As Reclassified</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">REVENUES</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Rental income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>106,561</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>105,078</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>315,519</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>311,171</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other operating</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>392</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,947</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,249</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,816</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>106,953</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>107,025</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>316,768</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>316,987</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">OTHER INCOME (EXPENSE)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest and other income, net</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>426</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>354</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>616</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>396</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">NET INCOME</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,173</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,173</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>60,243</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>60,243</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:8pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:8pt;font-style:italic;font-weight:bold;">Accounting Standards Update No. 2016-02, No. 2018-01 and No. 2018-11</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02, "Leases." In January 2018, the FASB issued ASU 2018-01, "Leases - Land Easement Practical Expedient for Transition to Topic 842," and in July 2018, the FASB issued ASU 2018-10, "Codification Improvements to Topic 842, Leases" and ASU 2018-11, "Leases - Targeted Improvements." These accounting standard updates are collectively referred to as "Topic 842." </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Topic 842 provides several practical expedients that the Company expects to elect. These are (a) the package of practical expedients offered that allows an entity not to reassess upon adoption (i) whether an expired or existing contract contains a lease, (ii) lease classification related to expired or existing lease arrangements, and (iii) whether costs incurred on expired or existing leases qualify as initial direct costs, and (b) the practical expedient not to separate certain non-lease components, such as common area maintenance, from the lease component if (i) the timing and pattern of transfer are the same for the non-lease component and associated lease component, and (ii) the lease component would be classified as an operating lease if accounted for separately.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For lessees, the new standard establishes a right-of-use ("ROU") model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with the classification affecting the pattern of expense recognition in the income statement. The Company expects that most of the leases where the Company is the lessee will be recorded on the Company's balance sheet as operating leases. These leases are primarily ground leases, but also include the Company's corporate office lease, management office leases in third party buildings and certain copier and postage machine leases. The impact to the Company's Consolidated Balance Sheets has not yet been determined. The Company is in the process of working with consultants to determine the appropriate discount rate required to calculate the present value of the future lease payments for ground leases that have lease terms longer than typical secured financing allows.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For lessors, the new standard requires a lessor to classify leases as either sales-type, direct-financing or operating. A lease will be treated as a sale if it is considered to transfer control of the underlying asset, to the lessee. A lease will be classified as direct-financing if risks and rewards are conveyed without the transfer of control. Otherwise, the lease is treated as an operating lease. Lessor accounting remains largely unchanged with some exceptions including the concept of separating lease and nonlease components. Nonlease components, such as common area maintenance, will be accounted for under Topic 606 and separated from the lease payments. However, the Company will elect the lessor practical expedient allowing the Company to not separate these components when certain conditions are met. The Company does not expect a material impact from the adoption of Topic 842 related to leases where the Company is the lessor.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The new standard is effective for the Company on January 1, 2019. Topic 842 provides two transition alternatives. The Company expects to choose the optional transition method available to apply the guidance in Accounting Standards Codification Topic 840 in the comparative periods presented in the year Topic 842 is adopted. Topic 842 includes extensive quantitative and qualitative disclosures as compared to Topic 840, Leases, for both lessees and lessors. The Company is continuing to evaluate the impact from the adoption of this new standard on the Consolidated Financial Statements and related notes.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:8pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:8pt;font-style:italic;font-weight:bold;">Accounting Standards Update No. 2016-13</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." This update is intended to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. This update requires that financial statement assets measured at an amortized cost and certain other financial instruments be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. This standard is effective for annual and interim periods beginning after December 15, 2019 with early adoption permitted. The Company is in the initial stages of evaluating the impact from the adoption of this new standard on the Consolidated Financial Statements and related notes.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:8pt;font-style:italic;font-weight:bold;">Accounting Standards Update No. 2017-04</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued ASU 2017-04, "Simplifying the Test for Goodwill Impairment." This update eliminates Step 2 of the goodwill impairment test. As such, an entity will perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize a goodwill impairment charge for the amount by which the reporting unit's carrying amount exceeds its fair value. This standard is effective for the Company for annual and interim periods beginning after December 15, 2019. The Company does not expect a material impact on the Consolidated Financial Statements and related notes from the adoption of this standard.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:8pt;font-style:italic;font-weight:bold;">Accounting Standards Update No. 2017-05</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2017, the FASB issued ASU 2017-05, "Other Income - Gains and Losses from the Derecognition of Nonfinancial Assets." This update defines an in-substance nonfinancial asset, unifies guidance related to partial sales of nonfinancial assets, eliminates rules specifically addressing the sales of real estate, removes exceptions to the financial asset derecognition model and clarifies the accounting for contributions of nonfinancial assets to joint ventures. The Company adopted this standard as of January 1, 2018 on the full retrospective adoption method. The adoption of this standard did not have a material impact to the Consolidated Financial Statements and related notes.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:8pt;font-style:italic;font-weight:bold;">Accounting Standards Update No. 2017-09</span></div>In May 2017, the FASB issued ASU 2017-09, "Compensation - Stock Compensation - Scope of Modification Accounting." This update provides guidance about which changes to the terms and conditions of share-based awards require an entity to apply modification accounting in Topic 718. The Company adopted this standard on January 1, 2018. The adoption of this standard did not have a material impact to the Consolidated Financial Statements and related notes. The following table represents the impact of the adoption of this standard on the Company's Condensed Consolidated Statements of Income for the three and <span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2017</span><span style="font-family:inherit;font-size:10pt;">:</span><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:97.65625%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:39%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Three months ended September 30, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Nine months ended September 30, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-style:italic;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">As Reported</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">As Reclassified</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">As Reported</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">As Reclassified</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">REVENUES</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Rental income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>106,561</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>105,078</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>315,519</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>311,171</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other operating</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>392</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,947</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,249</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,816</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>106,953</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>107,025</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>316,768</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>316,987</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">OTHER INCOME (EXPENSE)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest and other income, net</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>426</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>354</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>616</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>396</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">NET INCOME</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,173</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,173</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>60,243</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>60,243</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 106561000 105078000 315519000 311171000 392000 1947000 1249000 5816000 106953000 107025000 316768000 316987000 426000 354000 616000 396000 3173000 3173000 60243000 60243000 Real Estate Investments<div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">2018 Acquisitions</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table details the Company's acquisitions for the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2018</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.4140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="27"/></tr><tr><td style="width:22%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-style:italic;text-decoration:underline;">(Dollars in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Type </span><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Date<br/>Acquired</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Purchase Price</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Mortgage<br/>Notes Payable Assumed </span><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Cash<br/>Consideration</span><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(3)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Real<br/>Estate</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Other </span><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(4) </sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Square<br/>Footage<br/></span><span style="font-family:Arial;font-size:7pt;font-style:italic;">(Unaudited)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Seattle, Washington</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">MOB</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5/4/18</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13,314</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Denver, Colorado </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(5)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">MOB, OFC</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5/18/18</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>25.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(8.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>16.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>25.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>187,861</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Oklahoma City, Oklahoma</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">MOB</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5/21/18</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>11.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>11.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>11.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>82,647</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Seattle, Washington</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">MOB</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6/29/18</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>26.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>26.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>26.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>86,942</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Denver, Colorado</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">MOB</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8/24/18</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>17,084</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>74.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(8.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>66.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>75.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>387,848</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">______</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">MOB = medical office building; OFC = office</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">The mortgage note payable assumed in the acquisition does not reflect the fair value premium totaling </span><span style="font-family:inherit;font-size:9pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:9pt;"> recorded by the Company upon acquisition (included in Other).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">(3)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cash consideration excludes prorations of revenue and expense due to/from seller at the time of the acquisition.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">(4)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Includes other assets acquired, liabilities assumed, intangibles recognized at acquisition and fair value adjustments on debt assumed.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">(5)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Includes </span><span style="font-family:inherit;font-size:9pt;"><span>two</span></span><span style="font-family:inherit;font-size:9pt;"> properties.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">2018 Dispositions</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table details the Company's dispositions for the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2018</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="31"/></tr><tr><td style="width:13%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-style:italic;text-decoration:underline;">(Dollars in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Type </span><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Date<br/>Disposed</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Sales Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Closing Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Net<br/>Proceeds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Net Real<br/>Estate<br/>Investment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Other (including receivables) </span><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Gain</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Square<br/>Footage<br/>(</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Unaudited</span><span style="font-family:Arial;font-size:7pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Virginia </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(3)</sup></span><span style="font-family:Arial;font-size:9pt;"> </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(4)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">MOB, OFC</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4/26/18</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>46.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>46.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>23.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>22.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>460,881</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Michigan </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(3) (5)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">SNF</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6/27/18</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>121,672</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Missouri</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">MOB</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8/30/18</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>70,893</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Total dispositions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>65.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>64.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>34.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>29.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>653,446</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">______</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">MOB = medical office building; OFC = office; SNF = skilled nursing facility</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Includes straight-line rent receivables and leasing commissions.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">(3)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Previously classified as held for sale.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">(4)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Includes </span><span style="font-family:inherit;font-size:9pt;"><span>seven</span></span><span style="font-family:inherit;font-size:9pt;"> properties, comprised of </span><span style="font-family:inherit;font-size:9pt;"><span>five</span></span><span style="font-family:inherit;font-size:9pt;"> single-tenant net lease buildings and </span><span style="font-family:inherit;font-size:9pt;"><span>two</span></span><span style="font-family:inherit;font-size:9pt;"> multi-tenant buildings. These buildings were sold pursuant to the exercise of a fixed-price purchase option.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">(5)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Includes </span><span style="font-family:inherit;font-size:9pt;"><span>five</span></span><span style="font-family:inherit;font-size:9pt;"> skilled nursing facilities. Sales price includes </span><span style="font-family:inherit;font-size:9pt;"><span>$0.5 million</span></span><span style="font-family:inherit;font-size:9pt;"> of forfeited earnest money from a prior terminated transaction.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Non-monetary Exchange</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On June 29, 2018, the Company completed the swap of a non-revenue producing garage that was built by the Company in 2012 located in Denver, Colorado for </span><span style="font-family:inherit;font-size:10pt;"><span>20.5</span></span><span style="font-family:inherit;font-size:10pt;"> acres of land adjacent to the Catholic Health Initiative’s St. Anthony Hospital campus. A portion of this land, approximately </span><span style="font-family:inherit;font-size:10pt;"><span>4.6</span></span><span style="font-family:inherit;font-size:10pt;"> acres, has been allocated to an existing medical office building that was developed by the Company in 2017. This building is located on land previously ground leased from the hospital. The remaining land has been recorded in land held for development. The land acquired was appraised for </span><span style="font-family:inherit;font-size:10pt;"><span>$5.8 million</span></span><span style="font-family:inherit;font-size:10pt;">. The Company had a net investment of </span><span style="font-family:inherit;font-size:10pt;"><span>$3.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> in the parking garage and recognized a gain of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> in connection with this transaction. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Assets Held for Sale</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2017</span><span style="font-family:inherit;font-size:10pt;">, the Company had </span><span style="font-family:inherit;font-size:10pt;"><span>eight</span></span><span style="font-family:inherit;font-size:10pt;"> properties classified as held for sale. The following changes to assets held for sale have occurred during 2018:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company reclassified </span><span style="font-family:inherit;font-size:10pt;"><span>five</span></span><span style="font-family:inherit;font-size:10pt;"> single-tenant net leased properties to held for sale as of March 31, 2018.</span></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In April 2018, the Company sold </span><span style="font-family:inherit;font-size:10pt;"><span>seven</span></span><span style="font-family:inherit;font-size:10pt;"> properties, comprised of </span><span style="font-family:inherit;font-size:10pt;"><span>five</span></span><span style="font-family:inherit;font-size:10pt;"> single-tenant net leased properties and </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> multi-tenanted properties. The Company recognized a gain on disposition of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$22.3 million</span></span><span style="font-family:inherit;font-size:10pt;">. </span></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2018, the Company sold </span><span style="font-family:inherit;font-size:10pt;"><span>five</span></span><span style="font-family:inherit;font-size:10pt;"> single-tenant net leased properties. The Company recognized a gain on disposition of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$5.4 million</span></span><span style="font-family:inherit;font-size:10pt;">. </span></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company had </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> property remaining classified as held for sale.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The table below reflects the assets and liabilities of the properties classified as held for sale as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2017</span><span style="font-family:inherit;font-size:10pt;">:</span></div><span style="font-family:inherit;font-size:10pt;"> </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:75%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-style:italic;">(Dollars in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">September 30, <br/>2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">December 31, <br/>2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Balance Sheet data:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Land</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,125</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,636</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Buildings, improvements and lease intangibles</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18,231</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>63,654</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Personal property</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>82</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>19,356</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>68,372</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Accumulated depreciation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(10,657</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(35,790</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Real estate assets held for sale, net</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8,699</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>32,582</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other assets, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>127</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>565</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Assets held for sale, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8,826</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>33,147</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Accounts payable and accrued liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>119</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>38</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Liabilities of properties held for sale</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>141</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>93</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> The following table details the Company's acquisitions for the <span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2018</span><span style="font-family:inherit;font-size:10pt;">:</span><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.4140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="27"/></tr><tr><td style="width:22%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-style:italic;text-decoration:underline;">(Dollars in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Type </span><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Date<br/>Acquired</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Purchase Price</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Mortgage<br/>Notes Payable Assumed </span><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Cash<br/>Consideration</span><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(3)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Real<br/>Estate</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Other </span><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(4) </sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Square<br/>Footage<br/></span><span style="font-family:Arial;font-size:7pt;font-style:italic;">(Unaudited)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Seattle, Washington</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">MOB</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5/4/18</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13,314</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Denver, Colorado </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(5)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">MOB, OFC</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5/18/18</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>25.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(8.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>16.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>25.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>187,861</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Oklahoma City, Oklahoma</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">MOB</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5/21/18</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>11.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>11.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>11.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>82,647</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Seattle, Washington</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">MOB</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6/29/18</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>26.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>26.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>26.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>86,942</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Denver, Colorado</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">MOB</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8/24/18</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>17,084</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>74.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(8.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>66.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>75.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>387,848</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">______</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">MOB = medical office building; OFC = office</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">The mortgage note payable assumed in the acquisition does not reflect the fair value premium totaling </span><span style="font-family:inherit;font-size:9pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:9pt;"> recorded by the Company upon acquisition (included in Other).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">(3)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cash consideration excludes prorations of revenue and expense due to/from seller at the time of the acquisition.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">(4)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Includes other assets acquired, liabilities assumed, intangibles recognized at acquisition and fair value adjustments on debt assumed.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">(5)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Includes </span><span style="font-family:inherit;font-size:9pt;"><span>two</span></span><span style="font-family:inherit;font-size:9pt;"> properties.</span></div></td></tr></table><br/> 2018-05-04 7800000 0 7800000 7800000 0 13314 2018-05-18 25000000.0 8000000.0 16600000 25100000 -400000 187861 2018-05-21 11400000 0 11400000 11500000 -100000 82647 2018-06-29 26200000 0 26200000 26700000 -500000 86942 2018-08-24 4100000 0 4200000 4200000 0 17084 74500000 8000000.0 66200000 75300000 -1000000.0 387848 100000 2 The following table details the Company's dispositions for the <span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2018</span><span style="font-family:inherit;font-size:10pt;">:</span><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="31"/></tr><tr><td style="width:13%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-style:italic;text-decoration:underline;">(Dollars in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Type </span><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Date<br/>Disposed</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Sales Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Closing Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Net<br/>Proceeds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Net Real<br/>Estate<br/>Investment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Other (including receivables) </span><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Gain</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Square<br/>Footage<br/>(</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Unaudited</span><span style="font-family:Arial;font-size:7pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Virginia </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(3)</sup></span><span style="font-family:Arial;font-size:9pt;"> </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(4)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">MOB, OFC</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4/26/18</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>46.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>46.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>23.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>22.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>460,881</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Michigan </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(3) (5)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">SNF</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6/27/18</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>121,672</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Missouri</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">MOB</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8/30/18</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>70,893</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Total dispositions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>65.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>64.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>34.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>29.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>653,446</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">______</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">MOB = medical office building; OFC = office; SNF = skilled nursing facility</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Includes straight-line rent receivables and leasing commissions.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">(3)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Previously classified as held for sale.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">(4)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Includes </span><span style="font-family:inherit;font-size:9pt;"><span>seven</span></span><span style="font-family:inherit;font-size:9pt;"> properties, comprised of </span><span style="font-family:inherit;font-size:9pt;"><span>five</span></span><span style="font-family:inherit;font-size:9pt;"> single-tenant net lease buildings and </span><span style="font-family:inherit;font-size:9pt;"><span>two</span></span><span style="font-family:inherit;font-size:9pt;"> multi-tenant buildings. These buildings were sold pursuant to the exercise of a fixed-price purchase option.</span></div></td></tr></table><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">(5)</span></div><span style="font-family:inherit;font-size:9pt;">Includes </span><span style="font-family:inherit;font-size:9pt;"><span>five</span></span><span style="font-family:inherit;font-size:9pt;"> skilled nursing facilities. Sales price includes </span><span style="font-family:inherit;font-size:9pt;"><span>$0.5 million</span></span> of forfeited earnest money from a prior terminated transaction. 2018-04-26 46200000 0 46200000 23900000 0 22300000 460881 2018-06-27 9500000 700000 8800000 3400000 0 5400000 121672 2018-08-30 9800000 500000 9300000 7500000 500000 1300000 70893 65500000 1200000 64300000 34800000 500000 29000000.0 653446 7 5 2 5 500000 20.5 4.6 5800000 3900000 1900000 8 5 7 5 2 22300000 5 5400000 1 The table below reflects the assets and liabilities of the properties classified as held for sale as of <span style="font-family:inherit;font-size:10pt;">September 30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2017</span><span style="font-family:inherit;font-size:10pt;">:</span><span style="font-family:inherit;font-size:10pt;"> </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:75%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-style:italic;">(Dollars in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">September 30, <br/>2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">December 31, <br/>2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Balance Sheet data:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Land</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,125</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,636</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Buildings, improvements and lease intangibles</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18,231</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>63,654</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Personal property</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>82</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>19,356</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>68,372</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Accumulated depreciation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(10,657</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(35,790</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Real estate assets held for sale, net</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8,699</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>32,582</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other assets, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>127</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>565</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Assets held for sale, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8,826</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>33,147</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Accounts payable and accrued liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>119</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>38</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Liabilities of properties held for sale</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>141</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>93</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 1125000 4636000 18231000 63654000 0 82000 19356000 68372000 10657000 35790000 8699000 32582000 127000 565000 8826000 33147000 119000 38000 22000 55000 141000 93000 Notes and Bonds Payable<div style="line-height:120%;padding-top:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The table below details the Company’s notes and bonds payable.</span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:38%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"> </span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Maturity</span></div><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Dates</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Balance as of</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Effective Interest Rate as of </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-style:italic;text-decoration:underline;">(Dollars in thousands)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">September 30, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">December 31, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">September 30, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Unsecured Credit Facility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">7/20</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>245,000</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>189,000</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.26</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Unsecured Term Loan Facility, net of issuance costs </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">12/22</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>149,132</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>148,994</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.41</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Senior Notes due 2023, net of discount and issuance costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">4/23</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>248,013</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>247,703</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.95</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Senior Notes due 2025, net of discount and issuance costs </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">5/25</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>248,219</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>248,044</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.08</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Senior Notes due 2028, net of discount and issuance costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">1/28</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>295,087</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>294,757</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.84</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Mortgage notes payable, net of discounts and issuance costs and including premiums</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">12/18-5/40</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>159,308</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>155,382</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.83</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,344,759</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,283,880</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">______</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The effective interest rate includes the impact of interest rate swaps on </span><span style="font-family:inherit;font-size:8pt;"><span>$25.0 million</span></span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;"><span>$50.0 million</span></span><span style="font-family:inherit;font-size:8pt;"> of the outstanding balance at a rate of </span><span style="font-family:inherit;font-size:8pt;"><span>2.18%</span></span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;"><span>2.46%</span></span><span style="font-family:inherit;font-size:8pt;">, respectively (plus the applicable margin rate, currently 110 basis points).</span></div></td></tr></table><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;">(2)</span></div><span style="font-family:inherit;font-size:8pt;">The effective interest rate includes the impact of the </span><span style="font-family:inherit;font-size:8pt;"><span>$1.7 million</span></span> settlement of a forward-starting interest rate swap that is included in Accumulated other comprehensive income (loss) on the Company's Condensed Consolidated Balance Sheets. The table below details the Company’s notes and bonds payable.<span style="font-family:inherit;font-size:9pt;"> </span><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:38%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"> </span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Maturity</span></div><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Dates</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Balance as of</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Effective Interest Rate as of </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-style:italic;text-decoration:underline;">(Dollars in thousands)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">September 30, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">December 31, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">September 30, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Unsecured Credit Facility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">7/20</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>245,000</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>189,000</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.26</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Unsecured Term Loan Facility, net of issuance costs </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">12/22</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>149,132</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>148,994</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.41</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Senior Notes due 2023, net of discount and issuance costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">4/23</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>248,013</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>247,703</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.95</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Senior Notes due 2025, net of discount and issuance costs </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">5/25</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>248,219</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>248,044</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.08</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Senior Notes due 2028, net of discount and issuance costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">1/28</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>295,087</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>294,757</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3.84</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Mortgage notes payable, net of discounts and issuance costs and including premiums</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">12/18-5/40</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>159,308</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>155,382</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.83</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,344,759</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,283,880</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">______</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The effective interest rate includes the impact of interest rate swaps on </span><span style="font-family:inherit;font-size:8pt;"><span>$25.0 million</span></span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;"><span>$50.0 million</span></span><span style="font-family:inherit;font-size:8pt;"> of the outstanding balance at a rate of </span><span style="font-family:inherit;font-size:8pt;"><span>2.18%</span></span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;"><span>2.46%</span></span><span style="font-family:inherit;font-size:8pt;">, respectively (plus the applicable margin rate, currently 110 basis points).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The effective interest rate includes the impact of the </span><span style="font-family:inherit;font-size:8pt;"><span>$1.7 million</span></span><span style="font-family:inherit;font-size:8pt;"> settlement of a forward-starting interest rate swap that is included in Accumulated other comprehensive income (loss) on the Company's Condensed Consolidated Balance Sheets. </span></div></td></tr></table><br/> 245000000 189000000 0.0326 149132000 148994000 0.0341 248013000 247703000 0.0395 248219000 248044000 0.0408 295087000 294757000 0.0384 159308000 155382000 0.0483 1344759000 1283880000 25000000.0 50000000.0 0.0218 0.0246 1700000 Derivative Financial Instruments<div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Risk Management Objective of Using Derivatives</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company principally manages its exposures to a wide variety of business and operational risks through management of its core business activities. The Company manages economic risks, including interest rate, liquidity, and credit risk, primarily by managing the amount, sources, and duration of its assets and liabilities and the use of derivative financial instruments. Specifically, the Company enters into derivative financial instruments to manage exposures that arise from business activities that result in the</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">receipt or payment of future known and uncertain cash amounts, the value of which are determined by interest rates. The Company’s derivative financial instruments are used to manage differences in the amount, timing, and duration of the Company’s known or expected cash receipts and its known or expected cash payments principally related to the Company’s borrowings.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Cash Flow Hedges of Interest Rate Risk</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish this objective, the Company primarily uses interest rate swaps as part of its interest rate risk management strategy. Interest rate swaps designated as cash flow hedges involve the receipt of variable amounts from a counterparty in exchange for the Company making fixed-rate payments over the life of the agreements without exchange of the underlying notional amount. Such derivatives were used to hedge the variable cash flows associated with existing variable-rate debt.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For derivatives designated and that qualify as cash flow hedges of interest rate risk, the gain or loss on the derivative is recorded in Accumulated other comprehensive income (loss) and subsequently reclassified into interest expense in the same period(s) during which the hedged transaction affects earnings. Amounts reported in Accumulated other comprehensive income (loss) related to derivatives will be reclassified to interest expense as interest payments are made on the Company’s variable-rate debt. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company had </span><span style="font-family:inherit;font-size:10pt;"><span>four</span></span><span style="font-family:inherit;font-size:10pt;"> outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Derivative Instrument</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Number of Instruments</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Notional Amount</span></div><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest rate swaps</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$75.0</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Tabular Disclosure of Fair Values of Derivative Instruments on the Balance Sheet</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The table below presents the fair value of the Company's derivative financial instruments, as well as their classification on the Condensed Consolidated Balance Sheet as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:59%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Asset Derivatives</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Balance at September 30, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-style:italic;">(Dollars in thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Balance Sheet Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Derivatives designated as hedging instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest rate swaps</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,579</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total derivatives designated as hedging instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,579</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Tabular Disclosure of the Effect of Cash Flow Hedge Accounting on Accumulated Other Comprehensive Income (Loss)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The table below presents the effect of cash flow hedge accounting on Accumulated Other Comprehensive Income (Loss) ("OCI") during the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and 2017 related to the Company's outstanding interest rate swaps.</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:27%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Amount of Gain Recognized in OCI on Derivative</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Amount of Loss Reclassified from OCI into Income</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-style:italic;">(Dollars in thousands)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest rate products</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,403</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>243</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Settled interest rate swaps</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>126</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>127</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,403</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total interest expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>369</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>127</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Credit-risk-related Contingent Features</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's agreements with each of its derivative counterparties contain a cross-default provision under which the Company could be declared in default of its derivative obligations if repayment of the underlying indebtedness is accelerated by the lender due to the Company's default on the indebtedness.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">The Company estimates that </span><span style="font-family:inherit;font-size:10pt;"><span>$0.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> related to active interest rate swaps will be reclassified from OCI as a decrease to interest expense over the next 12 months, and that </span><span style="font-family:inherit;font-size:10pt;"><span>$0.2 million</span></span> related to settled interest rate swaps will be amortized from OCI as an increase to interest expense over the next 12 months. As of <span style="font-family:inherit;font-size:10pt;">September 30, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company had </span><span style="font-family:inherit;font-size:10pt;"><span>four</span></span><span style="font-family:inherit;font-size:10pt;"> outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Derivative Instrument</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Number of Instruments</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Notional Amount</span></div><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest rate swaps</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$75.0</span></span></div></td></tr></table></div> 4 4 75000000.0 The table below presents the fair value of the Company's derivative financial instruments, as well as their classification on the Condensed Consolidated Balance Sheet as of <span style="font-family:inherit;font-size:10pt;">September 30, 2018</span><span style="font-family:inherit;font-size:10pt;">.</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:59%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Asset Derivatives</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Balance at September 30, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-style:italic;">(Dollars in thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Balance Sheet Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Derivatives designated as hedging instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest rate swaps</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,579</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total derivatives designated as hedging instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,579</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 1579000 1579000 The table below presents the effect of cash flow hedge accounting on Accumulated Other Comprehensive Income (Loss) ("OCI") during the <span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and 2017 related to the Company's outstanding interest rate swaps.</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:27%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Amount of Gain Recognized in OCI on Derivative</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Amount of Loss Reclassified from OCI into Income</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-style:italic;">(Dollars in thousands)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest rate products</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,403</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>243</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Settled interest rate swaps</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>126</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>127</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,403</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total interest expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>369</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>127</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><br/> 1403000 243000 0 0 126000 127000 1403000 369000 127000 200000 -200000 Commitments and Contingencies<div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Legal Proceedings</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is, from time to time, involved in litigation arising in the ordinary course of business. The Company is not aware of any pending or threatened litigation that, if resolved against the Company, would have a material adverse effect on the Company’s consolidated financial position, results of operations or cash flows.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Redevelopment Activity</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is redeveloping a medical office building in Charlotte, North Carolina, which includes a </span><span style="font-family:inherit;font-size:10pt;"><span>38,000</span></span><span style="font-family:inherit;font-size:10pt;"> square foot vertical expansion. As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company has funded approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$9.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> on the redevelopment of this property. The project is expected to be completed in the first quarter of 2019.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Development Activity</span></div><span style="font-family:inherit;font-size:10pt;">The Company began the development of a </span><span style="font-family:inherit;font-size:10pt;"><span>151,000</span></span><span style="font-family:inherit;font-size:10pt;"> square foot medical office building in Seattle, Washington during 2017. As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company has funded approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$18.0 million</span></span> on the development. The Company expects the project to be completed in the second quarter of 2019. 38000 9200000 151000 18000000.0 Stockholders' Equity<div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Common Stock    </span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides a reconciliation of the beginning and ending shares of common stock outstanding for the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2017</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:69%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">September 30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Balance, beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>125,131,593</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>116,416,900</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Issuance of common stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>20,395</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8,395,607</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Nonvested share-based awards, net of withheld shares</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>85,196</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>319,086</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Balance, end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>125,237,184</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>125,131,593</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">At-The-Market Equity Offering Program</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>No</span></span><span style="font-family:inherit;font-size:10pt;"> shares were sold under the Company's At-the-Market Equity Offering Program during the nine months ended September 30, 2018. The Company had </span><span style="font-family:inherit;font-size:10pt;"><span>5,868,697</span></span><span style="font-family:inherit;font-size:10pt;"> authorized shares remaining available to be sold under the current sales agreements as of </span><span style="font-family:inherit;font-size:10pt;">October 26, 2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Common Stock Dividends</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company declared and paid common stock dividends totaling </span><span style="font-family:inherit;font-size:10pt;"><span>$0.90</span></span><span style="font-family:inherit;font-size:10pt;"> per share. On </span><span style="font-family:inherit;font-size:10pt;">October 30, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company declared a quarterly common stock dividend in the amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.30</span></span><span style="font-family:inherit;font-size:10pt;"> per share payable on </span><span style="font-family:inherit;font-size:10pt;">November 30, 2018</span><span style="font-family:inherit;font-size:10pt;"> to stockholders of record on</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;">November 15, 2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Accumulated Other Comprehensive Income (Loss)</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of September 30, 2018, the Company had </span><span style="font-family:inherit;font-size:10pt;"><span>four</span></span><span style="font-family:inherit;font-size:10pt;"> outstanding interest rate swaps to hedge the variable cash flows associated with existing variable-rate debt. The Company continues to amortize the 2015 settlement of forward-starting interest rate swaps that were entered into in connection with the issuance of the Company's Senior Notes due 2025. This amount will be reclassified out of OCI impacting net income over the </span><span style="font-family:inherit;font-size:10pt;"><span>10</span></span><span style="font-family:inherit;font-size:10pt;">-year term of the associated senior note issuance. See Note 4 for more information regarding the Company's derivative instruments. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table represents the changes in balances of each component and the amounts reclassified out of OCI related to the Company during the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:72%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Forward-starting Interest Rate Swaps</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-style:italic;">(Dollars in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Beginning balance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,299</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,401</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Gains arising during the period related to active interest rate swaps</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,403</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Amounts reclassified from accumulated other comprehensive (income) loss</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>369</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>127</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net accumulated other comprehensive income</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,772</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>127</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Ending balance</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>473</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,274</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table represents the details regarding the reclassifications from OCI during the nine months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2018</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:54%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:23%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Details about accumulated other comprehensive income (loss) components</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Amount reclassified from accumulated other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Affected line item in the statement where net income is presented</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">(Dollars in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Amounts reclassified from accumulated other comprehensive income (loss) related to settled interest rate swaps</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>126</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest Expense</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Amounts reclassified from accumulated other comprehensive income (loss) related to current interest rate swaps</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>243</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest Expense</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>369</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Earnings Per Common Share</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company uses the two-class method of computing net earnings per common shares. The Company's nonvested share-based awards are considered participating securities pursuant to the two-class method. The following table sets forth the computation of basic and diluted earnings per common share for the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.4609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:47%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-style:italic;">(Dollars in thousands, except per share data)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Weighted average Common Shares outstanding</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted average Common Shares outstanding</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>125,233,462</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>120,895,835</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>125,206,342</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>117,981,159</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Nonvested shares</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,933,653</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,797,686</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,925,589</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,800,180</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted average Common Shares outstanding—Basic</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>123,299,809</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>119,098,149</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>123,280,753</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>116,180,979</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted average Common Shares outstanding—Basic</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>123,299,809</span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>119,098,149</span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>123,280,753</span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>116,180,979</span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Dilutive effect of employee stock purchase plan</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>52,147</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>83,242</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>54,763</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>96,260</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted average Common Shares outstanding—Diluted</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>123,351,956</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>119,181,391</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>123,335,516</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>116,277,239</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Net Income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6,548</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,173</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>53,456</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>60,243</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Dividends paid on nonvested share-based awards</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(580</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(538</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,740</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,609</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net income applicable to common stockholders</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,968</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,635</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>51,716</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>58,634</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Basic earnings per common share - Net income </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.05</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.02</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.42</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.50</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Diluted earnings per common share - Net income </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.05</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.02</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.42</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.50</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:9pt;font-weight:bold;">Incentive Plans</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A summary of the activity under the Company's share-based incentive plans for the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> is included in the table below.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:41%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Share-based awards, beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,938,100</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,797,686</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,907,645</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,786,497</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>107,751</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>103,615</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Vested</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(5,051</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(82,347</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(92,426</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Share-based awards, end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,933,049</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,797,686</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,933,049</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,797,686</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, the Company withheld </span><span style="font-family:inherit;font-size:10pt;"><span>22,555</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>16,581</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock, respectively, from participants to pay estimated withholding taxes related to shares that vested. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to the share-based incentive plans, the Company maintains the 2000 Employee Stock Purchase Plan (the "Purchase Plan"). A summary of the activity under the Purchase Plan for the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> is included in the table below.</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:41%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Outstanding and exercisable, beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>350,535</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>344,572</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>318,100</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>316,321</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>203,836</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>206,824</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Exercised</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(2,531</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(5,452</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(13,236</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(24,482</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(9,583</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(9,291</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(34,489</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(36,524</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Expired</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(135,790</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(132,310</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Outstanding and exercisable, end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>338,421</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>329,829</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>338,421</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>329,829</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> The following table provides a reconciliation of the beginning and ending shares of common stock outstanding for the <span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2017</span><span style="font-family:inherit;font-size:10pt;">:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:69%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">September 30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Balance, beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>125,131,593</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>116,416,900</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Issuance of common stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>20,395</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8,395,607</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Nonvested share-based awards, net of withheld shares</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>85,196</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>319,086</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Balance, end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>125,237,184</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>125,131,593</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 125131593 116416900 20395 8395607 85196 319086 125237184 125131593 0 5868697 0.90 0.30 4 P10Y The following table represents the changes in balances of each component and the amounts reclassified out of OCI related to the Company during the <span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:72%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Forward-starting Interest Rate Swaps</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-style:italic;">(Dollars in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Beginning balance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,299</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,401</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Gains arising during the period related to active interest rate swaps</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,403</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Amounts reclassified from accumulated other comprehensive (income) loss</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>369</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>127</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net accumulated other comprehensive income</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,772</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>127</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Ending balance</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>473</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,274</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div> -1299000 -1401000 1403000 0 -369000 -127000 1772000 127000 473000 -1274000 The following table represents the details regarding the reclassifications from OCI during the nine months ended <span style="font-family:inherit;font-size:10pt;">September 30, 2018</span><span style="font-family:inherit;font-size:10pt;">:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:54%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:23%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Details about accumulated other comprehensive income (loss) components</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Amount reclassified from accumulated other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Affected line item in the statement where net income is presented</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">(Dollars in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Amounts reclassified from accumulated other comprehensive income (loss) related to settled interest rate swaps</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>126</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest Expense</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Amounts reclassified from accumulated other comprehensive income (loss) related to current interest rate swaps</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>243</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest Expense</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>369</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div> 126000 243000 369000 The following table sets forth the computation of basic and diluted earnings per common share for the <span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">.</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.4609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:47%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-style:italic;">(Dollars in thousands, except per share data)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Weighted average Common Shares outstanding</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted average Common Shares outstanding</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>125,233,462</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>120,895,835</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>125,206,342</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>117,981,159</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Nonvested shares</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,933,653</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,797,686</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,925,589</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,800,180</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted average Common Shares outstanding—Basic</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>123,299,809</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>119,098,149</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>123,280,753</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>116,180,979</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted average Common Shares outstanding—Basic</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>123,299,809</span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>119,098,149</span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>123,280,753</span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>116,180,979</span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Dilutive effect of employee stock purchase plan</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>52,147</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>83,242</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>54,763</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>96,260</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted average Common Shares outstanding—Diluted</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>123,351,956</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>119,181,391</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>123,335,516</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>116,277,239</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Net Income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6,548</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,173</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>53,456</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>60,243</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Dividends paid on nonvested share-based awards</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(580</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(538</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,740</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,609</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net income applicable to common stockholders</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,968</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,635</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>51,716</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>58,634</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Basic earnings per common share - Net income </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.05</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.02</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.42</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.50</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Diluted earnings per common share - Net income </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.05</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.02</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.42</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.50</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 125233462 120895835 125206342 117981159 1933653 1797686 1925589 1800180 123299809 119098149 123280753 116180979 123299809 119098149 123280753 116180979 52147 83242 54763 96260 123351956 119181391 123335516 116277239 6548000 3173000 53456000 60243000 580000 538000 1740000 1609000 5968000 2635000 51716000 58634000 0.05 0.02 0.42 0.50 0.05 0.02 0.42 0.50 A summary of the activity under the Company's share-based incentive plans for the <span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> is included in the table below.</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:41%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Share-based awards, beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,938,100</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,797,686</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,907,645</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,786,497</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>107,751</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>103,615</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Vested</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(5,051</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(82,347</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(92,426</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Share-based awards, end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,933,049</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,797,686</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,933,049</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,797,686</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 1938100 1797686 1907645 1786497 0 0 107751 103615 5051 0 82347 92426 1933049 1797686 1933049 1797686 22555 16581 A summary of the activity under the Purchase Plan for the <span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> is included in the table below.</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:41%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Outstanding and exercisable, beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>350,535</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>344,572</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>318,100</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>316,321</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>203,836</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>206,824</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Exercised</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(2,531</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(5,452</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(13,236</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(24,482</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(9,583</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(9,291</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(34,489</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(36,524</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Expired</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(135,790</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(132,310</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Outstanding and exercisable, end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>338,421</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>329,829</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>338,421</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>329,829</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 350535 344572 318100 316321 0 0 203836 206824 2531 5452 13236 24482 9583 9291 34489 36524 0 0 135790 132310 338421 329829 338421 329829 Fair Value of Financial Instruments<div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following methods and assumptions were used to estimate the fair value of each class of financial instrument for which it is practical to estimate that value.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash and cash equivalents - </span><span style="font-family:inherit;font-size:10pt;">The carrying amount approximates fair value due to the short term maturity of these investments. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Borrowings under the unsecured credit facility due 2020 and unsecured term loan facility due 2022 - </span><span style="font-family:inherit;font-size:10pt;">The carrying amount approximates fair value because the borrowings are based on variable market interest rates.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Senior Notes and Mortgage Notes payable - </span><span style="font-family:inherit;font-size:10pt;">The fair value of notes and bonds payable is estimated using cash flow analyses, based on the Company’s current interest rates for similar types of borrowing arrangements.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Interest rate swap agreements - </span><span style="font-family:inherit;font-size:10pt;">Interest rate swap agreements are recorded in other liabilities on the Company's Consolidated Balance Sheets at fair value. Fair value is estimated by utilizing pricing models that consider forward yield curves and discount rates.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The table below details the fair values and carrying values for notes and bonds payable at </span><span style="font-family:inherit;font-size:10pt;">September 30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2017</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">September 30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-style:italic;">(Dollars in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Carrying Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Carrying Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Notes and bonds payable </span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,344.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,300.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,283.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,269.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">______</span></div><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;">(1)</span></div>Level 2 – model-derived valuations in which significant inputs and significant value drivers are observable in active markets. The table below details the fair values and carrying values for notes and bonds payable at <span style="font-family:inherit;font-size:10pt;">September 30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2017</span><span style="font-family:inherit;font-size:10pt;">.</span><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">September 30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-style:italic;">(Dollars in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Carrying Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Carrying Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Notes and bonds payable </span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,344.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,300.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,283.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,269.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">______</span></div><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;">(1)</span></div>Level 2 – model-derived valuations in which significant inputs and significant value drivers are observable in active markets. 1344800000 1300200000 1283900000 1269700000 XML 11 R1.htm IDEA: XBRL DOCUMENT v3.10.0.1
Document and Entity Information - shares
9 Months Ended
Sep. 30, 2018
Oct. 26, 2018
Document and Entity Information [Abstract]    
Entity Registrant Name HEALTHCARE REALTY TRUST INCORPORATED  
Entity Central Index Key 0000899749  
Current Fiscal Year End Date --12-31  
Entity Filer Category Large Accelerated Filer  
Document Type 10-Q  
Document Period End Date Sep. 30, 2018  
Document Fiscal Year Focus 2018  
Document Fiscal Period Focus Q3  
Amendment Flag false  
Entity Common Stock, Shares Outstanding   125,237,283
Entity Emerging Growth Company false  
Entity Small Business false  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2018
Dec. 31, 2017
Real estate properties:    
Land $ 217,322 $ 201,283
Buildings, improvements and lease intangibles 3,669,852 3,601,460
Personal property 10,454 10,314
Construction in progress 26,960 5,458
Land held for development 24,645 20,123
Real estate properties, Total 3,949,233 3,838,638
Less accumulated depreciation and amortization (989,585) (897,430)
Total real estate properties, net 2,959,648 2,941,208
Cash and cash equivalents 10,027 6,215
Assets held for sale, net 8,826 33,147
Other assets, net 222,582 213,015
Total assets 3,201,083 3,193,585
Liabilities:    
Notes and bonds payable 1,344,759 1,283,880
Accounts payable and accrued liabilities 72,927 70,995
Liabilities of properties held for sale 141 93
Other liabilities 43,004 48,734
Total liabilities 1,460,831 1,403,702
Commitments and contingencies
Stockholders' equity:    
Preferred stock, $.01 par value per share; 50,000 shares authorized; none issued and outstanding 0 0
Common stock, $.01 par value per share; 300,000 shares authorized; 125,237 and 125,132 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively 1,252 1,251
Additional paid-in capital 3,181,263 3,173,429
Accumulated other comprehensive income (loss) 473 (1,299)
Cumulative net income attributable to common stockholders 1,071,804 1,018,348
Cumulative dividends (2,514,540) (2,401,846)
Total stockholders' equity 1,740,252 1,789,883
Total liabilities and stockholders' equity $ 3,201,083 $ 3,193,585
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Sep. 30, 2018
Dec. 31, 2017
Statement of Financial Position [Abstract]    
Preferred stock, par value (dollars per share) $ 0.01 $ 0.01
Preferred stock, authorized shares 50,000,000 50,000,000
Preferred stock, issued shares 0 0
Preferred stock, outstanding shares 0 0
Common stock, par value (dollars per share) $ 0.01 $ 0.01
Common stock, authorized shares 300,000,000 300,000,000
Common stock, issued shares 125,237,000 125,132,000
Common stock, outstanding shares 125,237,000 125,132,000
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Statements of Income (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
REVENUES        
Rental income $ 111,452 $ 105,078 $ 331,247 $ 311,171
Other operating 2,010 1,947 5,973 5,816
Revenues 113,462 107,025 337,220 316,987
EXPENSES        
Property operating 44,135 40,628 127,691 116,663
General and administrative 8,504 8,021 25,977 24,720
Acquisition and pursuit costs 141 507 538 1,878
Depreciation and amortization 42,061 35,873 121,764 105,148
Bad debts, net of recoveries (62) 4 42 175
Total Expenses 94,779 85,033 276,012 248,584
OTHER INCOME (EXPENSE)        
Gain (loss) on sales of real estate assets 1,288 (7) 30,879 39,525
Interest expense (13,464) (14,107) (39,202) (42,694)
Impairment of real estate assets 0 (5,059)   (5,387)
Interest and other income, net 41 354 571 396
Total other income (expense) (12,135) (18,819) (7,752) (8,160)
NET INCOME $ 6,548 $ 3,173 $ 53,456 $ 60,243
Basic earnings per common share (in dollars per share) $ 0.05 $ 0.02 $ 0.42 $ 0.50
Diluted earnings per common share (in dollars per share) $ 0.05 $ 0.02 $ 0.42 $ 0.50
Weighted average common shares outstanding - basic (in shares) 123,299,809 119,098,149 123,280,753 116,180,979
Weighted average common shares outstanding - diluted (in shares) 123,351,956 119,181,391 123,335,516 116,277,239
Dividends declared, per common share, during the period (in dollars per share) $ 0.30 $ 0.30 $ 0.90 $ 0.90
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Statement of Comprehensive Income [Abstract]        
NET INCOME $ 6,548 $ 3,173 $ 53,456 $ 60,243
Interest rate swaps:        
Reclassification adjustments for losses included in net income (interest expense) 95 43 369 127
Gains arising during the period on interest rate swaps 374   1,403  
Total other comprehensive income 469 43 1,772 127
COMPREHENSIVE INCOME $ 7,017 $ 3,216 $ 55,228 $ 60,370
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Statement of Equity (Unaudited) Statement - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Income (Loss)
Cumulative Net Income
Cumulative Dividends
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income $ 60,243          
Reclassification adjustments for losses included in net income (interest expense) 127          
Beginning balance at Dec. 31, 2017 1,789,883 $ 1,251 $ 3,173,429 $ (1,299) $ 1,018,348 $ (2,401,846)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock 464   464      
Common stock redemptions (719)   (719)      
Share-based compensation 8,090 1 8,089      
Net income 53,456       53,456  
Reclassification adjustments for losses included in net income (interest expense) 369     369    
Gains arising during the period on interest rate swaps 1,403     1,403    
Dividends to common stockholders ($0.90 per share) (112,694)         (112,694)
Ending balance at Sep. 30, 2018 $ 1,740,252 $ 1,252 $ 3,181,263 $ 473 $ 1,071,804 $ (2,514,540)
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Statement of Equity (Unaudited) (Parenthetical)
9 Months Ended
Sep. 30, 2018
$ / shares
Statement of Stockholders' Equity [Abstract]  
Dividend per share to common Stockholders (in dollars per share) $ 0.90
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
OPERATING ACTIVITIES    
Net income $ 53,456 $ 60,243
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 121,764 105,148
Other amortization 2,113 3,056
Share-based compensation 8,090 7,496
Amortization of straight-line rent receivable (3,599) (4,867)
Amortization of straight-line rent liability 1,147 492
Gain on sales of real estate assets (30,879) (39,525)
Impairment of real estate assets   5,387
Equity from unconsolidated joint ventures (income) (15)  
Distributions from unconsolidated joint ventures 182  
Provision for bad debts, net 42 175
Changes in operating assets and liabilities:    
Other assets (6,891) (6,037)
Accounts payable and accrued liabilities 5,908 (3,301)
Other liabilities (638) 1,098
Net cash provided by operating activities 150,680 129,365
INVESTING ACTIVITIES    
Acquisitions of real estate (67,445) (72,934)
Development of real estate (21,059) (11,753)
Additional long-lived assets (59,802) (52,305)
Proceeds from sales of real estate 64,271 119,425
Proceeds from notes receivable repayments 8 15
Net cash used in investing activities (84,027) (17,552)
FINANCING ACTIVITIES    
Net borrowings (repayments) on unsecured credit facility 56,000 (107,000)
Repayments on notes and bonds payable (3,808) (4,654)
Dividends paid (112,694) (104,860)
Net proceeds from issuance of common stock 459 248,384
Common stock redemptions (2,673) (1,125)
Debt issuance and assumption costs (125) (84)
Net cash (used in) provided by financing activities (62,841) 30,661
Increase in cash and cash equivalents 3,812 142,474
Cash and cash equivalents at beginning of period 6,215 54,507
Cash and cash equivalents at end of period 10,027 196,981
Supplemental Cash Flow Information:    
Interest paid 30,463 42,136
Invoices accrued for construction, tenant improvements and other capitalized costs 5,680 6,842
Mortgage notes payable assumed upon acquisition (adjusted to fair value) 7,995 12,460
Capitalized interest $ 684 $ 681
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.10.0.1
Summary of Significant Accounting Policies
9 Months Ended
Sep. 30, 2018
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies Business Overview
Healthcare Realty Trust Incorporated (the "Company") is a real estate investment trust ("REIT") that owns, leases, manages, acquires, finances, develops and redevelops income-producing real estate properties associated primarily with the delivery of outpatient healthcare services throughout the United States. As of September 30, 2018, the Company had gross investments of approximately $3.9 billion in 201 real estate properties located in 27 states totaling approximately 14.8 million square feet. The Company provided leasing and property management services to approximately 11.1 million square feet nationwide.

Basis of Presentation
The Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. They do not include all of the information and footnotes required by GAAP for complete financial statements. However, except as disclosed herein, management believes there has been no material change in the information disclosed in the Notes to the Consolidated Financial Statements included in the Annual Report on Form 10-K for the year ended December 31, 2017. All material intercompany transactions and balances have been eliminated in consolidation.

This interim financial information should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2017. Management believes that all adjustments of a normal, recurring nature considered necessary for a fair presentation have been included. In addition, the interim financial information does not necessarily represent or indicate what the operating results will be for the year ending December 31, 2018 for many reasons including, but not limited to, acquisitions, dispositions, capital financing transactions, changes in interest rates and the effects of other trends, risks and uncertainties.

Use of Estimates in the Condensed Consolidated Financial Statements
Preparation of the Condensed Consolidated Financial Statements in accordance with GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Actual results may differ from those estimates.
Revenue from Contracts with Customers (Topic 606)
The Company recognizes certain revenue under the core principle of Topic 606. This requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Lease revenue is not within the scope of Topic 606. To achieve the core principle, the Company applies the five step model specified in the guidance. See the New Accounting Pronouncements section below for additional information.

Revenue that is accounted for under Topic 606 is segregated on the Company’s Condensed Consolidated Statements of Income in the Other operating line item. This line item includes parking income, rental lease guaranty income, management fee income and other miscellaneous income. Below is a detail of the amounts by category:
(in thousands)
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
Type of Revenue
 
2018
 
2017
 
2018
 
2017
Parking income
 
$
1,752

 
$
1,669

 
$
5,197

 
$
4,907

Rental lease guaranty
 
168

 
168

 
488

 
545

Management fee income
 
68

 
70

 
205

 
237

Miscellaneous
 
22

 
40

 
83

 
127

 
 
$
2,010

 
$
1,947

 
$
5,973

 
$
5,816



The Company’s three major types of revenue that are accounted for under Topic 606 that are listed above are all accounted for as the performance obligation is satisfied. The performance obligations that are identified for each of these items are satisfied over time and the Company recognizes revenue monthly based on this principle.
Reclassifications
Condensed Consolidated Statements of Income
Certain reclassifications have been made on the Company's Condensed Consolidated Statements of Income. After the adoption of Accounting Standards Update ("ASU") 2014-08, "Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity," the Company's dispositions have not met the updated definition to be reported as discontinued operations. The Company had some residual impact from properties that were identified as discontinued operations prior to the adoption of ASU 2014-08. These amounts are considered immaterial and have been reclassified for the prior year presentation on the Company's Condensed Consolidated Statements of Income.
 
Three months ended September 30, 2017
 
Nine months ended September 30, 2017
(in thousands)
As Previously Reported
 
As Reclassified
 
As Previously Reported
 
As Reclassified
EXPENSES
 
 
 
 
 
 
 
Property operating expense
$
40,626

 
$
40,628

 
$
116,644

 
$
116,663

Bad debt, net
14

 
4

 
185

 
175

 
 
 
 
 
 
 
 
OTHER INCOME (EXPENSE)
 
 
 
 
 
 
 
Gain on sales of properties
(7
)
 
(7
)
 
39,519

 
39,525

 
 
 
 
 
 
 
 
INCOME FROM CONTINUING OPERATIONS
$
3,165

 
$
3,173

 
$
60,247

 
$
60,243

 
 
 
 
 
 
 
 
DISCONTINUED OPERATIONS
 
 
 
 
 
 
 
Income (loss) from discontinued operations
$
8

 
$

 
$
(9
)
 
$

Gain on sales of properties

 

 
5

 

INCOME (LOSS) FROM DISCONTINUED OPERATIONS
$
8

 
$

 
$
(4
)
 
$




New Accounting Pronouncements
Accounting Standards Update No. 2014-09 and No. 2015-14
In May 2014, the Financial Accounting Standards Board ("FASB") issued ASU No. 2014-09, "Revenue from Contracts with Customers," a comprehensive new revenue recognition standard that supersedes most existing revenue recognition guidance, including sales of real estate. This standard's core principle is that a company will recognize revenue when it transfers goods or services to customers in amounts that reflect the consideration to which the company expects to be entitled in exchange for those goods and services. However, leasing contracts, representing the major source of the Company's revenues, are not within the scope of the new standard and will continue to be accounted for under other standards.

In August 2015, the FASB issued ASU No. 2015-14, "Revenue from Contracts with Customers (Topic 606); Deferral of the Effective Date." This standard was effective for the Company for annual and interim periods beginning after December 15, 2017 with early adoption permitted only as of annual reporting periods beginning after December 15, 2016, including interim periods within that year.

The Company adopted this standard by using the full retrospective adoption method beginning on January 1, 2018. The Company's revenue-producing contracts are primarily leases that are not within the scope of this standard. As a result, the adoption of this standard did not have a material impact on the timing and measurement of the Company's leasing revenues. The Company has determined that parking income, rental lease guaranty income and management fee income are within the scope of Topic 606. However, these items were determined to have the same pattern of revenue recognition that the Company
had historically recognized. The Company reclassified these amounts along with all other items that are accounted for within the scope of Topic 606 into the Other operating line item on the Company's Condensed Consolidated Statements of Income. This line item historically contained the revenue associated with rental lease guaranty income, management fee income and other non-lease revenue. The Company reclassified parking income from rental income to other operating income.

The following table represents the impact of the adoption of this standard on the Company's Condensed Consolidated Statements of Income for the three and nine months ended September 30, 2017:

 
Three months ended September 30, 2017
 
Nine months ended September 30, 2017
(in thousands)
As Reported
 
As Reclassified
 
As Reported
 
As Reclassified
REVENUES
 
 
 
 
 
 
 
Rental income
$
106,561

 
$
105,078

 
$
315,519

 
$
311,171

Other operating
392

 
1,947

 
1,249

 
5,816

 
$
106,953

 
$
107,025

 
$
316,768

 
$
316,987

 
 
 
 
 
 
 
 
OTHER INCOME (EXPENSE)
 
 
 
 
 
 
 
Interest and other income, net
$
426

 
$
354

 
$
616

 
$
396

 
 
 
 
 
 
 
 
NET INCOME
$
3,173

 
$
3,173

 
$
60,243

 
$
60,243



Accounting Standards Update No. 2016-02, No. 2018-01 and No. 2018-11
In February 2016, the FASB issued ASU 2016-02, "Leases." In January 2018, the FASB issued ASU 2018-01, "Leases - Land Easement Practical Expedient for Transition to Topic 842," and in July 2018, the FASB issued ASU 2018-10, "Codification Improvements to Topic 842, Leases" and ASU 2018-11, "Leases - Targeted Improvements." These accounting standard updates are collectively referred to as "Topic 842."

Topic 842 provides several practical expedients that the Company expects to elect. These are (a) the package of practical expedients offered that allows an entity not to reassess upon adoption (i) whether an expired or existing contract contains a lease, (ii) lease classification related to expired or existing lease arrangements, and (iii) whether costs incurred on expired or existing leases qualify as initial direct costs, and (b) the practical expedient not to separate certain non-lease components, such as common area maintenance, from the lease component if (i) the timing and pattern of transfer are the same for the non-lease component and associated lease component, and (ii) the lease component would be classified as an operating lease if accounted for separately.

For lessees, the new standard establishes a right-of-use ("ROU") model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with the classification affecting the pattern of expense recognition in the income statement. The Company expects that most of the leases where the Company is the lessee will be recorded on the Company's balance sheet as operating leases. These leases are primarily ground leases, but also include the Company's corporate office lease, management office leases in third party buildings and certain copier and postage machine leases. The impact to the Company's Consolidated Balance Sheets has not yet been determined. The Company is in the process of working with consultants to determine the appropriate discount rate required to calculate the present value of the future lease payments for ground leases that have lease terms longer than typical secured financing allows.

For lessors, the new standard requires a lessor to classify leases as either sales-type, direct-financing or operating. A lease will be treated as a sale if it is considered to transfer control of the underlying asset, to the lessee. A lease will be classified as direct-financing if risks and rewards are conveyed without the transfer of control. Otherwise, the lease is treated as an operating lease. Lessor accounting remains largely unchanged with some exceptions including the concept of separating lease and nonlease components. Nonlease components, such as common area maintenance, will be accounted for under Topic 606 and separated from the lease payments. However, the Company will elect the lessor practical expedient allowing the Company to not separate these components when certain conditions are met. The Company does not expect a material impact from the adoption of Topic 842 related to leases where the Company is the lessor.

The new standard is effective for the Company on January 1, 2019. Topic 842 provides two transition alternatives. The Company expects to choose the optional transition method available to apply the guidance in Accounting Standards Codification Topic 840 in the comparative periods presented in the year Topic 842 is adopted. Topic 842 includes extensive quantitative and qualitative disclosures as compared to Topic 840, Leases, for both lessees and lessors. The Company is continuing to evaluate the impact from the adoption of this new standard on the Consolidated Financial Statements and related notes.

Accounting Standards Update No. 2016-13
In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." This update is intended to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. This update requires that financial statement assets measured at an amortized cost and certain other financial instruments be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. This standard is effective for annual and interim periods beginning after December 15, 2019 with early adoption permitted. The Company is in the initial stages of evaluating the impact from the adoption of this new standard on the Consolidated Financial Statements and related notes.

Accounting Standards Update No. 2017-04
In January 2017, the FASB issued ASU 2017-04, "Simplifying the Test for Goodwill Impairment." This update eliminates Step 2 of the goodwill impairment test. As such, an entity will perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize a goodwill impairment charge for the amount by which the reporting unit's carrying amount exceeds its fair value. This standard is effective for the Company for annual and interim periods beginning after December 15, 2019. The Company does not expect a material impact on the Consolidated Financial Statements and related notes from the adoption of this standard.

Accounting Standards Update No. 2017-05
In February 2017, the FASB issued ASU 2017-05, "Other Income - Gains and Losses from the Derecognition of Nonfinancial Assets." This update defines an in-substance nonfinancial asset, unifies guidance related to partial sales of nonfinancial assets, eliminates rules specifically addressing the sales of real estate, removes exceptions to the financial asset derecognition model and clarifies the accounting for contributions of nonfinancial assets to joint ventures. The Company adopted this standard as of January 1, 2018 on the full retrospective adoption method. The adoption of this standard did not have a material impact to the Consolidated Financial Statements and related notes.

Accounting Standards Update No. 2017-09
In May 2017, the FASB issued ASU 2017-09, "Compensation - Stock Compensation - Scope of Modification Accounting." This update provides guidance about which changes to the terms and conditions of share-based awards require an entity to apply modification accounting in Topic 718. The Company adopted this standard on January 1, 2018. The adoption of this standard did not have a material impact to the Consolidated Financial Statements and related notes.
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.10.0.1
Real Estate Investments
9 Months Ended
Sep. 30, 2018
Business Combinations [Abstract]  
Real Estate Investments Real Estate Investments
2018 Acquisitions
The following table details the Company's acquisitions for the nine months ended September 30, 2018:
(Dollars in millions)
Type (1)
 
Date
Acquired
 
Purchase Price

 
Mortgage
Notes Payable Assumed
(2)

 
Cash
Consideration
(3)

 
Real
Estate

 
Other (4)

 
Square
Footage
(Unaudited)

Seattle, Washington
MOB
 
5/4/18
 
$
7.8

 
$

 
$
7.8

 
$
7.8

 
$

 
13,314

Denver, Colorado (5)
MOB, OFC
 
5/18/18
 
25.0

 
(8.0
)
 
16.6

 
25.1

 
(0.4
)
 
187,861

Oklahoma City, Oklahoma
MOB
 
5/21/18
 
11.4

 

 
11.4

 
11.5

 
(0.1
)
 
82,647

Seattle, Washington
MOB
 
6/29/18
 
26.2

 

 
26.2

 
26.7

 
(0.5
)
 
86,942

Denver, Colorado
MOB
 
8/24/18
 
4.1

 

 
4.2

 
4.2

 

 
17,084

 
 
 
 
 
$
74.5

 
$
(8.0
)
 
$
66.2

 
$
75.3

 
$
(1.0
)
 
387,848

______
(1)
MOB = medical office building; OFC = office
(2)
The mortgage note payable assumed in the acquisition does not reflect the fair value premium totaling $0.1 million recorded by the Company upon acquisition (included in Other).
(3)
Cash consideration excludes prorations of revenue and expense due to/from seller at the time of the acquisition.
(4)
Includes other assets acquired, liabilities assumed, intangibles recognized at acquisition and fair value adjustments on debt assumed.
(5)
Includes two properties.

2018 Dispositions
The following table details the Company's dispositions for the nine months ended September 30, 2018:
(Dollars in millions)
Type (1)
 
Date
Disposed
 
Sales Price
 
Closing Adjustments
 
Net
Proceeds
 
Net Real
Estate
Investment
 
Other (including receivables) (2)
 
Gain
 
Square
Footage
(
Unaudited)
Virginia (3) (4)
MOB, OFC
 
4/26/18
 
$
46.2

 
$

 
$
46.2

 
$
23.9

 
$

 
$
22.3

 
460,881

Michigan (3) (5)
SNF
 
6/27/18
 
9.5

 
(0.7
)
 
8.8

 
3.4

 

 
5.4

 
121,672

Missouri
MOB
 
8/30/18
 
9.8

 
(0.5
)
 
9.3

 
7.5

 
0.5

 
1.3

 
70,893

Total dispositions
 
$
65.5

 
$
(1.2
)
 
$
64.3

 
$
34.8

 
$
0.5

 
$
29.0

 
653,446

______
(1)
MOB = medical office building; OFC = office; SNF = skilled nursing facility
(2)
Includes straight-line rent receivables and leasing commissions.
(3)
Previously classified as held for sale.
(4)
Includes seven properties, comprised of five single-tenant net lease buildings and two multi-tenant buildings. These buildings were sold pursuant to the exercise of a fixed-price purchase option.
(5)
Includes five skilled nursing facilities. Sales price includes $0.5 million of forfeited earnest money from a prior terminated transaction.

Non-monetary Exchange
On June 29, 2018, the Company completed the swap of a non-revenue producing garage that was built by the Company in 2012 located in Denver, Colorado for 20.5 acres of land adjacent to the Catholic Health Initiative’s St. Anthony Hospital campus. A portion of this land, approximately 4.6 acres, has been allocated to an existing medical office building that was developed by the Company in 2017. This building is located on land previously ground leased from the hospital. The remaining land has been recorded in land held for development. The land acquired was appraised for $5.8 million. The Company had a net investment of $3.9 million in the parking garage and recognized a gain of $1.9 million in connection with this transaction.

Assets Held for Sale
As of December 31, 2017, the Company had eight properties classified as held for sale. The following changes to assets held for sale have occurred during 2018:

The Company reclassified five single-tenant net leased properties to held for sale as of March 31, 2018.

In April 2018, the Company sold seven properties, comprised of five single-tenant net leased properties and two multi-tenanted properties. The Company recognized a gain on disposition of approximately $22.3 million.

In June 2018, the Company sold five single-tenant net leased properties. The Company recognized a gain on disposition of approximately $5.4 million.

As of September 30, 2018, the Company had one property remaining classified as held for sale.

The table below reflects the assets and liabilities of the properties classified as held for sale as of September 30, 2018 and December 31, 2017:
(Dollars in thousands)
September 30,
2018
 
December 31,
2017
Balance Sheet data:
 
 
 
Land
$
1,125

 
$
4,636

Buildings, improvements and lease intangibles
18,231

 
63,654

Personal property

 
82

 
19,356

 
68,372

Accumulated depreciation
(10,657
)
 
(35,790
)
Real estate assets held for sale, net
8,699

 
32,582

Other assets, net
127

 
565

Assets held for sale, net
$
8,826

 
$
33,147

 
 
 
 
Accounts payable and accrued liabilities
$
119

 
$
38

Other liabilities
22

 
55

Liabilities of properties held for sale
$
141

 
$
93

XML 21 R11.htm IDEA: XBRL DOCUMENT v3.10.0.1
Notes and Bonds Payable
9 Months Ended
Sep. 30, 2018
Debt Disclosure [Abstract]  
Notes and Bonds Payable Notes and Bonds Payable
The table below details the Company’s notes and bonds payable. 
 
Maturity
Dates
 
Balance as of
 
Effective Interest Rate as of

(Dollars in thousands)
September 30, 2018

 
December 31, 2017

September 30, 2018

Unsecured Credit Facility
7/20
 
$
245,000

 
$
189,000

 
3.26
%
Unsecured Term Loan Facility, net of issuance costs (1)
12/22
 
149,132

 
148,994

 
3.41
%
Senior Notes due 2023, net of discount and issuance costs
4/23
 
248,013

 
247,703

 
3.95
%
Senior Notes due 2025, net of discount and issuance costs (2)
5/25
 
248,219

 
248,044

 
4.08
%
Senior Notes due 2028, net of discount and issuance costs
1/28
 
295,087

 
294,757

 
3.84
%
Mortgage notes payable, net of discounts and issuance costs and including premiums
12/18-5/40
 
159,308

 
155,382

 
4.83
%
 
 
 
$
1,344,759

 
$
1,283,880

 
 


______
(1)
The effective interest rate includes the impact of interest rate swaps on $25.0 million and $50.0 million of the outstanding balance at a rate of 2.18% and 2.46%, respectively (plus the applicable margin rate, currently 110 basis points).
(2)
The effective interest rate includes the impact of the $1.7 million settlement of a forward-starting interest rate swap that is included in Accumulated other comprehensive income (loss) on the Company's Condensed Consolidated Balance Sheets.
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.10.0.1
Derivative Financial Instruments
9 Months Ended
Sep. 30, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Derivative Financial Instruments Derivative Financial Instruments
Risk Management Objective of Using Derivatives
The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company principally manages its exposures to a wide variety of business and operational risks through management of its core business activities. The Company manages economic risks, including interest rate, liquidity, and credit risk, primarily by managing the amount, sources, and duration of its assets and liabilities and the use of derivative financial instruments. Specifically, the Company enters into derivative financial instruments to manage exposures that arise from business activities that result in the
receipt or payment of future known and uncertain cash amounts, the value of which are determined by interest rates. The Company’s derivative financial instruments are used to manage differences in the amount, timing, and duration of the Company’s known or expected cash receipts and its known or expected cash payments principally related to the Company’s borrowings.

Cash Flow Hedges of Interest Rate Risk
The Company’s objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish this objective, the Company primarily uses interest rate swaps as part of its interest rate risk management strategy. Interest rate swaps designated as cash flow hedges involve the receipt of variable amounts from a counterparty in exchange for the Company making fixed-rate payments over the life of the agreements without exchange of the underlying notional amount. Such derivatives were used to hedge the variable cash flows associated with existing variable-rate debt.

For derivatives designated and that qualify as cash flow hedges of interest rate risk, the gain or loss on the derivative is recorded in Accumulated other comprehensive income (loss) and subsequently reclassified into interest expense in the same period(s) during which the hedged transaction affects earnings. Amounts reported in Accumulated other comprehensive income (loss) related to derivatives will be reclassified to interest expense as interest payments are made on the Company’s variable-rate debt.

As of September 30, 2018, the Company had four outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk:
Derivative Instrument
 
Number of Instruments

 
Notional Amount
(in millions)
Interest rate swaps
 
4

 
$75.0


Tabular Disclosure of Fair Values of Derivative Instruments on the Balance Sheet
The table below presents the fair value of the Company's derivative financial instruments, as well as their classification on the Condensed Consolidated Balance Sheet as of September 30, 2018.
 
Asset Derivatives
 
Balance at September 30, 2018
(Dollars in thousands)
Balance Sheet Location
 
Fair Value

Derivatives designated as hedging instruments
 
 
 
Interest rate swaps
Other assets
 
$
1,579

Total derivatives designated as hedging instruments
 
 
$
1,579



Tabular Disclosure of the Effect of Cash Flow Hedge Accounting on Accumulated Other Comprehensive Income (Loss)
The table below presents the effect of cash flow hedge accounting on Accumulated Other Comprehensive Income (Loss) ("OCI") during the nine months ended September 30, 2018 and 2017 related to the Company's outstanding interest rate swaps.
 
Amount of Gain Recognized in OCI on Derivative
 
Amount of Loss Reclassified from OCI into Income
(Dollars in thousands)
2018

2018

 
2017

Interest rate products
$
1,403

Interest expense
$
243

 
$

Settled interest rate swaps

Interest expense
126

 
127

 
$
1,403

Total interest expense
$
369

 
$
127


Credit-risk-related Contingent Features
The Company's agreements with each of its derivative counterparties contain a cross-default provision under which the Company could be declared in default of its derivative obligations if repayment of the underlying indebtedness is accelerated by the lender due to the Company's default on the indebtedness.

The Company estimates that $0.2 million related to active interest rate swaps will be reclassified from OCI as a decrease to interest expense over the next 12 months, and that $0.2 million related to settled interest rate swaps will be amortized from OCI as an increase to interest expense over the next 12 months.
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.10.0.1
Commitments and Contingencies
9 Months Ended
Sep. 30, 2018
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
Legal Proceedings
The Company is, from time to time, involved in litigation arising in the ordinary course of business. The Company is not aware of any pending or threatened litigation that, if resolved against the Company, would have a material adverse effect on the Company’s consolidated financial position, results of operations or cash flows.

Redevelopment Activity
The Company is redeveloping a medical office building in Charlotte, North Carolina, which includes a 38,000 square foot vertical expansion. As of September 30, 2018, the Company has funded approximately $9.2 million on the redevelopment of this property. The project is expected to be completed in the first quarter of 2019.

Development Activity
The Company began the development of a 151,000 square foot medical office building in Seattle, Washington during 2017. As of September 30, 2018, the Company has funded approximately $18.0 million on the development. The Company expects the project to be completed in the second quarter of 2019.
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stockholders' Equity
9 Months Ended
Sep. 30, 2018
Equity [Abstract]  
Stockholders' Equity Stockholders' Equity

Common Stock    
The following table provides a reconciliation of the beginning and ending shares of common stock outstanding for the nine months ended September 30, 2018 and the year ended December 31, 2017:
 
September 30, 2018
 
December 31, 2017
Balance, beginning of period
125,131,593

 
116,416,900

Issuance of common stock
20,395

 
8,395,607

Nonvested share-based awards, net of withheld shares
85,196

 
319,086

Balance, end of period
125,237,184

 
125,131,593



At-The-Market Equity Offering Program
No shares were sold under the Company's At-the-Market Equity Offering Program during the nine months ended September 30, 2018. The Company had 5,868,697 authorized shares remaining available to be sold under the current sales agreements as of October 26, 2018.

Common Stock Dividends
During the nine months ended September 30, 2018, the Company declared and paid common stock dividends totaling $0.90 per share. On October 30, 2018, the Company declared a quarterly common stock dividend in the amount of $0.30 per share payable on November 30, 2018 to stockholders of record on November 15, 2018.

Accumulated Other Comprehensive Income (Loss)
As of September 30, 2018, the Company had four outstanding interest rate swaps to hedge the variable cash flows associated with existing variable-rate debt. The Company continues to amortize the 2015 settlement of forward-starting interest rate swaps that were entered into in connection with the issuance of the Company's Senior Notes due 2025. This amount will be reclassified out of OCI impacting net income over the 10-year term of the associated senior note issuance. See Note 4 for more information regarding the Company's derivative instruments.

The following table represents the changes in balances of each component and the amounts reclassified out of OCI related to the Company during the nine months ended September 30, 2018 and 2017:
 
Forward-starting Interest Rate Swaps
 
(Dollars in thousands)
2018
 
2017
 
Beginning balance
$
(1,299
)
 
$
(1,401
)
 
Gains arising during the period related to active interest rate swaps
1,403

 

 
Amounts reclassified from accumulated other comprehensive (income) loss
369

 
127

 
Net accumulated other comprehensive income
1,772

 
127

 
Ending balance
$
473

 
$
(1,274
)
 


The following table represents the details regarding the reclassifications from OCI during the nine months ended September 30, 2018:
Details about accumulated other comprehensive income (loss) components
 
Amount reclassified from accumulated other comprehensive income (loss)

 
Affected line item in the statement where net income is presented
(Dollars in thousands)
 
 
 
 
Amounts reclassified from accumulated other comprehensive income (loss) related to settled interest rate swaps
 
$
126

 
Interest Expense
Amounts reclassified from accumulated other comprehensive income (loss) related to current interest rate swaps
 
243

 
Interest Expense
 
 
$
369

 
 


Earnings Per Common Share
The Company uses the two-class method of computing net earnings per common shares. The Company's nonvested share-based awards are considered participating securities pursuant to the two-class method. The following table sets forth the computation of basic and diluted earnings per common share for the three and nine months ended September 30, 2018 and 2017.
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
(Dollars in thousands, except per share data)
2018
 
2017
 
2018
 
2017
Weighted average Common Shares outstanding
 
 
 
 
 
 
 
Weighted average Common Shares outstanding
125,233,462

 
120,895,835

 
125,206,342

 
117,981,159

Nonvested shares
(1,933,653
)
 
(1,797,686
)
 
(1,925,589
)
 
(1,800,180
)
Weighted average Common Shares outstanding—Basic
123,299,809

 
119,098,149

 
123,280,753

 
116,180,979

Weighted average Common Shares outstanding—Basic
123,299,809

 
119,098,149

 
123,280,753

 
116,180,979

Dilutive effect of employee stock purchase plan
52,147

 
83,242

 
54,763

 
96,260

Weighted average Common Shares outstanding—Diluted
123,351,956

 
119,181,391

 
123,335,516

 
116,277,239

Net Income
$
6,548

 
$
3,173

 
$
53,456

 
$
60,243

Dividends paid on nonvested share-based awards
(580
)
 
(538
)
 
(1,740
)
 
(1,609
)
Net income applicable to common stockholders
$
5,968

 
$
2,635

 
$
51,716

 
$
58,634

Basic earnings per common share - Net income
$
0.05

 
$
0.02

 
$
0.42

 
$
0.50

Diluted earnings per common share - Net income
$
0.05

 
$
0.02

 
$
0.42

 
$
0.50



Incentive Plans
A summary of the activity under the Company's share-based incentive plans for the three and nine months ended September 30, 2018 and 2017 is included in the table below.
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Share-based awards, beginning of period
1,938,100

 
1,797,686

 
1,907,645

 
1,786,497

Granted

 

 
107,751

 
103,615

Vested
(5,051
)
 

 
(82,347
)
 
(92,426
)
Share-based awards, end of period
1,933,049

 
1,797,686

 
1,933,049

 
1,797,686



During the nine months ended September 30, 2018 and 2017, the Company withheld 22,555 and 16,581 shares of common stock, respectively, from participants to pay estimated withholding taxes related to shares that vested.

In addition to the share-based incentive plans, the Company maintains the 2000 Employee Stock Purchase Plan (the "Purchase Plan"). A summary of the activity under the Purchase Plan for the three and nine months ended September 30, 2018 and 2017 is included in the table below.
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Outstanding and exercisable, beginning of period
350,535

 
344,572

 
318,100

 
316,321

Granted

 

 
203,836

 
206,824

Exercised
(2,531
)
 
(5,452
)
 
(13,236
)
 
(24,482
)
Forfeited
(9,583
)
 
(9,291
)
 
(34,489
)
 
(36,524
)
Expired

 

 
(135,790
)
 
(132,310
)
Outstanding and exercisable, end of period
338,421

 
329,829

 
338,421

 
329,829

XML 25 R15.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fair Value of Financial Instruments
9 Months Ended
Sep. 30, 2018
Fair Value Disclosures [Abstract]  
Fair Value of Financial Instruments Fair Value of Financial Instruments
The following methods and assumptions were used to estimate the fair value of each class of financial instrument for which it is practical to estimate that value.

Cash and cash equivalents - The carrying amount approximates fair value due to the short term maturity of these investments.

Borrowings under the unsecured credit facility due 2020 and unsecured term loan facility due 2022 - The carrying amount approximates fair value because the borrowings are based on variable market interest rates.

Senior Notes and Mortgage Notes payable - The fair value of notes and bonds payable is estimated using cash flow analyses, based on the Company’s current interest rates for similar types of borrowing arrangements.

Interest rate swap agreements - Interest rate swap agreements are recorded in other liabilities on the Company's Consolidated Balance Sheets at fair value. Fair value is estimated by utilizing pricing models that consider forward yield curves and discount rates.

The table below details the fair values and carrying values for notes and bonds payable at September 30, 2018 and December 31, 2017.
 
September 30, 2018
 
December 31, 2017
(Dollars in millions)
Carrying Value
 
Fair Value
 
Carrying Value
 
Fair Value
Notes and bonds payable (1)
$
1,344.8

 
$
1,300.2

 
$
1,283.9

 
$
1,269.7


______
(1)
Level 2 – model-derived valuations in which significant inputs and significant value drivers are observable in active markets.
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.10.0.1
Summary of Significant Accounting Policies (Policies)
9 Months Ended
Sep. 30, 2018
Accounting Policies [Abstract]  
Business Overview Business OverviewHealthcare Realty Trust Incorporated (the "Company") is a real estate investment trust ("REIT") that owns, leases, manages, acquires, finances, develops and redevelops income-producing real estate properties associated primarily with the delivery of outpatient healthcare services throughout the United States. As of September 30, 2018, the Company had gross investments of approximately $3.9 billion in 201 real estate properties located in 27 states totaling approximately 14.8 million square feet. The Company provided leasing and property management services to approximately 11.1 million square feet nationwide.
Basis of Presentation Basis of Presentation
The Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. They do not include all of the information and footnotes required by GAAP for complete financial statements. However, except as disclosed herein, management believes there has been no material change in the information disclosed in the Notes to the Consolidated Financial Statements included in the Annual Report on Form 10-K for the year ended December 31, 2017. All material intercompany transactions and balances have been eliminated in consolidation.

This interim financial information should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2017. Management believes that all adjustments of a normal, recurring nature considered necessary for a fair presentation have been included. In addition, the interim financial information does not necessarily represent or indicate what the operating results will be for the year ending December 31, 2018 for many reasons including, but not limited to, acquisitions, dispositions, capital financing transactions, changes in interest rates and the effects of other trends, risks and uncertainties.
Use of Estimates in the Condensed Consolidated Financial Statements Use of Estimates in the Condensed Consolidated Financial StatementsPreparation of the Condensed Consolidated Financial Statements in accordance with GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Actual results may differ from those estimates.
Revenue from Contracts with Customers (Topic 606) Revenue from Contracts with Customers (Topic 606)
The Company recognizes certain revenue under the core principle of Topic 606. This requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Lease revenue is not within the scope of Topic 606. To achieve the core principle, the Company applies the five step model specified in the guidance. See the New Accounting Pronouncements section below for additional information.

Revenue that is accounted for under Topic 606 is segregated on the Company’s Condensed Consolidated Statements of Income in the Other operating line item. This line item includes parking income, rental lease guaranty income, management fee income and other miscellaneous income. Below is a detail of the amounts by category:
(in thousands)
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
Type of Revenue
 
2018
 
2017
 
2018
 
2017
Parking income
 
$
1,752

 
$
1,669

 
$
5,197

 
$
4,907

Rental lease guaranty
 
168

 
168

 
488

 
545

Management fee income
 
68

 
70

 
205

 
237

Miscellaneous
 
22

 
40

 
83

 
127

 
 
$
2,010

 
$
1,947

 
$
5,973

 
$
5,816



The Company’s three major types of revenue that are accounted for under Topic 606 that are listed above are all accounted for as the performance obligation is satisfied. The performance obligations that are identified for each of these items are satisfied over time and the Company recognizes revenue monthly based on this principle.
New Accounting Pronouncements New Accounting Pronouncements
Accounting Standards Update No. 2014-09 and No. 2015-14
In May 2014, the Financial Accounting Standards Board ("FASB") issued ASU No. 2014-09, "Revenue from Contracts with Customers," a comprehensive new revenue recognition standard that supersedes most existing revenue recognition guidance, including sales of real estate. This standard's core principle is that a company will recognize revenue when it transfers goods or services to customers in amounts that reflect the consideration to which the company expects to be entitled in exchange for those goods and services. However, leasing contracts, representing the major source of the Company's revenues, are not within the scope of the new standard and will continue to be accounted for under other standards.

In August 2015, the FASB issued ASU No. 2015-14, "Revenue from Contracts with Customers (Topic 606); Deferral of the Effective Date." This standard was effective for the Company for annual and interim periods beginning after December 15, 2017 with early adoption permitted only as of annual reporting periods beginning after December 15, 2016, including interim periods within that year.

The Company adopted this standard by using the full retrospective adoption method beginning on January 1, 2018. The Company's revenue-producing contracts are primarily leases that are not within the scope of this standard. As a result, the adoption of this standard did not have a material impact on the timing and measurement of the Company's leasing revenues. The Company has determined that parking income, rental lease guaranty income and management fee income are within the scope of Topic 606. However, these items were determined to have the same pattern of revenue recognition that the Company
had historically recognized. The Company reclassified these amounts along with all other items that are accounted for within the scope of Topic 606 into the Other operating line item on the Company's Condensed Consolidated Statements of Income. This line item historically contained the revenue associated with rental lease guaranty income, management fee income and other non-lease revenue. The Company reclassified parking income from rental income to other operating income.

The following table represents the impact of the adoption of this standard on the Company's Condensed Consolidated Statements of Income for the three and nine months ended September 30, 2017:

 
Three months ended September 30, 2017
 
Nine months ended September 30, 2017
(in thousands)
As Reported
 
As Reclassified
 
As Reported
 
As Reclassified
REVENUES
 
 
 
 
 
 
 
Rental income
$
106,561

 
$
105,078

 
$
315,519

 
$
311,171

Other operating
392

 
1,947

 
1,249

 
5,816

 
$
106,953

 
$
107,025

 
$
316,768

 
$
316,987

 
 
 
 
 
 
 
 
OTHER INCOME (EXPENSE)
 
 
 
 
 
 
 
Interest and other income, net
$
426

 
$
354

 
$
616

 
$
396

 
 
 
 
 
 
 
 
NET INCOME
$
3,173

 
$
3,173

 
$
60,243

 
$
60,243



Accounting Standards Update No. 2016-02, No. 2018-01 and No. 2018-11
In February 2016, the FASB issued ASU 2016-02, "Leases." In January 2018, the FASB issued ASU 2018-01, "Leases - Land Easement Practical Expedient for Transition to Topic 842," and in July 2018, the FASB issued ASU 2018-10, "Codification Improvements to Topic 842, Leases" and ASU 2018-11, "Leases - Targeted Improvements." These accounting standard updates are collectively referred to as "Topic 842."

Topic 842 provides several practical expedients that the Company expects to elect. These are (a) the package of practical expedients offered that allows an entity not to reassess upon adoption (i) whether an expired or existing contract contains a lease, (ii) lease classification related to expired or existing lease arrangements, and (iii) whether costs incurred on expired or existing leases qualify as initial direct costs, and (b) the practical expedient not to separate certain non-lease components, such as common area maintenance, from the lease component if (i) the timing and pattern of transfer are the same for the non-lease component and associated lease component, and (ii) the lease component would be classified as an operating lease if accounted for separately.

For lessees, the new standard establishes a right-of-use ("ROU") model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with the classification affecting the pattern of expense recognition in the income statement. The Company expects that most of the leases where the Company is the lessee will be recorded on the Company's balance sheet as operating leases. These leases are primarily ground leases, but also include the Company's corporate office lease, management office leases in third party buildings and certain copier and postage machine leases. The impact to the Company's Consolidated Balance Sheets has not yet been determined. The Company is in the process of working with consultants to determine the appropriate discount rate required to calculate the present value of the future lease payments for ground leases that have lease terms longer than typical secured financing allows.

For lessors, the new standard requires a lessor to classify leases as either sales-type, direct-financing or operating. A lease will be treated as a sale if it is considered to transfer control of the underlying asset, to the lessee. A lease will be classified as direct-financing if risks and rewards are conveyed without the transfer of control. Otherwise, the lease is treated as an operating lease. Lessor accounting remains largely unchanged with some exceptions including the concept of separating lease and nonlease components. Nonlease components, such as common area maintenance, will be accounted for under Topic 606 and separated from the lease payments. However, the Company will elect the lessor practical expedient allowing the Company to not separate these components when certain conditions are met. The Company does not expect a material impact from the adoption of Topic 842 related to leases where the Company is the lessor.

The new standard is effective for the Company on January 1, 2019. Topic 842 provides two transition alternatives. The Company expects to choose the optional transition method available to apply the guidance in Accounting Standards Codification Topic 840 in the comparative periods presented in the year Topic 842 is adopted. Topic 842 includes extensive quantitative and qualitative disclosures as compared to Topic 840, Leases, for both lessees and lessors. The Company is continuing to evaluate the impact from the adoption of this new standard on the Consolidated Financial Statements and related notes.

Accounting Standards Update No. 2016-13
In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." This update is intended to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. This update requires that financial statement assets measured at an amortized cost and certain other financial instruments be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. This standard is effective for annual and interim periods beginning after December 15, 2019 with early adoption permitted. The Company is in the initial stages of evaluating the impact from the adoption of this new standard on the Consolidated Financial Statements and related notes.

Accounting Standards Update No. 2017-04
In January 2017, the FASB issued ASU 2017-04, "Simplifying the Test for Goodwill Impairment." This update eliminates Step 2 of the goodwill impairment test. As such, an entity will perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize a goodwill impairment charge for the amount by which the reporting unit's carrying amount exceeds its fair value. This standard is effective for the Company for annual and interim periods beginning after December 15, 2019. The Company does not expect a material impact on the Consolidated Financial Statements and related notes from the adoption of this standard.

Accounting Standards Update No. 2017-05
In February 2017, the FASB issued ASU 2017-05, "Other Income - Gains and Losses from the Derecognition of Nonfinancial Assets." This update defines an in-substance nonfinancial asset, unifies guidance related to partial sales of nonfinancial assets, eliminates rules specifically addressing the sales of real estate, removes exceptions to the financial asset derecognition model and clarifies the accounting for contributions of nonfinancial assets to joint ventures. The Company adopted this standard as of January 1, 2018 on the full retrospective adoption method. The adoption of this standard did not have a material impact to the Consolidated Financial Statements and related notes.

Accounting Standards Update No. 2017-09
In May 2017, the FASB issued ASU 2017-09, "Compensation - Stock Compensation - Scope of Modification Accounting." This update provides guidance about which changes to the terms and conditions of share-based awards require an entity to apply modification accounting in Topic 718. The Company adopted this standard on January 1, 2018. The adoption of this standard did not have a material impact to the Consolidated Financial Statements and related notes.
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.10.0.1
Summary of Significant Accounting Policies (Tables)
9 Months Ended
Sep. 30, 2018
Accounting Policies [Abstract]  
Disaggregation of revenue Below is a detail of the amounts by category:
(in thousands)
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
Type of Revenue
 
2018
 
2017
 
2018
 
2017
Parking income
 
$
1,752

 
$
1,669

 
$
5,197

 
$
4,907

Rental lease guaranty
 
168

 
168

 
488

 
545

Management fee income
 
68

 
70

 
205

 
237

Miscellaneous
 
22

 
40

 
83

 
127

 
 
$
2,010

 
$
1,947

 
$
5,973

 
$
5,816

Schedule of reclassifications These amounts are considered immaterial and have been reclassified for the prior year presentation on the Company's Condensed Consolidated Statements of Income.
 
Three months ended September 30, 2017
 
Nine months ended September 30, 2017
(in thousands)
As Previously Reported
 
As Reclassified
 
As Previously Reported
 
As Reclassified
EXPENSES
 
 
 
 
 
 
 
Property operating expense
$
40,626

 
$
40,628

 
$
116,644

 
$
116,663

Bad debt, net
14

 
4

 
185

 
175

 
 
 
 
 
 
 
 
OTHER INCOME (EXPENSE)
 
 
 
 
 
 
 
Gain on sales of properties
(7
)
 
(7
)
 
39,519

 
39,525

 
 
 
 
 
 
 
 
INCOME FROM CONTINUING OPERATIONS
$
3,165

 
$
3,173

 
$
60,247

 
$
60,243

 
 
 
 
 
 
 
 
DISCONTINUED OPERATIONS
 
 
 
 
 
 
 
Income (loss) from discontinued operations
$
8

 
$

 
$
(9
)
 
$

Gain on sales of properties

 

 
5

 

INCOME (LOSS) FROM DISCONTINUED OPERATIONS
$
8

 
$

 
$
(4
)
 
$

Impact of Adoption of New Accounting Standard The following table represents the impact of the adoption of this standard on the Company's Condensed Consolidated Statements of Income for the three and nine months ended September 30, 2017:

 
Three months ended September 30, 2017
 
Nine months ended September 30, 2017
(in thousands)
As Reported
 
As Reclassified
 
As Reported
 
As Reclassified
REVENUES
 
 
 
 
 
 
 
Rental income
$
106,561

 
$
105,078

 
$
315,519

 
$
311,171

Other operating
392

 
1,947

 
1,249

 
5,816

 
$
106,953

 
$
107,025

 
$
316,768

 
$
316,987

 
 
 
 
 
 
 
 
OTHER INCOME (EXPENSE)
 
 
 
 
 
 
 
Interest and other income, net
$
426

 
$
354

 
$
616

 
$
396

 
 
 
 
 
 
 
 
NET INCOME
$
3,173

 
$
3,173

 
$
60,243

 
$
60,243

XML 28 R18.htm IDEA: XBRL DOCUMENT v3.10.0.1
Real Estate Investments (Tables)
9 Months Ended
Sep. 30, 2018
Business Combinations [Abstract]  
Summary of acquisitions The following table details the Company's acquisitions for the nine months ended September 30, 2018:
(Dollars in millions)
Type (1)
 
Date
Acquired
 
Purchase Price

 
Mortgage
Notes Payable Assumed
(2)

 
Cash
Consideration
(3)

 
Real
Estate

 
Other (4)

 
Square
Footage
(Unaudited)

Seattle, Washington
MOB
 
5/4/18
 
$
7.8

 
$

 
$
7.8

 
$
7.8

 
$

 
13,314

Denver, Colorado (5)
MOB, OFC
 
5/18/18
 
25.0

 
(8.0
)
 
16.6

 
25.1

 
(0.4
)
 
187,861

Oklahoma City, Oklahoma
MOB
 
5/21/18
 
11.4

 

 
11.4

 
11.5

 
(0.1
)
 
82,647

Seattle, Washington
MOB
 
6/29/18
 
26.2

 

 
26.2

 
26.7

 
(0.5
)
 
86,942

Denver, Colorado
MOB
 
8/24/18
 
4.1

 

 
4.2

 
4.2

 

 
17,084

 
 
 
 
 
$
74.5

 
$
(8.0
)
 
$
66.2

 
$
75.3

 
$
(1.0
)
 
387,848

______
(1)
MOB = medical office building; OFC = office
(2)
The mortgage note payable assumed in the acquisition does not reflect the fair value premium totaling $0.1 million recorded by the Company upon acquisition (included in Other).
(3)
Cash consideration excludes prorations of revenue and expense due to/from seller at the time of the acquisition.
(4)
Includes other assets acquired, liabilities assumed, intangibles recognized at acquisition and fair value adjustments on debt assumed.
(5)
Includes two properties.

Summary of dispositions The following table details the Company's dispositions for the nine months ended September 30, 2018:
(Dollars in millions)
Type (1)
 
Date
Disposed
 
Sales Price
 
Closing Adjustments
 
Net
Proceeds
 
Net Real
Estate
Investment
 
Other (including receivables) (2)
 
Gain
 
Square
Footage
(
Unaudited)
Virginia (3) (4)
MOB, OFC
 
4/26/18
 
$
46.2

 
$

 
$
46.2

 
$
23.9

 
$

 
$
22.3

 
460,881

Michigan (3) (5)
SNF
 
6/27/18
 
9.5

 
(0.7
)
 
8.8

 
3.4

 

 
5.4

 
121,672

Missouri
MOB
 
8/30/18
 
9.8

 
(0.5
)
 
9.3

 
7.5

 
0.5

 
1.3

 
70,893

Total dispositions
 
$
65.5

 
$
(1.2
)
 
$
64.3

 
$
34.8

 
$
0.5

 
$
29.0

 
653,446

______
(1)
MOB = medical office building; OFC = office; SNF = skilled nursing facility
(2)
Includes straight-line rent receivables and leasing commissions.
(3)
Previously classified as held for sale.
(4)
Includes seven properties, comprised of five single-tenant net lease buildings and two multi-tenant buildings. These buildings were sold pursuant to the exercise of a fixed-price purchase option.
(5)
Includes five skilled nursing facilities. Sales price includes $0.5 million of forfeited earnest money from a prior terminated transaction.
Assets held for sale The table below reflects the assets and liabilities of the properties classified as held for sale as of September 30, 2018 and December 31, 2017:
(Dollars in thousands)
September 30,
2018
 
December 31,
2017
Balance Sheet data:
 
 
 
Land
$
1,125

 
$
4,636

Buildings, improvements and lease intangibles
18,231

 
63,654

Personal property

 
82

 
19,356

 
68,372

Accumulated depreciation
(10,657
)
 
(35,790
)
Real estate assets held for sale, net
8,699

 
32,582

Other assets, net
127

 
565

Assets held for sale, net
$
8,826

 
$
33,147

 
 
 
 
Accounts payable and accrued liabilities
$
119

 
$
38

Other liabilities
22

 
55

Liabilities of properties held for sale
$
141

 
$
93

XML 29 R19.htm IDEA: XBRL DOCUMENT v3.10.0.1
Notes and Bonds Payable (Tables)
9 Months Ended
Sep. 30, 2018
Debt Disclosure [Abstract]  
Schedule of Debt The table below details the Company’s notes and bonds payable. 
 
Maturity
Dates
 
Balance as of
 
Effective Interest Rate as of

(Dollars in thousands)
September 30, 2018

 
December 31, 2017

September 30, 2018

Unsecured Credit Facility
7/20
 
$
245,000

 
$
189,000

 
3.26
%
Unsecured Term Loan Facility, net of issuance costs (1)
12/22
 
149,132

 
148,994

 
3.41
%
Senior Notes due 2023, net of discount and issuance costs
4/23
 
248,013

 
247,703

 
3.95
%
Senior Notes due 2025, net of discount and issuance costs (2)
5/25
 
248,219

 
248,044

 
4.08
%
Senior Notes due 2028, net of discount and issuance costs
1/28
 
295,087

 
294,757

 
3.84
%
Mortgage notes payable, net of discounts and issuance costs and including premiums
12/18-5/40
 
159,308

 
155,382

 
4.83
%
 
 
 
$
1,344,759

 
$
1,283,880

 
 


______
(1)
The effective interest rate includes the impact of interest rate swaps on $25.0 million and $50.0 million of the outstanding balance at a rate of 2.18% and 2.46%, respectively (plus the applicable margin rate, currently 110 basis points).
(2)
The effective interest rate includes the impact of the $1.7 million settlement of a forward-starting interest rate swap that is included in Accumulated other comprehensive income (loss) on the Company's Condensed Consolidated Balance Sheets.

XML 30 R20.htm IDEA: XBRL DOCUMENT v3.10.0.1
Derivative Financial Instruments (Tables)
9 Months Ended
Sep. 30, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) As of September 30, 2018, the Company had four outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk:
Derivative Instrument
 
Number of Instruments

 
Notional Amount
(in millions)
Interest rate swaps
 
4

 
$75.0
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value The table below presents the fair value of the Company's derivative financial instruments, as well as their classification on the Condensed Consolidated Balance Sheet as of September 30, 2018.
 
Asset Derivatives
 
Balance at September 30, 2018
(Dollars in thousands)
Balance Sheet Location
 
Fair Value

Derivatives designated as hedging instruments
 
 
 
Interest rate swaps
Other assets
 
$
1,579

Total derivatives designated as hedging instruments
 
 
$
1,579

Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss) The table below presents the effect of cash flow hedge accounting on Accumulated Other Comprehensive Income (Loss) ("OCI") during the nine months ended September 30, 2018 and 2017 related to the Company's outstanding interest rate swaps.
 
Amount of Gain Recognized in OCI on Derivative
 
Amount of Loss Reclassified from OCI into Income
(Dollars in thousands)
2018

2018

 
2017

Interest rate products
$
1,403

Interest expense
$
243

 
$

Settled interest rate swaps

Interest expense
126

 
127

 
$
1,403

Total interest expense
$
369

 
$
127


XML 31 R21.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stockholders' Equity (Tables)
9 Months Ended
Sep. 30, 2018
Equity [Abstract]  
Reconciliation of beginning and ending common stock outstanding The following table provides a reconciliation of the beginning and ending shares of common stock outstanding for the nine months ended September 30, 2018 and the year ended December 31, 2017:
 
September 30, 2018
 
December 31, 2017
Balance, beginning of period
125,131,593

 
116,416,900

Issuance of common stock
20,395

 
8,395,607

Nonvested share-based awards, net of withheld shares
85,196

 
319,086

Balance, end of period
125,237,184

 
125,131,593

Schedule of accumulated other comprehensive income (loss) The following table represents the changes in balances of each component and the amounts reclassified out of OCI related to the Company during the nine months ended September 30, 2018 and 2017:
 
Forward-starting Interest Rate Swaps
 
(Dollars in thousands)
2018
 
2017
 
Beginning balance
$
(1,299
)
 
$
(1,401
)
 
Gains arising during the period related to active interest rate swaps
1,403

 

 
Amounts reclassified from accumulated other comprehensive (income) loss
369

 
127

 
Net accumulated other comprehensive income
1,772

 
127

 
Ending balance
$
473

 
$
(1,274
)
 
Reclassification out of Accumulated Other Comprehensive Income The following table represents the details regarding the reclassifications from OCI during the nine months ended September 30, 2018:
Details about accumulated other comprehensive income (loss) components
 
Amount reclassified from accumulated other comprehensive income (loss)

 
Affected line item in the statement where net income is presented
(Dollars in thousands)
 
 
 
 
Amounts reclassified from accumulated other comprehensive income (loss) related to settled interest rate swaps
 
$
126

 
Interest Expense
Amounts reclassified from accumulated other comprehensive income (loss) related to current interest rate swaps
 
243

 
Interest Expense
 
 
$
369

 
 
Earnings (loss) per share The following table sets forth the computation of basic and diluted earnings per common share for the three and nine months ended September 30, 2018 and 2017.
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
(Dollars in thousands, except per share data)
2018
 
2017
 
2018
 
2017
Weighted average Common Shares outstanding
 
 
 
 
 
 
 
Weighted average Common Shares outstanding
125,233,462

 
120,895,835

 
125,206,342

 
117,981,159

Nonvested shares
(1,933,653
)
 
(1,797,686
)
 
(1,925,589
)
 
(1,800,180
)
Weighted average Common Shares outstanding—Basic
123,299,809

 
119,098,149

 
123,280,753

 
116,180,979

Weighted average Common Shares outstanding—Basic
123,299,809

 
119,098,149

 
123,280,753

 
116,180,979

Dilutive effect of employee stock purchase plan
52,147

 
83,242

 
54,763

 
96,260

Weighted average Common Shares outstanding—Diluted
123,351,956

 
119,181,391

 
123,335,516

 
116,277,239

Net Income
$
6,548

 
$
3,173

 
$
53,456

 
$
60,243

Dividends paid on nonvested share-based awards
(580
)
 
(538
)
 
(1,740
)
 
(1,609
)
Net income applicable to common stockholders
$
5,968

 
$
2,635

 
$
51,716

 
$
58,634

Basic earnings per common share - Net income
$
0.05

 
$
0.02

 
$
0.42

 
$
0.50

Diluted earnings per common share - Net income
$
0.05

 
$
0.02

 
$
0.42

 
$
0.50

Summary of the activity under the Incentive Plan A summary of the activity under the Company's share-based incentive plans for the three and nine months ended September 30, 2018 and 2017 is included in the table below.
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Share-based awards, beginning of period
1,938,100

 
1,797,686

 
1,907,645

 
1,786,497

Granted

 

 
107,751

 
103,615

Vested
(5,051
)
 

 
(82,347
)
 
(92,426
)
Share-based awards, end of period
1,933,049

 
1,797,686

 
1,933,049

 
1,797,686

Summary of employee stock purchase plan activity A summary of the activity under the Purchase Plan for the three and nine months ended September 30, 2018 and 2017 is included in the table below.
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Outstanding and exercisable, beginning of period
350,535

 
344,572

 
318,100

 
316,321

Granted

 

 
203,836

 
206,824

Exercised
(2,531
)
 
(5,452
)
 
(13,236
)
 
(24,482
)
Forfeited
(9,583
)
 
(9,291
)
 
(34,489
)
 
(36,524
)
Expired

 

 
(135,790
)
 
(132,310
)
Outstanding and exercisable, end of period
338,421

 
329,829

 
338,421

 
329,829

XML 32 R22.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fair Value of Financial Instruments (Tables)
9 Months Ended
Sep. 30, 2018
Fair Value Disclosures [Abstract]  
Fair value and carrying values for notes and bonds payable, mortgage notes receivable, and notes receivable The table below details the fair values and carrying values for notes and bonds payable at September 30, 2018 and December 31, 2017.
 
September 30, 2018
 
December 31, 2017
(Dollars in millions)
Carrying Value
 
Fair Value
 
Carrying Value
 
Fair Value
Notes and bonds payable (1)
$
1,344.8

 
$
1,300.2

 
$
1,283.9

 
$
1,269.7


______
(1)
Level 2 – model-derived valuations in which significant inputs and significant value drivers are observable in active markets.
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.10.0.1
Summary of Significant Accounting Policies (Details)
ft² in Millions, $ in Billions
Sep. 30, 2018
USD ($)
ft²
state
property
Business Overview:  
Gross investment amount, total | $ $ 3.9
Number of real estate properties | property 201
Number of states that the Company owns real estate in, whole units | state 27
Square footage of owned real estate properties 14.8
Approximate square feet for which Nationwide property management services provided by company 11.1
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.10.0.1
Summary of Significant Accounting Policies - Revenue Recognition (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Disaggregation of Revenue [Line Items]        
Other operating $ 2,010 $ 1,947 $ 5,973 $ 5,816
Parking Income        
Disaggregation of Revenue [Line Items]        
Other operating 1,752 1,669 5,197 4,907
Rental Lease Guaranty        
Disaggregation of Revenue [Line Items]        
Other operating 168 168 488 545
Management Fee Income        
Disaggregation of Revenue [Line Items]        
Other operating 68 70 205 237
Miscellaneous        
Disaggregation of Revenue [Line Items]        
Other operating $ 22 $ 40 $ 83 $ 127
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.10.0.1
Summary of Significant Accounting Policies - Reclassifications (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Reclassifications [Line Items]        
Property operating expense $ 44,135 $ 40,628 $ 127,691 $ 116,663
Bad debts, net of recoveries (62) 4 42 175
Gain on sales of properties 1,288 (7) 30,879 39,525
INCOME FROM CONTINUING OPERATIONS $ 6,548 3,173 $ 53,456 60,243
Income (loss) from discontinued operations   0   0
Gain on sales of properties   0   0
INCOME (LOSS) FROM DISCONTINUED OPERATIONS   0   0
As Previously Reported        
Reclassifications [Line Items]        
Property operating expense   40,626   116,644
Bad debts, net of recoveries   14   185
Gain on sales of properties   (7)   39,519
INCOME FROM CONTINUING OPERATIONS   3,165   60,247
Income (loss) from discontinued operations   8   (9)
Gain on sales of properties   0   5
INCOME (LOSS) FROM DISCONTINUED OPERATIONS   $ 8   $ (4)
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.10.0.1
Summary of Significant Accounting Policies - Impact of Adoption of New Accounting Standard (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
New Accounting Pronouncements or Change in Accounting Principle [Line Items]        
Rental income $ 111,452 $ 105,078 $ 331,247 $ 311,171
Other operating 2,010 1,947 5,973 5,816
Revenues 113,462 107,025 337,220 316,987
Interest and other income, net 41 354 571 396
NET INCOME $ 6,548 3,173 $ 53,456 60,243
As Reported        
New Accounting Pronouncements or Change in Accounting Principle [Line Items]        
Rental income   106,561   315,519
Other operating   392   1,249
Revenues   106,953   316,768
Interest and other income, net   426   616
NET INCOME   $ 3,173   $ 60,243
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.10.0.1
Real Estate Investments - Acquisitions (Details)
$ in Millions
9 Months Ended
Aug. 24, 2018
USD ($)
ft²
Jun. 29, 2018
USD ($)
a
ft²
Jun. 27, 2018
USD ($)
May 21, 2018
USD ($)
ft²
May 18, 2018
USD ($)
ft²
property
May 03, 2018
USD ($)
ft²
Apr. 26, 2018
USD ($)
Sep. 30, 2018
USD ($)
ft²
Business Acquisition [Line Items]                
Gain on disposition of property     $ 5.4       $ 22.3  
Real Estate Acquisition                
Business Acquisition [Line Items]                
Purchase price               $ 74.5
Mortgage Note Payable Assumed               (8.0)
Cash consideration               66.2
Real Estate               75.3
Other               $ (1.0)
Square footage | ft²               387,848
Fair value adjustments               $ 0.1
WASHINGTON | Real Estate Acquisition                
Business Acquisition [Line Items]                
Date Acquired   Jun. 29, 2018       May 04, 2018    
Purchase price   $ 26.2       $ 7.8    
Mortgage Note Payable Assumed   0.0       0.0    
Cash consideration   26.2       7.8    
Real Estate   26.7       7.8    
Other   $ (0.5)       $ 0.0    
Square footage | ft²   86,942       13,314    
COLORADO | Real Estate Acquisition                
Business Acquisition [Line Items]                
Date Acquired Aug. 24, 2018       May 18, 2018      
Purchase price $ 4.1       $ 25.0      
Mortgage Note Payable Assumed 0.0       (8.0)      
Cash consideration 4.2       16.6      
Real Estate 4.2       25.1      
Other $ 0.0       $ (0.4)      
Square footage | ft² 17,084       187,861      
Number of properties acquired | property         2      
OKLAHOMA | Real Estate Acquisition                
Business Acquisition [Line Items]                
Date Acquired       May 21, 2018        
Purchase price       $ 11.4        
Mortgage Note Payable Assumed       0.0        
Cash consideration       11.4        
Real Estate       11.5        
Other       $ (0.1)        
Square footage | ft²       82,647        
Land Held for Development | Real Estate Acquisition                
Business Acquisition [Line Items]                
Area of land acquired | a   20.5            
Real Estate Dispositions                
Business Acquisition [Line Items]                
Net Real Estate Investment               34.8
Gain on disposition of property               $ 29.0
Real Estate Dispositions | Garage                
Business Acquisition [Line Items]                
Net Real Estate Investment   $ 3.9            
Gain on disposition of property   $ 1.9            
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.10.0.1
Real Estate Investments - Dispositions (Details)
$ in Millions
9 Months Ended
Aug. 30, 2018
USD ($)
ft²
Jun. 29, 2018
USD ($)
a
Jun. 27, 2018
USD ($)
ft²
property
Apr. 26, 2018
USD ($)
ft²
building
property
Sep. 30, 2018
USD ($)
ft²
Real Estate Dispositions [Line Items]          
Number of properties exercising purchase option | property     5 7  
Number of single-tenant net leased buildings | building       5  
Number of multi-tenant buildings | building       2  
Gain/(Impairment)     $ 5.4 $ 22.3  
Real Estate Dispositions          
Real Estate Dispositions [Line Items]          
Sales price         $ 65.5
Net Proceeds         64.3
Closing Adjustments         (1.2)
Net Real Estate Investment         34.8
Real Estate Other         0.5
Gain/(Impairment)         $ 29.0
Square footage | ft²         653,446
Real Estate Dispositions | VIRGINIA          
Real Estate Dispositions [Line Items]          
Disposal Date       Apr. 26, 2018  
Sales price       $ 46.2  
Net Proceeds       46.2  
Closing Adjustments       0.0  
Net Real Estate Investment       23.9  
Real Estate Other       0.0  
Gain/(Impairment)       $ 22.3  
Square footage | ft²       460,881  
Real Estate Dispositions | MICHIGAN          
Real Estate Dispositions [Line Items]          
Disposal Date     Jun. 27, 2018    
Number of properties exercising purchase option | property     5    
Sales price     $ 9.5    
Net Proceeds     8.8    
Closing Adjustments     (0.7)    
Net Real Estate Investment     3.4    
Real Estate Other     0.0    
Gain/(Impairment)     $ 5.4    
Square footage | ft²     121,672    
Forfeited earnest money     $ 0.5    
Real Estate Dispositions | MISSOURI          
Real Estate Dispositions [Line Items]          
Disposal Date Aug. 30, 2018        
Sales price $ 9.8        
Net Proceeds 9.3        
Closing Adjustments (0.5)        
Net Real Estate Investment 7.5        
Real Estate Other 0.5        
Gain/(Impairment) $ 1.3        
Square footage | ft² 70,893        
Garage | Real Estate Dispositions          
Real Estate Dispositions [Line Items]          
Net Real Estate Investment   $ 3.9      
Gain/(Impairment)   $ 1.9      
Real Estate Acquisition | Medical Office Building          
Real Estate Dispositions [Line Items]          
Area of land acquired | a   4.6      
Real Estate Acquisition | Land Held for Development          
Real Estate Dispositions [Line Items]          
Appraised value of land   $ 5.8      
Area of land acquired | a   20.5      
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.10.0.1
Real Estate Investments - Assets Held for Sale (Details)
$ in Millions
3 Months Ended
Jun. 27, 2018
USD ($)
property
Apr. 26, 2018
USD ($)
building
property
Mar. 31, 2018
property
Sep. 30, 2018
property
Dec. 31, 2017
property
Business Combinations [Abstract]          
Number of properties held for sale       1 8
Number of properties reclassified to held for sale     5    
Gain on disposition of property | $ $ 5.4 $ 22.3      
Number of properties exercising purchase option 5 7      
Number of single-tenant net leased buildings | building   5      
Number of multi-tenant buildings | building   2      
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.10.0.1
Real Estate Investments - Discontinued Operations and Assets Held for Sale - Balance Sheet (Details) - USD ($)
$ in Thousands
Sep. 30, 2018
Dec. 31, 2017
Balance Sheet data (as of the period ended):    
Land $ 217,322 $ 201,283
Buildings, improvements and lease intangibles 3,669,852 3,601,460
Personal property 10,454 10,314
Real estate properties, Total 3,949,233 3,838,638
Accumulated depreciation (989,585) (897,430)
Total real estate properties, net 2,959,648 2,941,208
Other assets, net 222,582 213,015
Assets held for sale, net 8,826 33,147
Liabilities of properties held for sale 141 93
Discontinued Operations    
Balance Sheet data (as of the period ended):    
Land 1,125 4,636
Buildings, improvements and lease intangibles 18,231 63,654
Personal property 0 82
Real estate properties, Total 19,356 68,372
Accumulated depreciation (10,657) (35,790)
Total real estate properties, net 8,699 32,582
Other assets, net 127 565
Assets held for sale, net 8,826 33,147
Accounts payable and accrued liabilities 119 38
Other liabilities 22 55
Liabilities of properties held for sale $ 141 $ 93
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.10.0.1
Notes and Bonds Payable (Details) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2018
Dec. 31, 2017
Debt Instrument [Line Items]    
Notes and bonds payable $ 1,344,759 $ 1,283,880
Line of Credit | Unsecured Credit Facility    
Debt Instrument [Line Items]    
Notes and bonds payable $ 245,000 189,000
Effective interest rate (percent) 3.26%  
Medium-term Notes | Unsecured Term Loan Facility, net of issuance costs (1)    
Debt Instrument [Line Items]    
Notes and bonds payable $ 149,132 148,994
Effective interest rate (percent) 3.41%  
Notional amount $ 50,000  
Derivative, fixed interest rate (percent) 2.46%  
Basis spread on variable rate (percent) 1.10%  
Senior Notes | Senior Notes due 2023, net of discount and issuance costs    
Debt Instrument [Line Items]    
Notes and bonds payable $ 248,013 247,703
Effective interest rate (percent) 3.95%  
Senior Notes | Senior Notes due 2025, net of discount and issuance costs (2)    
Debt Instrument [Line Items]    
Notes and bonds payable $ 248,219 248,044
Effective interest rate (percent) 4.08%  
Senior Notes | Senior Notes due 2028, net of discount and issuance costs    
Debt Instrument [Line Items]    
Notes and bonds payable $ 295,087 294,757
Effective interest rate (percent) 3.84%  
Mortgages | Mortgage notes payable, net of discounts and issuance costs and including premiums    
Debt Instrument [Line Items]    
Notes and bonds payable $ 159,308 $ 155,382
Effective interest rate (percent) 4.83%  
Interest Rate Swap | Medium-term Notes | Unsecured Term Loan Facility, net of issuance costs (1)    
Debt Instrument [Line Items]    
Notional amount $ 25,000  
Derivative, fixed interest rate (percent) 2.18%  
Interest Rate Swap | Senior Notes | Senior Notes due 2025, net of discount and issuance costs (2)    
Debt Instrument [Line Items]    
Loss on forward starting interest rate swap agreement recognized in OCI $ 1,700  
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.10.0.1
Derivative Financial Instruments - Derivative Instruments Designated as Cash Flow Hedges (Details)
$ in Millions
Sep. 30, 2018
USD ($)
swap_agreement
Derivative [Line Items]  
Number of instruments 4
Cash Flow Hedging | Designated as Hedging Instrument | Interest Rate Swap  
Derivative [Line Items]  
Number of instruments 4
Notional amount | $ $ 75.0
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.10.0.1
Derivative Financial Instruments - Fair Value of Derivative Instruments on the Balance Sheet (Details) - Designated as Hedging Instrument - Interest Rate Swap
$ in Thousands
Sep. 30, 2018
USD ($)
Derivative [Line Items]  
Asset derivatives $ 1,579
Other assets  
Derivative [Line Items]  
Asset derivatives $ 1,579
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.10.0.1
Derivative Financial Instruments - Effect of Cash Flow Hedging on AOCI (Details) - Cash Flow Hedging - Designated as Hedging Instrument - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Derivative [Line Items]    
Amount of Gain Recognized in OCI on Derivative $ 1,403  
Interest Rate Products    
Derivative [Line Items]    
Amount of Gain Recognized in OCI on Derivative 1,403  
Settled Interest Rate Swaps    
Derivative [Line Items]    
Amount of Gain Recognized in OCI on Derivative 0  
Interest Expense    
Derivative [Line Items]    
Amount of Loss Reclassified from OCI into Income 369 $ 127
Interest Expense | Interest Rate Products    
Derivative [Line Items]    
Amount of Loss Reclassified from OCI into Income 243 0
Interest Expense | Settled Interest Rate Swaps    
Derivative [Line Items]    
Amount of Loss Reclassified from OCI into Income $ 126 $ 127
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.10.0.1
Derivative Financial Instruments - Additional Information (Details)
$ in Millions
Sep. 30, 2018
USD ($)
Active Interest Rate Swap  
Derivative Instruments, Gain (Loss) [Line Items]  
Interest rate cash flow hedge gain (loss) to be reclassified to interest expense during the next 12 months $ 0.2
Settled Interest Rate Swap  
Derivative Instruments, Gain (Loss) [Line Items]  
Interest rate cash flow hedge gain (loss) to be reclassified to interest expense during the next 12 months $ (0.2)
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.10.0.1
Commitments and Contingencies - Construction Activity (Details)
$ in Millions
Sep. 30, 2018
USD ($)
ft²
Other Commitments [Line Items]  
Approximate Square Feet 14,800,000
Medical Office Building Expansion | NORTH CAROLINA  
Other Commitments [Line Items]  
Approximate Square Feet 38,000
Medical Office Building | NORTH CAROLINA  
Other Commitments [Line Items]  
Total amount funded | $ $ 9.2
Medical Office Building | COLORADO  
Other Commitments [Line Items]  
Approximate Square Feet 151,000
Total amount funded | $ $ 18.0
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stockholders' Equity - Reconciliation of beginning and ending common stock outstanding (Details) - shares
9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Reconciliation of the beginning and ending common stock outstanding    
Balance, beginning of period 125,132,000  
Balance, end of period 125,237,000  
Common Stock    
Reconciliation of the beginning and ending common stock outstanding    
Balance, beginning of period 125,131,593 116,416,900
Issuance of common stock 20,395 8,395,607
Nonvested share-based awards, net of withheld shares 85,196 319,086
Balance, end of period 125,237,184  
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stockholders' Equity (Stock Transactions - Narrative) (Details) - $ / shares
3 Months Ended 9 Months Ended
Oct. 30, 2018
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Oct. 26, 2018
Class of Stock [Line Items]            
Dividends declared per common share, during the period (in dollars per share)   $ 0.30 $ 0.30 $ 0.90 $ 0.90  
At The Market Equity Offering Program            
Class of Stock [Line Items]            
Issuance of common stock (shares)       0    
Subsequent Event            
Class of Stock [Line Items]            
Dividends declared per common share, during the period (in dollars per share) $ 0.30          
Subsequent Event | At The Market Equity Offering Program            
Class of Stock [Line Items]            
Number of authorized shares remaining under offering program (shares)           5,868,697
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stockholders' Equity - Changes in accumulated other comprehensive income (Details)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2018
USD ($)
swap_agreement
Sep. 30, 2017
USD ($)
Sep. 30, 2018
USD ($)
swap_agreement
Sep. 30, 2017
USD ($)
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Number of instruments | swap_agreement 4   4  
Period for reclassification out of AOCI     10 years  
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]        
Beginning balance     $ 1,789,883  
Total other comprehensive income $ 469 $ 43 1,772 $ 127
Ending balance 1,740,252   1,740,252  
Forward-starting Interest Rate Swaps        
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]        
Beginning balance     (1,299) (1,401)
Gains arising during the period related to active interest rate swaps     1,403 0
Amounts reclassified from accumulated other comprehensive (income) loss     369 127
Total other comprehensive income     1,772 127
Ending balance $ 473 $ (1,274) $ 473 $ (1,274)
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stockholders' Equity - Reclassifications out of AOCI (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]        
Interest Expense $ 13,464 $ 14,107 $ 39,202 $ 42,694
NET INCOME $ 6,548 $ 3,173 53,456 $ 60,243
Reclassification out of Accumulated Other Comprehensive Income        
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]        
NET INCOME     369  
Amounts reclassified from accumulated other comprehensive income (loss) related to settled interest rate swaps | Reclassification out of Accumulated Other Comprehensive Income        
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]        
Interest Expense     126  
Amounts reclassified from accumulated other comprehensive income (loss) related to current interest rate swaps | Reclassification out of Accumulated Other Comprehensive Income        
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]        
Interest Expense     $ 243  
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stockholders' Equity - Computation of basic and diluted earnings (loss) per common share (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Weighted average Common Shares outstanding        
Weighted average Common Shares outstanding 125,233,462 120,895,835 125,206,342 117,981,159
Nonvested shares (1,933,653) (1,797,686) (1,925,589) (1,800,180)
Weighted average Common Shares—Basic 123,299,809 119,098,149 123,280,753 116,180,979
Dilutive effect of employee stock purchase plan 52,147 83,242 54,763 96,260
Weighted average Common Shares outstanding—Diluted 123,351,956 119,181,391 123,335,516 116,277,239
Net Income $ 6,548 $ 3,173 $ 53,456 $ 60,243
Dividends paid on nonvested share-based awards (580) (538) (1,740) (1,609)
Net income applicable to common stockholders $ 5,968 $ 2,635 $ 51,716 $ 58,634
Basic earnings per common share (in dollars per share) $ 0.05 $ 0.02 $ 0.42 $ 0.50
Diluted earnings per common share (in dollars per share) $ 0.05 $ 0.02 $ 0.42 $ 0.50
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stockholders' Equity - Summary of activity under stock-based incentive plans (Details) - Stock Incentive Plan - shares
3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Summary of the activity under the incentive plans        
Share-based awards, beginning of period 1,938,100 1,797,686 1,907,645 1,786,497
Granted (shares) 0 0 107,751 103,615
Vested (shares) (5,051) 0 (82,347) (92,426)
Share-based awards, end of period 1,933,049 1,797,686 1,933,049 1,797,686
Restricted Stock        
Summary of the activity under the incentive plans        
Shares withheld to pay estimated withholding taxes     22,555 16,581
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stockholders' Equity - Summary of activity under Employee Stock Purchase Plan (Details) - Employee Stock Purchase Plan - shares
3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Summary of the Employee Stock Purchase Plan activity        
Outstanding and exercisable, beginning of period (shares) 350,535 344,572 318,100 316,321
Granted (shares) 0 0 203,836 206,824
Exercised (shares) (2,531) (5,452) (13,236) (24,482)
Forfeited (shares) (9,583) (9,291) (34,489) (36,524)
Expired (shares) 0 0 (135,790) (132,310)
Outstanding and exercisable, end of period (shares) 338,421 329,829 338,421 329,829
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fair Value of Financial Instruments (Details) - USD ($)
$ in Millions
Sep. 30, 2018
Dec. 31, 2017
Carrying Value    
Derivative [Line Items]    
Notes and bonds payable $ 1,344.8 $ 1,283.9
Fair Value    
Derivative [Line Items]    
Notes and bonds payable $ 1,300.2 $ 1,269.7
EXCEL 55 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 57 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 59 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 143 204 1 false 53 0 false 10 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://healthcarerealty.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 1001501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1002000 - Statement - Condensed Consolidated Statements of Income (Unaudited) Sheet http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited Condensed Consolidated Statements of Income (Unaudited) Statements 4 false false R5.htm 1003000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited) Sheet http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited Condensed Consolidated Statements of Comprehensive Income (Unaudited) Statements 5 false false R6.htm 1004000 - Statement - Condensed Consolidated Statement of Equity (Unaudited) Statement Sheet http://healthcarerealty.com/role/CondensedConsolidatedStatementOfEquityUnauditedStatement Condensed Consolidated Statement of Equity (Unaudited) Statement Statements 6 false false R7.htm 1004001 - Statement - Condensed Consolidated Statement of Equity (Unaudited) (Parenthetical) Sheet http://healthcarerealty.com/role/CondensedConsolidatedStatementOfEquityUnauditedParenthetical Condensed Consolidated Statement of Equity (Unaudited) (Parenthetical) Statements 7 false false R8.htm 1005000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 8 false false R9.htm 2101100 - Disclosure - Summary of Significant Accounting Policies Sheet http://healthcarerealty.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 2102100 - Disclosure - Real Estate Investments Sheet http://healthcarerealty.com/role/RealEstateInvestments Real Estate Investments Notes 10 false false R11.htm 2103100 - Disclosure - Notes and Bonds Payable Notes http://healthcarerealty.com/role/NotesAndBondsPayable Notes and Bonds Payable Notes 11 false false R12.htm 2104100 - Disclosure - Derivative Financial Instruments Sheet http://healthcarerealty.com/role/DerivativeFinancialInstruments Derivative Financial Instruments Notes 12 false false R13.htm 2105100 - Disclosure - Commitments and Contingencies Sheet http://healthcarerealty.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 13 false false R14.htm 2106100 - Disclosure - Stockholders' Equity Sheet http://healthcarerealty.com/role/StockholdersEquity Stockholders' Equity Notes 14 false false R15.htm 2108100 - Disclosure - Fair Value of Financial Instruments Sheet http://healthcarerealty.com/role/FairValueOfFinancialInstruments Fair Value of Financial Instruments Notes 15 false false R16.htm 2201201 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://healthcarerealty.com/role/SummaryOfSignificantAccountingPolicies 16 false false R17.htm 2301302 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://healthcarerealty.com/role/SummaryOfSignificantAccountingPolicies 17 false false R18.htm 2302301 - Disclosure - Real Estate Investments (Tables) Sheet http://healthcarerealty.com/role/RealEstateInvestmentsTables Real Estate Investments (Tables) Tables http://healthcarerealty.com/role/RealEstateInvestments 18 false false R19.htm 2303301 - Disclosure - Notes and Bonds Payable (Tables) Notes http://healthcarerealty.com/role/NotesAndBondsPayableTables Notes and Bonds Payable (Tables) Tables http://healthcarerealty.com/role/NotesAndBondsPayable 19 false false R20.htm 2304301 - Disclosure - Derivative Financial Instruments (Tables) Sheet http://healthcarerealty.com/role/DerivativeFinancialInstrumentsTables Derivative Financial Instruments (Tables) Tables http://healthcarerealty.com/role/DerivativeFinancialInstruments 20 false false R21.htm 2306301 - Disclosure - Stockholders' Equity (Tables) Sheet http://healthcarerealty.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://healthcarerealty.com/role/StockholdersEquity 21 false false R22.htm 2308301 - Disclosure - Fair Value of Financial Instruments (Tables) Sheet http://healthcarerealty.com/role/FairValueOfFinancialInstrumentsTables Fair Value of Financial Instruments (Tables) Tables http://healthcarerealty.com/role/FairValueOfFinancialInstruments 22 false false R23.htm 2401403 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesTables 23 false false R24.htm 2401404 - Disclosure - Summary of Significant Accounting Policies - Revenue Recognition (Details) Sheet http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails Summary of Significant Accounting Policies - Revenue Recognition (Details) Details 24 false false R25.htm 2401405 - Disclosure - Summary of Significant Accounting Policies - Reclassifications (Details) Sheet http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesReclassificationsDetails Summary of Significant Accounting Policies - Reclassifications (Details) Details 25 false false R26.htm 2401406 - Disclosure - Summary of Significant Accounting Policies - Impact of Adoption of New Accounting Standard (Details) Sheet http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfNewAccountingStandardDetails Summary of Significant Accounting Policies - Impact of Adoption of New Accounting Standard (Details) Details 26 false false R27.htm 2402402 - Disclosure - Real Estate Investments - Acquisitions (Details) Sheet http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails Real Estate Investments - Acquisitions (Details) Details 27 false false R28.htm 2402403 - Disclosure - Real Estate Investments - Dispositions (Details) Sheet http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails Real Estate Investments - Dispositions (Details) Details 28 false false R29.htm 2402404 - Disclosure - Real Estate Investments - Assets Held for Sale (Details) Sheet http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldForSaleDetails Real Estate Investments - Assets Held for Sale (Details) Details 29 false false R30.htm 2402405 - Disclosure - Real Estate Investments - Discontinued Operations and Assets Held for Sale - Balance Sheet (Details) Sheet http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails Real Estate Investments - Discontinued Operations and Assets Held for Sale - Balance Sheet (Details) Details 30 false false R31.htm 2403402 - Disclosure - Notes and Bonds Payable (Details) Notes http://healthcarerealty.com/role/NotesAndBondsPayableDetails Notes and Bonds Payable (Details) Details http://healthcarerealty.com/role/NotesAndBondsPayableTables 31 false false R32.htm 2404402 - Disclosure - Derivative Financial Instruments - Derivative Instruments Designated as Cash Flow Hedges (Details) Sheet http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails Derivative Financial Instruments - Derivative Instruments Designated as Cash Flow Hedges (Details) Details 32 false false R33.htm 2404403 - Disclosure - Derivative Financial Instruments - Fair Value of Derivative Instruments on the Balance Sheet (Details) Sheet http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueOfDerivativeInstrumentsOnBalanceSheetDetails Derivative Financial Instruments - Fair Value of Derivative Instruments on the Balance Sheet (Details) Details 33 false false R34.htm 2404404 - Disclosure - Derivative Financial Instruments - Effect of Cash Flow Hedging on AOCI (Details) Sheet http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectOfCashFlowHedgingOnAociDetails Derivative Financial Instruments - Effect of Cash Flow Hedging on AOCI (Details) Details 34 false false R35.htm 2404405 - Disclosure - Derivative Financial Instruments - Additional Information (Details) Sheet http://healthcarerealty.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails Derivative Financial Instruments - Additional Information (Details) Details 35 false false R36.htm 2405401 - Disclosure - Commitments and Contingencies - Construction Activity (Details) Sheet http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails Commitments and Contingencies - Construction Activity (Details) Details 36 false false R37.htm 2406402 - Disclosure - Stockholders' Equity - Reconciliation of beginning and ending common stock outstanding (Details) Sheet http://healthcarerealty.com/role/StockholdersEquityReconciliationOfBeginningAndEndingCommonStockOutstandingDetails Stockholders' Equity - Reconciliation of beginning and ending common stock outstanding (Details) Details 37 false false R38.htm 2406403 - Disclosure - Stockholders' Equity (Stock Transactions - Narrative) (Details) Sheet http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails Stockholders' Equity (Stock Transactions - Narrative) (Details) Details http://healthcarerealty.com/role/StockholdersEquityTables 38 false false R39.htm 2406404 - Disclosure - Stockholders' Equity - Changes in accumulated other comprehensive income (Details) Sheet http://healthcarerealty.com/role/StockholdersEquityChangesInAccumulatedOtherComprehensiveIncomeDetails Stockholders' Equity - Changes in accumulated other comprehensive income (Details) Details 39 false false R40.htm 2406405 - Disclosure - Stockholders' Equity - Reclassifications out of AOCI (Details) Sheet http://healthcarerealty.com/role/StockholdersEquityReclassificationsOutOfAociDetails Stockholders' Equity - Reclassifications out of AOCI (Details) Details 40 false false R41.htm 2406406 - Disclosure - Stockholders' Equity - Computation of basic and diluted earnings (loss) per common share (Details) Sheet http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails Stockholders' Equity - Computation of basic and diluted earnings (loss) per common share (Details) Details 41 false false R42.htm 2406407 - Disclosure - Stockholders' Equity - Summary of activity under stock-based incentive plans (Details) Sheet http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderStockBasedIncentivePlansDetails Stockholders' Equity - Summary of activity under stock-based incentive plans (Details) Details 42 false false R43.htm 2406408 - Disclosure - Stockholders' Equity - Summary of activity under Employee Stock Purchase Plan (Details) Sheet http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderEmployeeStockPurchasePlanDetails Stockholders' Equity - Summary of activity under Employee Stock Purchase Plan (Details) Details 43 false false R44.htm 2408402 - Disclosure - Fair Value of Financial Instruments (Details) Sheet http://healthcarerealty.com/role/FairValueOfFinancialInstrumentsDetails Fair Value of Financial Instruments (Details) Details http://healthcarerealty.com/role/FairValueOfFinancialInstrumentsTables 44 false false All Reports Book All Reports hr-2018930xsinglesourc.htm hr-20180930.xsd hr-20180930_cal.xml hr-20180930_def.xml hr-20180930_lab.xml hr-20180930_pre.xml hr-2018930xex311.htm hr-2018930xex312.htm hr-2018930xex32.htm http://xbrl.sec.gov/stpr/2018-01-31 http://xbrl.sec.gov/invest/2013-01-31 http://fasb.org/us-gaap/2018-01-31 http://xbrl.sec.gov/naics/2017-01-31 http://fasb.org/srt/2018-01-31 http://xbrl.sec.gov/dei/2018-01-31 true true JSON 61 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "hr-2018930xsinglesourc.htm": { "axisCustom": 3, "axisStandard": 18, "contextCount": 143, "dts": { "calculationLink": { "local": [ "hr-20180930_cal.xml" ] }, "definitionLink": { "local": [ "hr-20180930_def.xml" ], "remote": [ "http://xbrl.fasb.org/srt/2018/elts/srt-eedm1-def-2018-01-31.xml", "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-eedm-def-2018-01-31.xml" ] }, "inline": { "local": [ "hr-2018930xsinglesourc.htm" ] }, "labelLink": { "local": [ "hr-20180930_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-doc-2018-01-31.xml", "http://xbrl.sec.gov/invest/2013/invest-doc-2013-01-31.xml", "https://xbrl.sec.gov/dei/2018/dei-doc-2018-01-31.xml" ] }, "presentationLink": { "local": [ "hr-20180930_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-ref-2018-01-31.xml", "http://xbrl.sec.gov/invest/2013/invest-ref-2013-01-31.xml", "https://xbrl.sec.gov/dei/2018/dei-ref-2018-01-31.xml" ] }, "schema": { "local": [ "hr-20180930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-roles-2018-01-31.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-types-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-parts-codification-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd", "http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd", "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd", "https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" ] } }, "elementCount": 367, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2018-01-31": 18, "http://xbrl.sec.gov/dei/2018-01-31": 9, "total": 27 }, "keyCustom": 36, "keyStandard": 168, "memberCustom": 23, "memberStandard": 30, "nsprefix": "hr", "nsuri": "http://healthcarerealty.com/20180930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Document and Entity Information", "role": "http://healthcarerealty.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "hr:AcquisitionsAndDispositionsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2102100 - Disclosure - Real Estate Investments", "role": "http://healthcarerealty.com/role/RealEstateInvestments", "shortName": "Real Estate Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "hr:AcquisitionsAndDispositionsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103100 - Disclosure - Notes and Bonds Payable", "role": "http://healthcarerealty.com/role/NotesAndBondsPayable", "shortName": "Notes and Bonds Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104100 - Disclosure - Derivative Financial Instruments", "role": "http://healthcarerealty.com/role/DerivativeFinancialInstruments", "shortName": "Derivative Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2105100 - Disclosure - Commitments and Contingencies", "role": "http://healthcarerealty.com/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2106100 - Disclosure - Stockholders' Equity", "role": "http://healthcarerealty.com/role/StockholdersEquity", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108100 - Disclosure - Fair Value of Financial Instruments", "role": "http://healthcarerealty.com/role/FairValueOfFinancialInstruments", "shortName": "Fair Value of Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "hr:NatureOfOperationsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2201201 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2018Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "hr:NatureOfOperationsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2301302 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2302301 - Disclosure - Real Estate Investments (Tables)", "role": "http://healthcarerealty.com/role/RealEstateInvestmentsTables", "shortName": "Real Estate Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2303301 - Disclosure - Notes and Bonds Payable (Tables)", "role": "http://healthcarerealty.com/role/NotesAndBondsPayableTables", "shortName": "Notes and Bonds Payable (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FI2018Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Land", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001000 - Statement - Condensed Consolidated Balance Sheets (Unaudited)", "role": "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FI2018Q3", "decimals": "-3", "lang": null, "name": "us-gaap:DevelopmentInProcess", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2304301 - Disclosure - Derivative Financial Instruments (Tables)", "role": "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsTables", "shortName": "Derivative Financial Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "hr:ReconciliationOfBeginningAndEndingCommonStockOutstandingTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2306301 - Disclosure - Stockholders' Equity (Tables)", "role": "http://healthcarerealty.com/role/StockholdersEquityTables", "shortName": "Stockholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "hr:ReconciliationOfBeginningAndEndingCommonStockOutstandingTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2308301 - Disclosure - Fair Value of Financial Instruments (Tables)", "role": "http://healthcarerealty.com/role/FairValueOfFinancialInstrumentsTables", "shortName": "Fair Value of Financial Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q3", "decimals": "-8", "first": true, "lang": null, "name": "hr:InvestmentInRealEstatePropertiesAndMortgageNotes", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401403 - Disclosure - Summary of Significant Accounting Policies (Details)", "role": "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesDetails", "shortName": "Summary of Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q3", "decimals": "-8", "first": true, "lang": null, "name": "hr:InvestmentInRealEstatePropertiesAndMortgageNotes", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401404 - Disclosure - Summary of Significant Accounting Policies - Revenue Recognition (Details)", "role": "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails", "shortName": "Summary of Significant Accounting Policies - Revenue Recognition (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q3QTD_srt_ProductOrServiceAxis_hr_ParkingIncomeMember", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2018Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DirectCostsOfLeasedAndRentedPropertyOrEquipment", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401405 - Disclosure - Summary of Significant Accounting Policies - Reclassifications (Details)", "role": "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesReclassificationsDetails", "shortName": "Summary of Significant Accounting Policies - Reclassifications (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q3QTD", "decimals": "-3", "lang": null, "name": "us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2018Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesIncomeStatementLeaseRevenue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401406 - Disclosure - Summary of Significant Accounting Policies - Impact of Adoption of New Accounting Standard (Details)", "role": "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfNewAccountingStandardDetails", "shortName": "Summary of Significant Accounting Policies - Impact of Adoption of New Accounting Standard (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q3QTD_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember", "decimals": "-3", "lang": null, "name": "us-gaap:OperatingLeasesIncomeStatementLeaseRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "ix:continuation", "body", "html" ], "contextRef": "D2018Q2Jun27", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:GainLossOnDispositionOfAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402402 - Disclosure - Real Estate Investments - Acquisitions (Details)", "role": "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails", "shortName": "Real Estate Investments - Acquisitions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q3YTD_hr_RealEstateAcquisitionsAndMortgageNoteFinancingAxis_hr_RealEstateAcquisitionsMember", "decimals": "-5", "lang": null, "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "ix:continuation", "body", "html" ], "contextRef": "D2018Q2Jun27", "decimals": "INF", "first": true, "lang": null, "name": "hr:NumberofPropertiesExercisingPurchaseOption", "reportCount": 1, "unitRef": "property", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402403 - Disclosure - Real Estate Investments - Dispositions (Details)", "role": "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails", "shortName": "Real Estate Investments - Dispositions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q3_hr_RealEstateDispositionsAndMortgageNoteRepaymentsAxis_hr_RealEstateDispositionsMember", "decimals": "-5", "lang": null, "name": "hr:DispositionSalesPrice", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q3", "decimals": "INF", "first": true, "lang": null, "name": "hr:NumberOfPropertiesHeldForSale", "reportCount": 1, "unique": true, "unitRef": "property", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402404 - Disclosure - Real Estate Investments - Assets Held for Sale (Details)", "role": "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldForSaleDetails", "shortName": "Real Estate Investments - Assets Held for Sale (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q3", "decimals": "INF", "first": true, "lang": null, "name": "hr:NumberOfPropertiesHeldForSale", "reportCount": 1, "unique": true, "unitRef": "property", "xsiNil": "false" } }, "R3": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1001501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FI2018Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Land", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402405 - Disclosure - Real Estate Investments - Discontinued Operations and Assets Held for Sale - Balance Sheet (Details)", "role": "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails", "shortName": "Real Estate Investments - Discontinued Operations and Assets Held for Sale - Balance Sheet (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "contextRef": "FI2018Q3_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember", "decimals": "-3", "lang": null, "name": "us-gaap:Land", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FI2018Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403402 - Disclosure - Notes and Bonds Payable (Details)", "role": "http://healthcarerealty.com/role/NotesAndBondsPayableDetails", "shortName": "Notes and Bonds Payable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q3_us-gaap_DebtInstrumentAxis_hr_UnsecuredCreditFacilityDue2020Member_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember", "decimals": "-3", "lang": null, "name": "us-gaap:LongTermDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q3", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfInterestRateDerivativesHeld", "reportCount": 1, "unitRef": "swap_agreement", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404402 - Disclosure - Derivative Financial Instruments - Derivative Instruments Designated as Cash Flow Hedges (Details)", "role": "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails", "shortName": "Derivative Financial Instruments - Derivative Instruments Designated as Cash Flow Hedges (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember", "decimals": "INF", "lang": null, "name": "us-gaap:NumberOfInterestRateDerivativesHeld", "reportCount": 1, "unique": true, "unitRef": "swap_agreement", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404403 - Disclosure - Derivative Financial Instruments - Fair Value of Derivative Instruments on the Balance Sheet (Details)", "role": "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueOfDerivativeInstrumentsOnBalanceSheetDetails", "shortName": "Derivative Financial Instruments - Fair Value of Derivative Instruments on the Balance Sheet (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q3YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404404 - Disclosure - Derivative Financial Instruments - Effect of Cash Flow Hedging on AOCI (Details)", "role": "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectOfCashFlowHedgingOnAociDetails", "shortName": "Derivative Financial Instruments - Effect of Cash Flow Hedging on AOCI (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q3YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "body", "html" ], "contextRef": "FI2018Q3_us-gaap_DerivativeInstrumentRiskAxis_hr_ActiveInterestRateSwapsMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404405 - Disclosure - Derivative Financial Instruments - Additional Information (Details)", "role": "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails", "shortName": "Derivative Financial Instruments - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "body", "html" ], "contextRef": "FI2018Q3_us-gaap_DerivativeInstrumentRiskAxis_hr_ActiveInterestRateSwapsMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q3", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AreaOfRealEstateProperty", "reportCount": 1, "unitRef": "sqft", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405401 - Disclosure - Commitments and Contingencies - Construction Activity (Details)", "role": "http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails", "shortName": "Commitments and Contingencies - Construction Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q3_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_hr_MedicalOfficeBuildingExpansionMember_srt_StatementGeographicalAxis_stpr_NC", "decimals": "-3", "lang": null, "name": "us-gaap:AreaOfRealEstateProperty", "reportCount": 1, "unique": true, "unitRef": "sqft", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - Stockholders' Equity - Reconciliation of beginning and ending common stock outstanding (Details)", "role": "http://healthcarerealty.com/role/StockholdersEquityReconciliationOfBeginningAndEndingCommonStockOutstandingDetails", "shortName": "Stockholders' Equity - Reconciliation of beginning and ending common stock outstanding (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2018Q3QTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406403 - Disclosure - Stockholders' Equity (Stock Transactions - Narrative) (Details)", "role": "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails", "shortName": "Stockholders' Equity (Stock Transactions - Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q3YTD_hr_StockIssuanceProgramAxis_hr_AtTheMarketEquityOfferingProgramMember", "decimals": "INF", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q3", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfInterestRateDerivativesHeld", "reportCount": 1, "unitRef": "swap_agreement", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406404 - Disclosure - Stockholders' Equity - Changes in accumulated other comprehensive income (Details)", "role": "http://healthcarerealty.com/role/StockholdersEquityChangesInAccumulatedOtherComprehensiveIncomeDetails", "shortName": "Stockholders' Equity - Changes in accumulated other comprehensive income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q3YTD", "decimals": null, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2018Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesIncomeStatementLeaseRevenue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002000 - Statement - Condensed Consolidated Statements of Income (Unaudited)", "role": "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited", "shortName": "Condensed Consolidated Statements of Income (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2018Q3QTD", "decimals": "-3", "lang": null, "name": "us-gaap:GeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2018Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InterestExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406405 - Disclosure - Stockholders' Equity - Reclassifications out of AOCI (Details)", "role": "http://healthcarerealty.com/role/StockholdersEquityReclassificationsOutOfAociDetails", "shortName": "Stockholders' Equity - Reclassifications out of AOCI (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "decimals": "-3", "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q3QTD", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:WeightedAverageNumberOfSharesIssuedBasic", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406406 - Disclosure - Stockholders' Equity - Computation of basic and diluted earnings (loss) per common share (Details)", "role": "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails", "shortName": "Stockholders' Equity - Computation of basic and diluted earnings (loss) per common share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2018Q3QTD", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:WeightedAverageNumberOfSharesIssuedBasic", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q2_us-gaap_PlanNameAxis_hr_StockIncentivePlanMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406407 - Disclosure - Stockholders' Equity - Summary of activity under stock-based incentive plans (Details)", "role": "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderStockBasedIncentivePlansDetails", "shortName": "Stockholders' Equity - Summary of activity under stock-based incentive plans (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q2_us-gaap_PlanNameAxis_hr_StockIncentivePlanMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "contextRef": "FI2018Q2_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406408 - Disclosure - Stockholders' Equity - Summary of activity under Employee Stock Purchase Plan (Details)", "role": "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderEmployeeStockPurchasePlanDetails", "shortName": "Stockholders' Equity - Summary of activity under Employee Stock Purchase Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "contextRef": "FI2018Q2_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q3_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408402 - Disclosure - Fair Value of Financial Instruments (Details)", "role": "http://healthcarerealty.com/role/FairValueOfFinancialInstrumentsDetails", "shortName": "Fair Value of Financial Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FI2018Q3_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2018Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)", "role": "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited", "shortName": "Condensed Consolidated Statements of Comprehensive Income (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2018Q3QTD", "decimals": "-3", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2017Q3YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004000 - Statement - Condensed Consolidated Statement of Equity (Unaudited) Statement", "role": "http://healthcarerealty.com/role/CondensedConsolidatedStatementOfEquityUnauditedStatement", "shortName": "Condensed Consolidated Statement of Equity (Unaudited) Statement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "-3", "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1004001 - Statement - Condensed Consolidated Statement of Equity (Unaudited) (Parenthetical)", "role": "http://healthcarerealty.com/role/CondensedConsolidatedStatementOfEquityUnauditedParenthetical", "shortName": "Condensed Consolidated Statement of Equity (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R8": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2018Q3YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "role": "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2018Q3YTD", "decimals": "-3", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "hr:NatureOfOperationsPolicyTextBlock", "span", "div", "body", "html" ], "contextRef": "FD2018Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101100 - Disclosure - Summary of Significant Accounting Policies", "role": "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "hr:NatureOfOperationsPolicyTextBlock", "span", "div", "body", "html" ], "contextRef": "FD2018Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 53, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "If the value is true, then the document is an amendment to previously-filed/accepted document.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r283" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r283" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r283" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r283" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r283" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a smaller reporting company with both a public float and revenues of less than $75 million.", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "hr_AcquisitionsAndDispositionsTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Acquisitions and dispositions.", "label": "Acquisitions and Dispositions [Text Block]", "verboseLabel": "Real Estate Investments" } } }, "localname": "AcquisitionsAndDispositionsTextBlock", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestments" ], "xbrltype": "textBlockItemType" }, "hr_ActiveInterestRateSwapsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Active Interest Rate Swaps [Member]", "label": "Active Interest Rate Swaps [Member]", "terseLabel": "Active Interest Rate Swap" } } }, "localname": "ActiveInterestRateSwapsMember", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "hr_AmountReclassifiedfromAOCIforCurrentDerivativesAttributabletoParentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Amount Reclassified from AOCI for Current Derivatives Attributable to Parent [Member]", "label": "Amount Reclassified from AOCI for Current Derivatives Attributable to Parent [Member]", "terseLabel": "Amounts reclassified from accumulated other comprehensive income (loss) related to current interest rate swaps" } } }, "localname": "AmountReclassifiedfromAOCIforCurrentDerivativesAttributabletoParentMember", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityReclassificationsOutOfAociDetails" ], "xbrltype": "domainItemType" }, "hr_AmountReclassifiedfromAOCIforSettledDerivativesAttributabletoParentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Amount Reclassified from AOCI for Settled Derivatives Attributable to Parent [Member]", "label": "Amount Reclassified from AOCI for Settled Derivatives Attributable to Parent [Member]", "terseLabel": "Amounts reclassified from accumulated other comprehensive income (loss) related to settled interest rate swaps" } } }, "localname": "AmountReclassifiedfromAOCIforSettledDerivativesAttributabletoParentMember", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityReclassificationsOutOfAociDetails" ], "xbrltype": "domainItemType" }, "hr_AppraisedValueofLand": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Appraised Value of Land", "label": "Appraised Value of Land", "terseLabel": "Appraised value of land" } } }, "localname": "AppraisedValueofLand", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "monetaryItemType" }, "hr_ApproximateSquareFeetProvidedByCompany": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Approximate square feet for which Nationwide property management services provided by company", "label": "Approximate Square Feet Provided by Company", "verboseLabel": "Approximate square feet for which Nationwide property management services provided by company" } } }, "localname": "ApproximateSquareFeetProvidedByCompany", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "areaItemType" }, "hr_AreaCoveredUnderRealEstateInvestmentSoldInMeasurementUnits": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area covered under real estate investment sold in measurement units.", "label": "Area Covered Under Real Estate Investment Sold in Measurement Units", "terseLabel": "Square footage" } } }, "localname": "AreaCoveredUnderRealEstateInvestmentSoldInMeasurementUnits", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "areaItemType" }, "hr_AssetDispositionsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Asset Dispositions.", "label": "Asset Dispositions [Table Text Block]", "terseLabel": "Summary of dispositions" } } }, "localname": "AssetDispositionsTableTextBlock", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "hr_AssetsAndLiabilitiesRelatedToHeldForSaleAndDiscontinuedOperationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Assets and liabilities related to held for sale and discontinued operations.", "label": "Assets and Liabilities Related to Held for Sale and Discontinued Operations [Abstract]", "verboseLabel": "Asset Dispositions and Potential Dispositions" } } }, "localname": "AssetsAndLiabilitiesRelatedToHeldForSaleAndDiscontinuedOperationsAbstract", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails" ], "xbrltype": "stringItemType" }, "hr_AssetsHeldForSaleAndDiscontinuedOperationsNet": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Assets held for sale and discontinued operations, net.", "label": "Assets Held-for-sale and Discontinued Operations Net", "totalLabel": "Assets held for sale, net", "verboseLabel": "Assets held for sale, net" } } }, "localname": "AssetsHeldForSaleAndDiscontinuedOperationsNet", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "hr_AtTheMarketEquityOfferingProgramMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "At The Market Equity Offering Program [Member]", "label": "At The Market Equity Offering Program [Member]", "terseLabel": "At The Market Equity Offering Program" } } }, "localname": "AtTheMarketEquityOfferingProgramMember", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "hr_BusinessAcquisitionPurchasePriceAllocationSquareFootage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Business Acquisition Purchase Price Allocation Square Footage.", "label": "Business Acquisition Purchase Price Allocation Square Footage", "verboseLabel": "Square footage" } } }, "localname": "BusinessAcquisitionPurchasePriceAllocationSquareFootage", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "areaItemType" }, "hr_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRealProperty": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Real Property", "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Real Property", "terseLabel": "Real Estate" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRealProperty", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "hr_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedIntangibleAssetsFairValueAdjustmentsandOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Fair Value Adjustments and Other", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Fair Value Adjustments and Other", "terseLabel": "Other" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedIntangibleAssetsFairValueAdjustmentsandOther", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "hr_BusinessOverviewAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Business Overview [Abstract]", "label": "Business Overview [Abstract]", "terseLabel": "Business Overview:" } } }, "localname": "BusinessOverviewAbstract", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "hr_ClosingAdjustmentsDisposedEntity": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Closing Adjustments Disposed Entity, including closing costs and other adjustments to the sales price.", "label": "Closing Adjustments Disposed Entity", "negatedTerseLabel": "Closing Adjustments" } } }, "localname": "ClosingAdjustmentsDisposedEntity", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "monetaryItemType" }, "hr_ConstructionActivityTotalAmountFunded": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Construction Activity, Total Amount Funded", "label": "Construction Activity, Total Amount Funded", "terseLabel": "Total amount funded" } } }, "localname": "ConstructionActivityTotalAmountFunded", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails" ], "xbrltype": "monetaryItemType" }, "hr_CumulativeDividendsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cumulative Dividends [Member].", "label": "Cumulative Dividends [Member]", "terseLabel": "Cumulative Dividends" } } }, "localname": "CumulativeDividendsMember", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementOfEquityUnauditedStatement" ], "xbrltype": "domainItemType" }, "hr_CumulativeNetIncomeAttributableToCommonStockholders": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Cumulative net income attributable to common stockholders.", "label": "Cumulative Net Income Attributable to Common Stockholders", "verboseLabel": "Cumulative net income attributable to common stockholders" } } }, "localname": "CumulativeNetIncomeAttributableToCommonStockholders", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "hr_CumulativeNetIncomeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cumulative Net Income [Member].", "label": "Cumulative Net Income [Member]", "terseLabel": "Cumulative Net Income" } } }, "localname": "CumulativeNetIncomeMember", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementOfEquityUnauditedStatement" ], "xbrltype": "domainItemType" }, "hr_DispositionSalesPrice": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Disposition Sales Price", "label": "Disposition Sales Price", "terseLabel": "Sales price" } } }, "localname": "DispositionSalesPrice", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "monetaryItemType" }, "hr_DocumentAndEntityInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Document and Entity Information.", "label": "Document and Entity Information [Abstract]" } } }, "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://healthcarerealty.com/20180930", "xbrltype": "stringItemType" }, "hr_GainsLossesonSalesofInvestmentRealEstateIncludingDiscontinuedOperation": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Gains (Losses) on Sales of Investment Real Estate, Including Discontinued Operation", "label": "Gains (Losses) on Sales of Investment Real Estate, Including Discontinued Operation", "negatedLabel": "Gain on sales of real estate assets" } } }, "localname": "GainsLossesonSalesofInvestmentRealEstateIncludingDiscontinuedOperation", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "hr_ImpairmentOfRealEstateContinuingAndDiscontinuedOperations": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Impairment of Real Estate, Continuing and Discontinued Operations", "label": "Impairment of Real Estate, Continuing and Discontinued Operations", "terseLabel": "Impairment of real estate assets" } } }, "localname": "ImpairmentOfRealEstateContinuingAndDiscontinuedOperations", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "hr_IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Incremental common shares attributable to dilutive effect of employee stock purchase plan.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Employee Stock Purchase Plan", "verboseLabel": "Dilutive effect of employee stock purchase plan" } } }, "localname": "IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "hr_InvestmentInRealEstatePropertiesAndMortgageNotes": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Investment in real estate properties and mortgage notes.", "label": "Investment in Real Estate Properties and Mortgage Notes", "terseLabel": "Gross investment amount, total" } } }, "localname": "InvestmentInRealEstatePropertiesAndMortgageNotes", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "hr_LandHeldForDevelopmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Land Held for Development [Member]", "label": "Land Held for Development [Member]", "terseLabel": "Land Held for Development" } } }, "localname": "LandHeldForDevelopmentMember", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "domainItemType" }, "hr_ManagementFeeIncomeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Management Fee Income [Member]", "label": "Management Fee Income [Member]", "terseLabel": "Management Fee Income" } } }, "localname": "ManagementFeeIncomeMember", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "hr_MedicalOfficeBuildingExpansionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Medical Office Building Expansion [Member]", "label": "Medical Office Building Expansion [Member]", "terseLabel": "Medical Office Building Expansion" } } }, "localname": "MedicalOfficeBuildingExpansionMember", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails" ], "xbrltype": "domainItemType" }, "hr_MedicalOfficeBuildingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Medical Office Building [Member]", "label": "Medical Office Building [Member]", "terseLabel": "Medical Office Building" } } }, "localname": "MedicalOfficeBuildingMember", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "domainItemType" }, "hr_MiscellaneousMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Miscellaneous [Member]", "label": "Miscellaneous [Member]", "terseLabel": "Miscellaneous" } } }, "localname": "MiscellaneousMember", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "hr_MortgageNotesPayableNetMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Mortgage Notes Payable, Net [Member]", "label": "Mortgage Notes Payable, Net [Member]", "terseLabel": "Mortgage notes payable, net of discounts and issuance costs and including premiums" } } }, "localname": "MortgageNotesPayableNetMember", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "hr_NatureOfOperationsPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Nature Of Operations Policy.", "label": "Nature of Operations [Policy Text Block]", "terseLabel": "Business Overview" } } }, "localname": "NatureOfOperationsPolicyTextBlock", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "hr_NetIncomeLossfromContinuingOperationsAvailabletoCommonStockholdersBasic": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Net Income (Loss) from Continuing Operations Available to Common Stockholders, Basic", "label": "Net Income (Loss) from Continuing Operations Available to Common Stockholders, Basic", "totalLabel": "Net income applicable to common stockholders" } } }, "localname": "NetIncomeLossfromContinuingOperationsAvailabletoCommonStockholdersBasic", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "hr_NotesAssumedUnamortizedPremium": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Notes Assumed, Unamortized Premium", "label": "Notes Assumed, Unamortized Premium", "terseLabel": "Fair value adjustments" } } }, "localname": "NotesAssumedUnamortizedPremium", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "hr_NumberOfPropertiesHeldForSale": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of properties held for sale.", "label": "Number of Properties Held for Sale", "terseLabel": "Number of properties held for sale" } } }, "localname": "NumberOfPropertiesHeldForSale", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldForSaleDetails" ], "xbrltype": "integerItemType" }, "hr_NumberOfRealEstateInvestments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of real estate investments.", "label": "Number of Real Estate Investments", "terseLabel": "Number of real estate properties" } } }, "localname": "NumberOfRealEstateInvestments", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "integerItemType" }, "hr_NumberofAuthorizedSharesRemainingUnderOfferingProgram": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of Authorized Shares Remaining Under Offering Program", "label": "Number of Authorized Shares Remaining Under Offering Program", "terseLabel": "Number of authorized shares remaining under offering program (shares)" } } }, "localname": "NumberofAuthorizedSharesRemainingUnderOfferingProgram", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "hr_NumberofMultitenantBuildings": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of Multi-tenant Buildings", "label": "Number of Multi-tenant Buildings", "terseLabel": "Number of multi-tenant buildings" } } }, "localname": "NumberofMultitenantBuildings", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldForSaleDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "integerItemType" }, "hr_NumberofPropertiesAcquired": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of Properties Acquired", "label": "Number of Properties Acquired", "terseLabel": "Number of properties acquired" } } }, "localname": "NumberofPropertiesAcquired", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "integerItemType" }, "hr_NumberofPropertiesExercisingPurchaseOption": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of Properties Exercising Purchase Option", "label": "Number of Properties Exercising Purchase Option", "terseLabel": "Number of properties exercising purchase option" } } }, "localname": "NumberofPropertiesExercisingPurchaseOption", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldForSaleDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "integerItemType" }, "hr_NumberofPropertiesReclassifiedtoHeldforSale": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of Properties Reclassified to Held for Sale", "label": "Number of Properties Reclassified to Held for Sale", "terseLabel": "Number of properties reclassified to held for sale" } } }, "localname": "NumberofPropertiesReclassifiedtoHeldforSale", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldForSaleDetails" ], "xbrltype": "integerItemType" }, "hr_NumberofSingletenantNetLeasedBuildings": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of Single-tenant Net Leased Buildings", "label": "Number of Single-tenant Net Leased Buildings", "terseLabel": "Number of single-tenant net leased buildings" } } }, "localname": "NumberofSingletenantNetLeasedBuildings", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldForSaleDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "integerItemType" }, "hr_ParkingIncomeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Parking Income [Member]", "label": "Parking Income [Member]", "terseLabel": "Parking Income" } } }, "localname": "ParkingIncomeMember", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "hr_PersonalProperty": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Personal property.", "label": "Personal Property", "terseLabel": "Personal property" } } }, "localname": "PersonalProperty", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "hr_RealEstateAcquisitionsAndMortgageNoteFinancingAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Real Estate Acquisitions and Mortgage Note Financing.", "label": "Real Estate Acquisitions and Mortgage Note Financing [Axis]", "terseLabel": "Real Estate Acquisitions and Mortgage Note Financing [Axis]" } } }, "localname": "RealEstateAcquisitionsAndMortgageNoteFinancingAxis", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "stringItemType" }, "hr_RealEstateAcquisitionsAndMortgageNoteFinancingDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Real Estate Acquisitions and Mortgage Note Financing.", "label": "Real Estate Acquisitions and Mortgage Note Financing [Domain]", "terseLabel": "Real Estate Acquisitions and Mortgage Note Financing [Domain]" } } }, "localname": "RealEstateAcquisitionsAndMortgageNoteFinancingDomain", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "domainItemType" }, "hr_RealEstateAcquisitionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Real estate acquisitions.", "label": "Real Estate Acquisitions [Member]", "terseLabel": "Real Estate Acquisition" } } }, "localname": "RealEstateAcquisitionsMember", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "domainItemType" }, "hr_RealEstateDispositionsAndMortgageNoteRepaymentsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Real Estate Dispositions and Mortgage Note Repayments [Axis]", "label": "Real Estate Dispositions and Mortgage Note Repayments [Axis]", "terseLabel": "Real Estate Dispositions and Mortgage Note Repayments [Axis]" } } }, "localname": "RealEstateDispositionsAndMortgageNoteRepaymentsAxis", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "stringItemType" }, "hr_RealEstateDispositionsAndMortgageNoteRepaymentsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Real Estate Dispositions and Mortgage Note Repayments [Domain]", "label": "Real Estate Dispositions and Mortgage Note Repayments [Domain]", "terseLabel": "Real Estate Dispositions and Mortgage Note Repayments [Domain]" } } }, "localname": "RealEstateDispositionsAndMortgageNoteRepaymentsDomain", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "domainItemType" }, "hr_RealEstateDispositionsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Real estate dispositions.", "label": "Real Estate Dispositions [Line Items]", "terseLabel": "Real Estate Dispositions [Line Items]" } } }, "localname": "RealEstateDispositionsLineItems", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "stringItemType" }, "hr_RealEstateDispositionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Real Estate Dispositions [Member]", "label": "Real Estate Dispositions [Member]", "terseLabel": "Real Estate Dispositions" } } }, "localname": "RealEstateDispositionsMember", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "domainItemType" }, "hr_RealEstateInvestmentNetDisposedOfDuringPeriod": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Real estate investment net disposed of during the Period.", "label": "Real Estate Investment Net Disposed of During Period", "verboseLabel": "Net Real Estate Investment" } } }, "localname": "RealEstateInvestmentNetDisposedOfDuringPeriod", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "monetaryItemType" }, "hr_RealEstateInvestmentsPropertyOwnedInNumberOfStates": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Real estate investments property owned in number of states.", "label": "Real Estate Investments Property Owned in Number of States", "verboseLabel": "Number of states that the Company owns real estate in, whole units" } } }, "localname": "RealEstateInvestmentsPropertyOwnedInNumberOfStates", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "integerItemType" }, "hr_RealEstateOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Real estate other.", "label": "Real Estate Other", "terseLabel": "Real Estate Other" } } }, "localname": "RealEstateOther", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "monetaryItemType" }, "hr_ReconciliationOfBeginningAndEndingCommonStockOutstandingRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Reconciliation of the beginning and ending common stock outstanding.", "label": "Reconciliation of Beginning and Ending Common Stock Outstanding [Roll Forward]", "verboseLabel": "Reconciliation of the beginning and ending common stock outstanding" } } }, "localname": "ReconciliationOfBeginningAndEndingCommonStockOutstandingRollForward", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityReconciliationOfBeginningAndEndingCommonStockOutstandingDetails" ], "xbrltype": "stringItemType" }, "hr_ReconciliationOfBeginningAndEndingCommonStockOutstandingTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Reconciliation of beginning and ending common stock outstanding.", "label": "Reconciliation of Beginning and Ending Common Stock Outstanding [Table Text Block]", "terseLabel": "Reconciliation of beginning and ending common stock outstanding" } } }, "localname": "ReconciliationOfBeginningAndEndingCommonStockOutstandingTableTextBlock", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "hr_RentalLeaseGuarantyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Rental Lease Guaranty [Member]", "label": "Rental Lease Guaranty [Member]", "terseLabel": "Rental Lease Guaranty" } } }, "localname": "RentalLeaseGuarantyMember", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "hr_ScheduleOfRealEstateDispositionsTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of real estate dispositions.", "label": "Schedule of Real Estate Dispositions [Table]", "terseLabel": "Schedule of Real Estate Dispositions [Table]" } } }, "localname": "ScheduleOfRealEstateDispositionsTable", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "stringItemType" }, "hr_ScheduleofReclassificationsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of Reclassifications [Table Text Block]", "label": "Schedule of Reclassifications [Table Text Block]", "terseLabel": "Schedule of reclassifications" } } }, "localname": "ScheduleofReclassificationsTableTextBlock", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "hr_SeniorNotesdue2023Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Senior Notes due 2023 [Member]", "label": "Senior Notes due 2023 [Member]", "terseLabel": "Senior Notes due 2023, net of discount and issuance costs" } } }, "localname": "SeniorNotesdue2023Member", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "hr_SeniorNotesdue2025Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Senior Notes due 2025 [Member]", "label": "Senior Notes due 2025 [Member]", "terseLabel": "Senior Notes due 2025, net of discount and issuance costs (2)" } } }, "localname": "SeniorNotesdue2025Member", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "hr_SeniorNotesdue2028Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Senior Notes due 2028 [Member]", "label": "Senior Notes due 2028 [Member]", "terseLabel": "Senior Notes due 2028, net of discount and issuance costs" } } }, "localname": "SeniorNotesdue2028Member", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "hr_SettledInterestRateSwapMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Settled Interest Rate Swap [Member]", "label": "Settled Interest Rate Swap [Member]", "terseLabel": "Settled Interest Rate Swap" } } }, "localname": "SettledInterestRateSwapMember", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "hr_StockIncentivePlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock Incentive Plan [Member]", "label": "Stock Incentive Plan [Member]", "terseLabel": "Stock Incentive Plan" } } }, "localname": "StockIncentivePlanMember", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderStockBasedIncentivePlansDetails" ], "xbrltype": "domainItemType" }, "hr_StockIssuanceProgramAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock Issuance Program [Axis]", "label": "Stock Issuance Program [Axis]", "terseLabel": "Stock Issuance Program [Axis]" } } }, "localname": "StockIssuanceProgramAxis", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "hr_StockIssuanceProgramDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Stock Issuance Program [Axis]", "label": "Stock Issuance Program [Domain]", "terseLabel": "Stock Issuance Program [Domain]" } } }, "localname": "StockIssuanceProgramDomain", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "hr_StraightLineRentReceivable": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Straight-line rent receivable.", "label": "Straight-line Rent Receivable", "negatedLabel": "Amortization of straight-line rent receivable" } } }, "localname": "StraightLineRentReceivable", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "hr_StraightlineRentLiability": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Straight-line rent liability.", "label": "Straight-line Rent Liability", "terseLabel": "Amortization of straight-line rent liability" } } }, "localname": "StraightlineRentLiability", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "hr_TermLoandue2022Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Term Loan due 2022 [Member]", "label": "Term Loan due 2022 [Member]", "terseLabel": "Unsecured Term Loan Facility, net of issuance costs (1)" } } }, "localname": "TermLoandue2022Member", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "hr_UnsecuredCreditFacilityDue2020Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Unsecured Credit Facility Due 2020 [Member]", "label": "Unsecured Credit Facility Due 2020 [Member]", "terseLabel": "Unsecured Credit Facility" } } }, "localname": "UnsecuredCreditFacilityDue2020Member", "nsuri": "http://healthcarerealty.com/20180930", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "invest_DerivativeNotionalAmount": { "auth_ref": [ "r284" ], "lang": { "en-US": { "role": { "documentation": "Aggregate notional amount specified by the derivative(s). Expressed as an absolute value.", "label": "Derivative, Notional Amount", "terseLabel": "Notional amount" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://xbrl.sec.gov/invest/2013-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails", "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "monetaryItemType" }, "naics_ZZ812930": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "812930 Parking Lots and Garages [Member]", "terseLabel": "Garage" } } }, "localname": "ZZ812930", "nsuri": "http://xbrl.sec.gov/naics/2017-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "domainItemType" }, "srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis": { "auth_ref": [ "r281", "r282" ], "lang": { "en-US": { "role": { "label": "Real Estate, Type of Property [Axis]", "terseLabel": "Real Estate, Type of Property [Axis]" } } }, "localname": "MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "stringItemType" }, "srt_MortgageLoansOnRealEstateNamePropertyTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Real Estate [Domain]", "terseLabel": "Real Estate [Domain]" } } }, "localname": "MortgageLoansOnRealEstateNamePropertyTypeDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r133", "r168", "r169", "r280" ], "lang": { "en-US": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "srt_RestatementAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Restatement [Axis]", "terseLabel": "Restatement [Axis]" } } }, "localname": "RestatementAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfNewAccountingStandardDetails", "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesReclassificationsDetails" ], "xbrltype": "stringItemType" }, "srt_RestatementDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Restatement [Domain]", "terseLabel": "Restatement [Domain]" } } }, "localname": "RestatementDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfNewAccountingStandardDetails", "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesReclassificationsDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioPreviouslyReportedMember": { "auth_ref": [ "r103", "r104", "r105" ], "lang": { "en-US": { "role": { "label": "Previously Reported [Member]", "terseLabel": "As Previously Reported", "verboseLabel": "As Reported" } } }, "localname": "ScenarioPreviouslyReportedMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfNewAccountingStandardDetails", "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesReclassificationsDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r134", "r168", "r170", "r281", "r282" ], "lang": { "en-US": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "stringItemType" }, "stpr_CO": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "COLORADO", "terseLabel": "COLORADO" } } }, "localname": "CO", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "stpr_MI": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "MICHIGAN", "terseLabel": "MICHIGAN" } } }, "localname": "MI", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "domainItemType" }, "stpr_MO": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "MISSOURI", "terseLabel": "MISSOURI" } } }, "localname": "MO", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "domainItemType" }, "stpr_NC": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "NORTH CAROLINA", "terseLabel": "NORTH CAROLINA" } } }, "localname": "NC", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails" ], "xbrltype": "domainItemType" }, "stpr_OK": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "OKLAHOMA", "terseLabel": "OKLAHOMA" } } }, "localname": "OK", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "stpr_VA": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "VIRGINIA", "terseLabel": "VIRGINIA" } } }, "localname": "VA", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "domainItemType" }, "stpr_WA": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "WASHINGTON", "terseLabel": "WASHINGTON" } } }, "localname": "WA", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent": { "auth_ref": [ "r255", "r275" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.", "label": "Accounts Payable and Accrued Liabilities", "verboseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember": { "auth_ref": [ "r47", "r51", "r54", "r203" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges, attributable to the parent.", "label": "Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member]", "terseLabel": "Forward-starting Interest Rate Swaps" } } }, "localname": "AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityChangesInAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax": { "auth_ref": [ "r48", "r51" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).", "label": "Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax", "negatedLabel": "Accumulated other comprehensive income (loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityChangesInAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityChangesInAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r49", "r51", "r54", "r204" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementOfEquityUnauditedStatement" ], "xbrltype": "domainItemType" }, "us-gaap_AcquisitionCosts": { "auth_ref": [ "r248", "r249" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The capitalized costs incurred during the period (excluded from amortization) to purchase, lease or otherwise acquire an unproved property, including costs of lease bonuses and options to purchase or lease properties, the portion of costs applicable to minerals when land including mineral rights is purchased in fee, brokers' fees, recording fees, legal costs, and other costs incurred in acquiring properties.", "label": "Acquisition Costs, Period Cost", "terseLabel": "Acquisition and pursuit costs" } } }, "localname": "AcquisitionCosts", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r33" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "verboseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementOfEquityUnauditedStatement" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r173", "r175", "r187", "r188" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.", "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition", "terseLabel": "Share-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementOfEquityUnauditedStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AreaOfLand": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area of land held.", "label": "Area of Land", "terseLabel": "Area of land acquired" } } }, "localname": "AreaOfLand", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "areaItemType" }, "us-gaap_AreaOfRealEstateProperty": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area of a real estate property.", "label": "Area of Real Estate Property", "netLabel": "Approximate Square Feet", "verboseLabel": "Square footage of owned real estate properties" } } }, "localname": "AreaOfRealEstateProperty", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails", "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "areaItemType" }, "us-gaap_Assets": { "auth_ref": [ "r131", "r251", "r267" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "verboseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r176", "r186" ], "lang": { "en-US": { "role": { "documentation": "Information by award type pertaining to equity-based compensation.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderEmployeeStockPurchasePlanDetails", "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderStockBasedIncentivePlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueOfDerivativeInstrumentsOnBalanceSheetDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r213", "r217" ], "lang": { "en-US": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueOfDerivativeInstrumentsOnBalanceSheetDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1": { "auth_ref": [ "r189", "r190", "r191" ], "lang": { "en-US": { "role": { "documentation": "Date when the acquirer obtains control of the acquiree, in CCYY-MM-DD format.", "label": "Business Acquisition, Effective Date of Acquisition", "terseLabel": "Date Acquired" } } }, "localname": "BusinessAcquisitionEffectiveDateOfAcquisition1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "dateItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r195", "r196", "r197" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "verboseLabel": "Purchase price" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": { "auth_ref": [ "r194", "r195", "r196", "r199" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.", "label": "Business Combination, Consideration Transferred, Liabilities Incurred", "negatedTerseLabel": "Mortgage Note Payable Assumed" } } }, "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r91", "r92", "r93" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "verboseLabel": "Invoices accrued for construction, tenant improvements and other capitalized costs" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "auth_ref": [ "r238", "r239" ], "lang": { "en-US": { "role": { "documentation": "Measured as reported on the statement of financial position (balance sheet).", "label": "Reported Value Measurement [Member]", "terseLabel": "Carrying Value" } } }, "localname": "CarryingReportedAmountFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r25", "r37", "r89" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes effect from exchange rate changes.", "label": "Cash and Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Increase in cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgingMember": { "auth_ref": [ "r209" ], "lang": { "en-US": { "role": { "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.", "label": "Cash Flow Hedging [Member]", "terseLabel": "Cash Flow Hedging" } } }, "localname": "CashFlowHedgingMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectOfCashFlowHedgingOnAociDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityReconciliationOfBeginningAndEndingCommonStockOutstandingDetails", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r42", "r147", "r257", "r271" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "verboseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r146", "r148" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "verboseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockDividendsPerShareCashPaid": { "auth_ref": [ "r163" ], "lang": { "en-US": { "role": { "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Cash Paid", "verboseLabel": "Dividend per share to common Stockholders (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareCashPaid", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementOfEquityUnauditedParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r163" ], "lang": { "en-US": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Dividends declared per common share, during the period (in dollars per share)", "verboseLabel": "Dividends declared, per common share, during the period (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementOfEquityUnauditedStatement", "http://healthcarerealty.com/role/StockholdersEquityReconciliationOfBeginningAndEndingCommonStockOutstandingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r32" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r32" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "verboseLabel": "Common stock, authorized shares" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r32" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "verboseLabel": "Common stock, issued shares" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r32", "r156" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Balance, end of period", "periodStartLabel": "Balance, beginning of period", "verboseLabel": "Common stock, outstanding shares" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://healthcarerealty.com/role/StockholdersEquityReconciliationOfBeginningAndEndingCommonStockOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r32" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock, $.01 par value per share; 300,000 shares authorized; 125,237 and 125,132 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r57", "r59", "r60" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "COMPREHENSIVE INCOME" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CumulativeDividends": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cumulative cash dividends distributed to shareholders.", "label": "Cumulative Dividends", "negatedLabel": "Cumulative dividends" } } }, "localname": "CumulativeDividends", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r152" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "verboseLabel": "Notes and Bonds Payable" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r28", "r29", "r30", "r252", "r253", "r265" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Basis spread on variable rate (percent)" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentFairValue": { "auth_ref": [ "r237" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.", "label": "Debt Instrument, Fair Value Disclosure", "verboseLabel": "Notes and bonds payable" } } }, "localname": "DebtInstrumentFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r40", "r151", "r242" ], "lang": { "en-US": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Effective interest rate (percent)" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r41" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r41", "r95", "r157", "r160", "r161", "r162", "r241", "r242", "r244", "r264" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r87", "r139" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r87", "r129" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "verboseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectOfCashFlowHedgingOnAociDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueOfDerivativeInstrumentsOnBalanceSheetDetails", "http://healthcarerealty.com/role/NotesAndBondsPayableDetails", "http://healthcarerealty.com/role/StockholdersEquityChangesInAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "auth_ref": [ "r45", "r46", "r215", "r247" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.", "label": "Derivative Asset, Fair Value, Gross Asset", "terseLabel": "Asset derivatives" } } }, "localname": "DerivativeFairValueOfDerivativeAsset", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueOfDerivativeInstrumentsOnBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFixedInterestRate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fixed interest rate related to the interest rate derivative.", "label": "Derivative, Fixed Interest Rate", "terseLabel": "Derivative, fixed interest rate (percent)" } } }, "localname": "DerivativeFixedInterestRate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r214", "r216", "r221", "r224" ], "lang": { "en-US": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectOfCashFlowHedgingOnAociDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueOfDerivativeInstrumentsOnBalanceSheetDetails", "http://healthcarerealty.com/role/NotesAndBondsPayableDetails", "http://healthcarerealty.com/role/StockholdersEquityChangesInAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r232" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "terseLabel": "Derivative Financial Instruments" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r210", "r214", "r221" ], "lang": { "en-US": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]", "terseLabel": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectOfCashFlowHedgingOnAociDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "auth_ref": [ "r210", "r214", "r221", "r224", "r225", "r228", "r229" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table]", "terseLabel": "Derivative Instruments, Gain (Loss) [Table]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]" } } }, "localname": "DerivativeInstrumentsGainLossLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Estimated period for the anticipated transfer of gain (loss), net, from accumulated other comprehensive income into earnings, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimate of Time to Transfer", "terseLabel": "Period for reclassification out of AOCI" } } }, "localname": "DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityChangesInAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DerivativeInstrumentsLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion": { "auth_ref": [ "r220" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The effective portion of loss reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments.", "label": "Derivative Instruments, Loss Reclassified from Accumulated OCI into Income, Effective Portion", "terseLabel": "Amount of Loss Reclassified from OCI into Income" } } }, "localname": "DerivativeInstrumentsLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectOfCashFlowHedgingOnAociDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]", "terseLabel": "Derivative [Line Items]" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectOfCashFlowHedgingOnAociDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueOfDerivativeInstrumentsOnBalanceSheetDetails", "http://healthcarerealty.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r96", "r205", "r207", "r208", "r210", "r212", "r218", "r221", "r226", "r227", "r229" ], "lang": { "en-US": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectOfCashFlowHedgingOnAociDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueOfDerivativeInstrumentsOnBalanceSheetDetails", "http://healthcarerealty.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r210" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Designated as Hedging Instrument" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectOfCashFlowHedgingOnAociDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueOfDerivativeInstrumentsOnBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DevelopmentInProcess": { "auth_ref": [ "r274" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The current amount of expenditures for a real estate project that has not yet been completed.", "label": "Development in Process", "terseLabel": "Construction in progress" } } }, "localname": "DevelopmentInProcess", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DirectCostsOfLeasedAndRentedPropertyOrEquipment": { "auth_ref": [ "r70" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense incurred and directly related to generating revenue from leased and rented property or equipment.", "label": "Direct Costs of Leased and Rented Property or Equipment", "terseLabel": "Property operating expense", "verboseLabel": "Property operating" } } }, "localname": "DirectCostsOfLeasedAndRentedPropertyOrEquipment", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited", "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesReclassificationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r168" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Disaggregation of revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "auth_ref": [ "r176", "r186" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of components of a stock option or other award plan under which equity-based compensation is awarded to employees, typically comprised of the amount of unearned compensation (deferred compensation cost), compensation expense, and changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan. Disclosure may also include nature and general terms of such arrangements that existed during the period and potential effects of those arrangements on shareholders, effect of compensation cost arising from equity-based payment arrangements on the income statement, method of estimating the fair value of the goods or services received, or the fair value of the equity instruments granted, during the period, cash flow effects resulting from equity-based payment arrangements and, for registrants that accelerate vesting of out of the money share options, reasons for the decision to accelerate.", "label": "Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]", "terseLabel": "Summary of the activity under the Incentive Plan" } } }, "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax": { "auth_ref": [ "r6", "r7", "r21" ], "calculation": { "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesReclassificationsDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of income (loss) from operations classified as a discontinued operation. Excludes gain (loss) on disposal and provision for gain (loss) until disposal.", "label": "Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of Tax", "terseLabel": "Income (loss) from discontinued operations" } } }, "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesReclassificationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalDate1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Date the entity disposed of a business or a group of assets, in CCYY-MM-DD format.", "label": "Disposal Date", "terseLabel": "Disposal Date" } } }, "localname": "DisposalDate1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r0", "r1", "r18", "r143" ], "calculation": { "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount classified as accounts payable and accrued liabilities attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities": { "auth_ref": [ "r0", "r1", "r18", "r143" ], "calculation": { "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Other Liabilities", "terseLabel": "Other liabilities" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsCommonStockCash": { "auth_ref": [ "r163" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.", "label": "Dividends, Common Stock, Cash", "negatedTerseLabel": "Dividends to common stockholders ($0.90 per share)" } } }, "localname": "DividendsCommonStockCash", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementOfEquityUnauditedStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsShareBasedCompensation": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails": { "order": 2.0, "parentTag": "hr_NetIncomeLossfromContinuingOperationsAvailabletoCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared and applicable to holders of share-based compensation, for example, but not limited to, non-vested shares, stock options, or restricted stock units.", "label": "Dividends, Share-based Compensation", "negatedTerseLabel": "Dividends paid on nonvested share-based awards" } } }, "localname": "DividendsShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarnestMoneyDeposits": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "A deposit made by a purchaser of real estate to evidence good faith. It is customary for a buyer to give the seller earnest money at the time a sales contract is signed. The earnest money generally is credited to the down payment at closing, which is applied at closing as a component of payment against the purchase price.", "label": "Earnest Money Deposits", "terseLabel": "Forfeited earnest money" } } }, "localname": "EarnestMoneyDeposits", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r65", "r100", "r109", "r110", "r111", "r112", "r115", "r261", "r278" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic earnings per common share (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited", "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r65", "r100", "r109", "r110", "r111", "r112", "r115", "r261", "r278" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted earnings per common share (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited", "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "verboseLabel": "Employee Stock Purchase Plan" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderEmployeeStockPurchasePlanDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r156" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementOfEquityUnauditedStatement", "http://healthcarerealty.com/role/StockholdersEquityChangesInAccumulatedOtherComprehensiveIncomeDetails", "http://healthcarerealty.com/role/StockholdersEquityReclassificationsOutOfAociDetails", "http://healthcarerealty.com/role/StockholdersEquityReconciliationOfBeginningAndEndingCommonStockOutstandingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentDividendsOrDistributions": { "auth_ref": [ "r63", "r83", "r87", "r276" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.", "label": "Proceeds from Equity Method Investment, Distribution", "terseLabel": "Distributions from unconsolidated joint ventures" } } }, "localname": "EquityMethodInvestmentDividendsOrDistributions", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Error Corrections and Prior Period Adjustments Restatement [Line Items]", "terseLabel": "Reclassifications [Line Items]" } } }, "localname": "ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesReclassificationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "auth_ref": [ "r237" ], "lang": { "en-US": { "role": { "documentation": "Measured as an estimate of fair value.", "label": "Estimate of Fair Value Measurement [Member]", "terseLabel": "Fair Value" } } }, "localname": "EstimateOfFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "auth_ref": [ "r233", "r238" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]", "terseLabel": "Fair value and carrying values for notes and bonds payable, mortgage notes receivable, and notes receivable" } } }, "localname": "FairValueByBalanceSheetGroupingTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/FairValueOfFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByMeasurementBasisAxis": { "auth_ref": [ "r233", "r234" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement basis.", "label": "Measurement Basis [Axis]", "terseLabel": "Measurement Basis [Axis]" } } }, "localname": "FairValueByMeasurementBasisAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.", "label": "Fair Value Measurement [Domain]", "terseLabel": "Fair Value Measurement [Domain]" } } }, "localname": "FairValueDisclosureItemAmountsDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r235" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "verboseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/FairValueOfFinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_GainLossOnDispositionOfAssets": { "auth_ref": [ "r87", "r138", "r141" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.", "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property", "netLabel": "Gain/(Impairment)", "verboseLabel": "Gain on disposition of property" } } }, "localname": "GainLossOnDispositionOfAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldForSaleDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnDispositionOfRealEstateDiscontinuedOperations": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesReclassificationsDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of difference between the carrying amount and the sales price of real estate properties sold as part of discontinued operations.", "label": "Gain (Loss) on Disposition of Real Estate, Discontinued Operations", "terseLabel": "Gain on sales of properties" } } }, "localname": "GainLossOnDispositionOfRealEstateDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesReclassificationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnSalesOfInvestmentRealEstate": { "auth_ref": [ "r66", "r67", "r87", "r259", "r279" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net gain (loss) resulting from sales and other disposals of real estate owned for investment purposes.", "label": "Gains (Losses) on Sales of Investment Real Estate", "terseLabel": "Gain (loss) on sales of real estate assets", "verboseLabel": "Gain on sales of properties" } } }, "localname": "GainsLossesOnSalesOfInvestmentRealEstate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited", "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesReclassificationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r72" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "verboseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r210", "r225" ], "lang": { "en-US": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectOfCashFlowHedgingOnAociDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueOfDerivativeInstrumentsOnBalanceSheetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r210" ], "lang": { "en-US": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectOfCashFlowHedgingOnAociDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueOfDerivativeInstrumentsOnBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r210" ], "lang": { "en-US": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectOfCashFlowHedgingOnAociDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfRealEstate": { "auth_ref": [ "r87", "r140" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The charge against earnings in the period to reduce the carrying amount of real property to fair value.", "label": "Impairment of Real Estate", "negatedLabel": "Impairment of real estate assets" } } }, "localname": "ImpairmentOfRealEstate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperations": { "auth_ref": [ "r69", "r88", "r112", "r200" ], "calculation": { "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails": { "order": 1.0, "parentTag": "hr_NetIncomeLossfromContinuingOperationsAvailabletoCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.", "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent", "terseLabel": "Net Income", "verboseLabel": "INCOME FROM CONTINUING OPERATIONS" } } }, "localname": "IncomeLossFromContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails", "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesReclassificationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": { "auth_ref": [ "r6", "r7", "r8", "r9", "r10", "r17", "r21", "r201" ], "calculation": { "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesReclassificationsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent", "totalLabel": "INCOME (LOSS) FROM DISCONTINUED OPERATIONS" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesReclassificationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r63", "r87", "r130", "r137", "r258", "r276" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee.", "label": "Income (Loss) from Equity Method Investments", "negatedTerseLabel": "Equity from unconsolidated joint ventures (income)" } } }, "localname": "IncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "auth_ref": [ "r1", "r11", "r12", "r13", "r14", "r15", "r16", "r19", "r22", "r23", "r24", "r144", "r145" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table]", "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Table]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r142" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectOfCashFlowHedgingOnAociDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectOfCashFlowHedgingOnAociDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r86" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "verboseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "verboseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r86" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "Increase (Decrease) in Other Operating Assets", "negatedLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "auth_ref": [ "r86" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Liabilities", "verboseLabel": "Other liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementOfEquityUnauditedStatement" ], "xbrltype": "stringItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r62", "r128", "r240", "r243", "r263" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense", "terseLabel": "Interest Expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited", "http://healthcarerealty.com/role/StockholdersEquityReclassificationsOutOfAociDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseMember": { "auth_ref": [ "r223" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing interest expense.", "label": "Interest Expense [Member]", "terseLabel": "Interest Expense" } } }, "localname": "InterestExpenseMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectOfCashFlowHedgingOnAociDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestPaid": { "auth_ref": [ "r90" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.", "label": "Interest Paid, Including Capitalized Interest, Operating and Investing Activities", "verboseLabel": "Interest paid" } } }, "localname": "InterestPaid", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidCapitalized": { "auth_ref": [ "r78", "r90" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash paid for interest capitalized, classified as investing activity.", "label": "Interest Paid, Capitalized, Investing Activities", "terseLabel": "Capitalized interest" } } }, "localname": "InterestPaidCapitalized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet": { "auth_ref": [ "r231" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The estimated net amount of unrealized gains or losses on interest rate cash flow hedges as of the balance sheet date expected to be reclassified to earnings within the next twelve months.", "label": "Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net", "terseLabel": "Interest rate cash flow hedge gain (loss) to be reclassified to interest expense during the next 12 months" } } }, "localname": "InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateContractMember": { "auth_ref": [ "r172", "r222" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate.", "label": "Interest Rate Contract [Member]", "terseLabel": "Interest Rate Products" } } }, "localname": "InterestRateContractMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectOfCashFlowHedgingOnAociDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestRateSwapMember": { "auth_ref": [ "r222" ], "lang": { "en-US": { "role": { "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.", "label": "Interest Rate Swap [Member]", "terseLabel": "Interest Rate Swap", "verboseLabel": "Settled Interest Rate Swaps" } } }, "localname": "InterestRateSwapMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectOfCashFlowHedgingOnAociDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueOfDerivativeInstrumentsOnBalanceSheetDetails", "http://healthcarerealty.com/role/NotesAndBondsPayableDetails", "http://healthcarerealty.com/role/StockholdersEquityChangesInAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentBuildingAndBuildingImprovements": { "auth_ref": [ "r273" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Aggregate of the carrying amounts as of the balance sheet date of investments in building and building improvements.", "label": "Investment Building and Building Improvements", "verboseLabel": "Buildings, improvements and lease intangibles" } } }, "localname": "InvestmentBuildingAndBuildingImprovements", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Land": { "auth_ref": [ "r26", "r38" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.", "label": "Land", "verboseLabel": "Land" } } }, "localname": "Land", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LandAvailableForDevelopment": { "auth_ref": [ "r270" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount of land available for development.", "label": "Land Available for Development", "terseLabel": "Land held for development" } } }, "localname": "LandAvailableForDevelopment", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r39" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities [Abstract]", "verboseLabel": "Liabilities:" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r36", "r254", "r269" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "verboseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": { "auth_ref": [ "r0", "r1", "r18", "r20", "r143" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Liabilities", "totalLabel": "Liabilities of properties held for sale", "verboseLabel": "Liabilities of properties held for sale" } } }, "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Line of Credit" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r30", "r150", "r253", "r268" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "verboseLabel": "Notes and bonds payable" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r41" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r41", "r149" ], "lang": { "en-US": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MediumTermNotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt instruments with maturities ranging from five to ten years.", "label": "Medium-term Notes [Member]", "terseLabel": "Medium-term Notes" } } }, "localname": "MediumTermNotesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MortgagesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A loan to finance the purchase of real estate where the lender has a lien on the property as collateral for the loan.", "label": "Mortgages [Member]", "terseLabel": "Mortgages" } } }, "localname": "MortgagesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r84" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash (used in) provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "verboseLabel": "FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r84" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "verboseLabel": "INVESTING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r84", "r85", "r88" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r55", "r58", "r64", "r88", "r114", "r260", "r277" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "NET INCOME", "totalLabel": "NET INCOME", "verboseLabel": "Net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementOfEquityUnauditedStatement", "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited", "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited", "http://healthcarerealty.com/role/StockholdersEquityReclassificationsOutOfAociDetails", "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfNewAccountingStandardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfNewAccountingStandardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r99", "r101", "r102" ], "lang": { "en-US": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Table]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfNewAccountingStandardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "New Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r74" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income (expense)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "verboseLabel": "OTHER INCOME (EXPENSE)" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NotesAssumed1": { "auth_ref": [ "r91", "r92", "r93" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The fair value of notes assumed in noncash investing or financing activities.", "label": "Notes Assumed", "terseLabel": "Mortgage notes payable assumed upon acquisition (adjusted to fair value)" } } }, "localname": "NotesAssumed1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfInterestRateDerivativesHeld": { "auth_ref": [ "r206", "r208" ], "lang": { "en-US": { "role": { "documentation": "Number of interest rate derivative instruments held by the entity at the reporting date.", "label": "Number of Interest Rate Derivatives Held", "terseLabel": "Number of instruments" } } }, "localname": "NumberOfInterestRateDerivativesHeld", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails", "http://healthcarerealty.com/role/StockholdersEquityChangesInAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent": { "auth_ref": [ "r51", "r61" ], "calculation": { "http://healthcarerealty.com/role/StockholdersEquityChangesInAccumulatedOtherComprehensiveIncomeDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent.", "label": "OCI, before Reclassifications, Net of Tax, Attributable to Parent", "terseLabel": "Gains arising during the period related to active interest rate swaps" } } }, "localname": "OciBeforeReclassificationsNetOfTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityChangesInAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total Expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Expenses [Abstract]", "verboseLabel": "EXPENSES" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeasesIncomeStatementLeaseRevenue": { "auth_ref": [ "r245" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The total amount of revenue recognized for the period from operating leases, including minimum lease revenue, contingent revenue, percentage revenue and sublease revenue.", "label": "Operating Leases, Income Statement, Lease Revenue", "terseLabel": "Rental income" } } }, "localname": "OperatingLeasesIncomeStatementLeaseRevenue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited", "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfNewAccountingStandardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAmortizationOfDeferredCharges": { "auth_ref": [ "r71", "r87" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization of other deferred costs recognized in the income statement.", "label": "Amortization of Other Deferred Charges", "terseLabel": "Other amortization" } } }, "localname": "OtherAmortizationOfDeferredCharges", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssets": { "auth_ref": [ "r27", "r250", "r266" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails": { "order": 2.0, "parentTag": "hr_AssetsHeldForSaleAndDiscontinuedOperationsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of assets classified as other.", "label": "Other Assets", "terseLabel": "Other assets, net", "verboseLabel": "Other assets, net" } } }, "localname": "OtherAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsMember": { "auth_ref": [ "r213", "r228" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other assets.", "label": "Other Assets [Member]", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueOfDerivativeInstrumentsOnBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherCommitmentsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Other Commitments [Line Items]", "terseLabel": "Other Commitments [Line Items]" } } }, "localname": "OtherCommitmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCommitmentsTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about obligations resulting from other commitments.", "label": "Other Commitments [Table]", "terseLabel": "Other Commitments [Table]" } } }, "localname": "OtherCommitmentsTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax [Abstract]", "terseLabel": "Interest rate swaps:" } } }, "localname": "OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax": { "auth_ref": [ "r47" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax, after reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).", "label": "Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, before Tax", "terseLabel": "Loss on forward starting interest rate swap agreement recognized in OCI" } } }, "localname": "OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive income:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r56", "r59", "r201", "r202", "r203" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://healthcarerealty.com/role/StockholdersEquityChangesInAccumulatedOtherComprehensiveIncomeDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "totalLabel": "Total other comprehensive income" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited", "http://healthcarerealty.com/role/StockholdersEquityChangesInAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax": { "auth_ref": [ "r50", "r52", "r53", "r211" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income of accumulated gain (loss) realized from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's deferred hedging gain (loss).", "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Net of Tax", "negatedTerseLabel": "Reclassification adjustments for losses included in net income (interest expense)" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementOfEquityUnauditedStatement", "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax": { "auth_ref": [ "r47", "r50", "r230" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).", "label": "Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax", "terseLabel": "Amount of Gain Recognized in OCI on Derivative" } } }, "localname": "OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectOfCashFlowHedgingOnAociDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r47", "r50", "r230" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).", "label": "Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Net of Tax", "terseLabel": "Gains arising during the period on interest rate swaps" } } }, "localname": "OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementOfEquityUnauditedStatement", "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilities": { "auth_ref": [ "r256" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other.", "label": "Other Liabilities", "verboseLabel": "Other liabilities" } } }, "localname": "OtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncome": { "auth_ref": [ "r74" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income", "verboseLabel": "Interest and other income, net" } } }, "localname": "OtherNonoperatingIncome", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited", "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfNewAccountingStandardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForCapitalImprovements": { "auth_ref": [ "r78" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for acquisition of or capital improvements to properties held for investment (operating, managed, leased) or for use.", "label": "Payments for Capital Improvements", "negatedTerseLabel": "Additional long-lived assets" } } }, "localname": "PaymentsForCapitalImprovements", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r80" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Common stock redemptions" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r82" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "negatedLabel": "Debt issuance and assumption costs" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividendsCommonStock": { "auth_ref": [ "r80" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.", "label": "Payments of Ordinary Dividends, Common Stock", "negatedLabel": "Dividends paid" } } }, "localname": "PaymentsOfDividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r77", "r198" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Cash consideration" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireRealEstate": { "auth_ref": [ "r78" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow from the acquisition of a piece of land, anything permanently fixed to it, including buildings, structures on it and so forth; includes real estate intended to generate income for the owner; excludes real estate acquired for use by the owner.", "label": "Payments to Acquire Real Estate", "negatedTerseLabel": "Acquisitions of real estate" } } }, "localname": "PaymentsToAcquireRealEstate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToDevelopRealEstateAssets": { "auth_ref": [ "r78" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Payments to develop real estate assets is the process of adding improvements on or to a parcel of land. Such improvements may include drainage, utilities, subdividing, access, buildings, and any combination of these elements; and are generally classified as cash flow from investing activities.", "label": "Payments to Develop Real Estate Assets", "negatedLabel": "Development of real estate" } } }, "localname": "PaymentsToDevelopRealEstateAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r176", "r186" ], "lang": { "en-US": { "role": { "documentation": "Information by plan name pertaining to equity-based compensation arrangements.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderStockBasedIncentivePlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the equity-based compensation arrangement plan.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderStockBasedIncentivePlansDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "auth_ref": [ "r236" ], "lang": { "en-US": { "role": { "documentation": "Measured at fair value for financial reporting purposes.", "label": "Portion at Fair Value Measurement [Member]", "terseLabel": "Portion at Fair Value Measurement [Member]" } } }, "localname": "PortionAtFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r31" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "verboseLabel": "Preferred stock, par value (dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r31" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "verboseLabel": "Preferred stock, authorized shares" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r31" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "verboseLabel": "Preferred stock, issued shares" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r31" ], "lang": { "en-US": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "verboseLabel": "Preferred stock, outstanding shares" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r31" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "verboseLabel": "Preferred stock, $.01 par value per share; 50,000 shares authorized; none issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r79" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "verboseLabel": "Net proceeds from issuance of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfLinesOfCredit": { "auth_ref": [ "r97" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).", "label": "Proceeds from (Repayments of) Lines of Credit", "terseLabel": "Net borrowings (repayments) on unsecured credit facility" } } }, "localname": "ProceedsFromRepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndCollectionOfNotesReceivable": { "auth_ref": [ "r75" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the proceeds from sale of notes receivable, as well as principal collections from a borrowing supported by a written promise to pay an obligation (note receivable).", "label": "Proceeds from Sale and Collection of Notes Receivable", "verboseLabel": "Proceeds from notes receivable repayments" } } }, "localname": "ProceedsFromSaleAndCollectionOfNotesReceivable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyHeldForSale": { "auth_ref": [ "r76" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the sale of formerly productive land held for sale, anything permanently fixed to it, including buildings, structures on it, and so forth.", "label": "Proceeds from Sale of Property Held-for-sale", "terseLabel": "Proceeds from sales of real estate" } } }, "localname": "ProceedsFromSaleOfPropertyHeldForSale", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfRealEstateHeldforinvestment": { "auth_ref": [ "r76" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Cash received from the sale of real estate that is held for investment, that is, it is part of an investing activity during the period.", "label": "Proceeds from Sale of Real Estate Held-for-investment", "terseLabel": "Net Proceeds" } } }, "localname": "ProceedsFromSaleOfRealEstateHeldforinvestment", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDispositionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r73", "r165" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense related to write-down of receivables to the amount expected to be collected. Includes, but is not limited to, accounts receivable and notes receivable.", "label": "Provision for Doubtful Accounts", "verboseLabel": "Provision for bad debts, net" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProvisionForLoanAndLeaseLosses": { "auth_ref": [ "r86", "r135", "r262" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense related to estimated loss from loan and lease transactions.", "label": "Provision for Loan and Lease Losses", "terseLabel": "Bad debts, net of recoveries" } } }, "localname": "ProvisionForLoanAndLeaseLosses", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited", "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesReclassificationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateInvestmentPropertyAccumulatedDepreciation": { "auth_ref": [ "r272" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of depreciation for real estate property held for investment purposes.", "label": "Real Estate Investment Property, Accumulated Depreciation", "negatedLabel": "Less accumulated depreciation and amortization", "negatedTerseLabel": "Accumulated depreciation" } } }, "localname": "RealEstateInvestmentPropertyAccumulatedDepreciation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateInvestmentPropertyAtCost": { "auth_ref": [ "r273" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of real estate investment property which may include the following: (1) land available-for-sale; (2) land available-for-development; (3) investments in building and building improvements; (4) tenant allowances; (5) developments in-process; (6) rental properties; and (7) other real estate investments.", "label": "Real Estate Investment Property, at Cost", "totalLabel": "Real estate properties, Total" } } }, "localname": "RealEstateInvestmentPropertyAtCost", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateInvestmentPropertyNet": { "auth_ref": [ "r273" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails": { "order": 1.0, "parentTag": "hr_AssetsHeldForSaleAndDiscontinuedOperationsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of real estate investment property, net of accumulated depreciation, which may include the following: (1) land available-for-sale; (2) land available-for-development; (3) investments in building and building improvements; (4) tenant allowances; (5) developments in-process; (6) rental properties; and (7) other real estate investments.", "label": "Real Estate Investment Property, Net", "totalLabel": "Total real estate properties, net" } } }, "localname": "RealEstateInvestmentPropertyNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateInvestmentPropertyNetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Real Estate Investment Property, Net [Abstract]", "verboseLabel": "Real estate properties:" } } }, "localname": "RealEstateInvestmentPropertyNetAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]", "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]" } } }, "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityReclassificationsOutOfAociDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]", "terseLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityChangesInAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": { "auth_ref": [ "r51", "r61" ], "calculation": { "http://healthcarerealty.com/role/StockholdersEquityChangesInAccumulatedOtherComprehensiveIncomeDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.", "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent", "negatedLabel": "Amounts reclassified from accumulated other comprehensive (income) loss" } } }, "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityChangesInAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityReclassificationsOutOfAociDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityReclassificationsOutOfAociDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityReclassificationsOutOfAociDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityReclassificationsOutOfAociDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r81" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.", "label": "Repayments of Debt", "negatedTerseLabel": "Repayments on notes and bonds payable" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r113" ], "lang": { "en-US": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted Stock" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderStockBasedIncentivePlansDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r166", "r167", "r168" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Other operating" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited", "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfNewAccountingStandardDetails", "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r98", "r171" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue from Contracts with Customers (Topic 606)" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r68", "r126", "r127", "r132" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Revenues", "totalLabel": "Revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited", "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfNewAccountingStandardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenues [Abstract]", "verboseLabel": "REVENUES" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r51" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of accumulated other comprehensive income (loss)" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r192", "r193" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": { "auth_ref": [ "r192", "r193" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.", "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]", "terseLabel": "Summary of acquisitions" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r220" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings.", "label": "Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Debt [Table Text Block]", "terseLabel": "Schedule of Debt" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r219" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the effective portion of the gains and losses on derivative instruments designated (and non-derivative instruments) designated and qualifying in cash flow hedges and net investment hedges that was recognized in other comprehensive income (loss) during the current period.", "label": "Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss)" } } }, "localname": "ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "auth_ref": [ "r218" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "terseLabel": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value" } } }, "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "auth_ref": [ "r1", "r11", "r12", "r13", "r14", "r15", "r16", "r19", "r22", "r23", "r24", "r144", "r145" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "terseLabel": "Assets held for sale" } } }, "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r114" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Earnings (loss) per share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable": { "auth_ref": [ "r103", "r104", "r105" ], "lang": { "en-US": { "role": { "documentation": "Schedule of prior period adjustments to correct an error in previously issued financial statements. The disclosure may include, but is not limited to: (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustment (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made. This table can be used to disclose the amounts as previously reported and the effect of the correction or other adjustment on per line item or per share amount basis. This table uses as its line items financial statement line items that are affected by prior period adjustments.", "label": "Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]", "terseLabel": "Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]" } } }, "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesReclassificationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r99", "r101", "r102", "r116", "r117", "r118" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.", "label": "Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]", "terseLabel": "Impact of Adoption of New Accounting Standard" } } }, "localname": "ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r176", "r186" ], "lang": { "en-US": { "role": { "documentation": "Components of an equity-based arrangement under which compensation is awarded to employees, typically comprised of compensation expense; changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan; and cash flow effects resulting from the equity-based payment arrangement. Component disclosures are by type of award and plan name.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderEmployeeStockPurchasePlanDetails", "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderStockBasedIncentivePlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock": { "auth_ref": [ "r185" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of employee stock purchase plan activity.", "label": "Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block]", "terseLabel": "Summary of employee stock purchase plan activity" } } }, "localname": "ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r43", "r94", "r153", "r154", "r155", "r157", "r158", "r159", "r160", "r161", "r162", "r163" ], "lang": { "en-US": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityReconciliationOfBeginningAndEndingCommonStockOutstandingDetails", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentDiscontinuedOperationsMember": { "auth_ref": [ "r2", "r3", "r4", "r5" ], "lang": { "en-US": { "role": { "documentation": "Component or group of components disposed of or classified as held-for-sale and representing a strategic shift that has or will have a major effect on operations and financial results. Includes a business or nonprofit activity on acquisition classified as held-for-sale.", "label": "Discontinued Operations [Member]", "verboseLabel": "Discontinued Operations" } } }, "localname": "SegmentDiscontinuedOperationsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentOperatingActivitiesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Operations of an entity including continuing and discontinued operations.", "label": "Operating Activities [Domain]", "terseLabel": "Operating Activities [Domain]" } } }, "localname": "SegmentOperatingActivitiesDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeniorNotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.", "label": "Senior Notes [Member]", "terseLabel": "Senior Notes" } } }, "localname": "SeniorNotesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r86" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.", "label": "Share-based Compensation", "verboseLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r183" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "verboseLabel": "Granted (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderStockBasedIncentivePlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r182" ], "lang": { "en-US": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Share-based awards, end of period", "periodStartLabel": "Share-based awards, beginning of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderStockBasedIncentivePlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "verboseLabel": "Summary of the activity under the incentive plans" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderStockBasedIncentivePlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r184" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Vested (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderStockBasedIncentivePlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderEmployeeStockPurchasePlanDetails", "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderStockBasedIncentivePlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r181" ], "lang": { "en-US": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period", "negatedTerseLabel": "Expired (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderEmployeeStockPurchasePlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r180" ], "lang": { "en-US": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedTerseLabel": "Forfeited (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderEmployeeStockPurchasePlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "verboseLabel": "Granted (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderEmployeeStockPurchasePlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r178", "r186" ], "lang": { "en-US": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding and exercisable, end of period (shares)", "periodStartLabel": "Outstanding and exercisable, beginning of period (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderEmployeeStockPurchasePlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "verboseLabel": "Summary of the Employee Stock Purchase Plan activity" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderEmployeeStockPurchasePlanDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r174", "r177" ], "lang": { "en-US": { "role": { "documentation": "Equity-based compensation award.", "label": "Equity Award [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderEmployeeStockPurchasePlanDetails", "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderStockBasedIncentivePlansDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "For net-share settlement of share-based awards when the employer settles employees' income tax withholding obligations, this element represents the number of shares the employees use to repay the employer.", "label": "Shares Paid for Tax Withholding for Share Based Compensation", "terseLabel": "Shares withheld to pay estimated withholding taxes" } } }, "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderStockBasedIncentivePlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r98" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r44", "r156" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementOfEquityUnauditedStatement", "http://healthcarerealty.com/role/StockholdersEquityChangesInAccumulatedOtherComprehensiveIncomeDetails", "http://healthcarerealty.com/role/StockholdersEquityReclassificationsOutOfAociDetails", "http://healthcarerealty.com/role/StockholdersEquityReconciliationOfBeginningAndEndingCommonStockOutstandingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementOfEquityUnauditedStatement" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Balance Sheet data (as of the period ended):" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOperatingActivitiesSegmentAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by continuing and discontinuing operations.", "label": "Operating Activities [Axis]", "terseLabel": "Operating Activities [Axis]" } } }, "localname": "StatementOperatingActivitiesSegmentAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsDiscontinuedOperationsAndAssetsHeldForSaleBalanceSheetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementOfEquityUnauditedStatement" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r31", "r32", "r156", "r163" ], "lang": { "en-US": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock (shares)", "verboseLabel": "Issuance of common stock" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityReconciliationOfBeginningAndEndingCommonStockOutstandingDetails", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r31", "r32", "r156", "r163" ], "lang": { "en-US": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Nonvested share-based awards, net of withheld shares" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityReconciliationOfBeginningAndEndingCommonStockOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r31", "r32", "r156", "r163", "r179" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedTerseLabel": "Exercised (shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderEmployeeStockPurchasePlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r31", "r32", "r156", "r163" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementOfEquityUnauditedStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": { "auth_ref": [ "r31", "r32", "r156", "r163" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).", "label": "Stock Repurchased and Retired During Period, Value", "negatedTerseLabel": "Common stock redemptions" } } }, "localname": "StockRepurchasedAndRetiredDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementOfEquityUnauditedStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r32", "r34", "r35", "r136" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://healthcarerealty.com/role/CondensedConsolidatedStatementOfEquityUnauditedStatement", "http://healthcarerealty.com/role/StockholdersEquityChangesInAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]", "verboseLabel": "Stockholders' equity:" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r164" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "verboseLabel": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r246" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r246" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "verboseLabel": "Supplemental Cash Flow Information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r119", "r120", "r121", "r122", "r123", "r124", "r125" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates in the Condensed Consolidated Financial Statements" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r108", "r112" ], "calculation": { "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Weighted average Common Shares outstanding\u2014Diluted", "verboseLabel": "Weighted average common shares outstanding - diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited", "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesIssuedBasic": { "auth_ref": [ "r106", "r107", "r114" ], "calculation": { "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).", "label": "Weighted Average Number of Shares Issued, Basic", "verboseLabel": "Weighted average Common Shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesIssuedBasic", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "verboseLabel": "Weighted average Common Shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r106", "r112" ], "calculation": { "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "totalLabel": "Weighted average Common Shares\u2014Basic", "verboseLabel": "Weighted average common shares outstanding - basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited", "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesRestrictedStock": { "auth_ref": [ "r107" ], "calculation": { "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic", "weight": -1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of shares of restricted stock determined by relating the portion of time within a reporting period that restricted shares have been outstanding to the total time in that period. Restricted shares are subject to sales, contractual, regulatory or other restrictions that prevent or inhibit the holder from freely disposing of them before the restriction ends.", "label": "Weighted Average Number of Shares, Restricted Stock", "negatedTerseLabel": "Nonvested shares" } } }, "localname": "WeightedAverageNumberOfSharesRestrictedStock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 10 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22580-107794" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1448-109256" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e2646-109256" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1505-109256" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=109236672&loc=d3e725-108305" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=109236672&loc=d3e765-108305" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.10-01.(b)(6))", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84173941&loc=SL6953423-111524" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2443-110228" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230" }, "r146": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349" }, "r148": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870" }, "r152": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r164": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=82913815&loc=SL49130534-203044" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046" }, "r171": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=79507207&loc=d3e4534-113899" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109196918&loc=d3e11149-113907" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109196918&loc=d3e11178-113907" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=84229725&loc=d3e845-128460" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=84229725&loc=d3e848-128460" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=109124213&loc=d3e6578-128477" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=109124213&loc=d3e6613-128477" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721491-107759" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613673-111683" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579240-113959" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5580258-113959" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(ii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "c", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41638-113959" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41638-113959" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624181-113959" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41641-113959" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41678-113959" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109975725&loc=SL5629052-113961" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109977999&loc=d3e76258-113986" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109978405&loc=d3e80720-113993" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=112277219&loc=d3e80748-113994" }, "r232": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "http://asc.fasb.org/topic&trid=2229140" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=SL6742756-110258" }, "r235": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "820", "URI": "http://asc.fasb.org/topic&trid=2155941" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75026489&loc=d3e13220-108610" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13433-108611" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13467-108611" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13476-108611" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902458&loc=d3e39896-112707" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=SL51823488-111719" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-10(c)(3)(ii)(A))", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=82851474&loc=d3e511914-122862" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-10(c)(7)(ii))", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=82851474&loc=d3e511914-122862" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(1),(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(f))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(14)(d))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6812-107765" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.11)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),1(d))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(d))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.10)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99384497&loc=SL65671331-158438" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r283": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r284": { "Article": "12", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "13", "Sentence": "Column B" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721501-107759" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i-k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721503-107759" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e637-108580" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669686-108580" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e689-108580" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "17A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL34724391-108580" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL34724394-108580" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e557-108580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=109228884&loc=d3e1436-108581" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(12))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(7)(c))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(9)(a))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.13)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(c))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.5)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "3B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "21D", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=SL94080555-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(d),(e))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(n)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690" }, "r98": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" } }, "version": "2.0" } ZIP 62 0000899749-18-000066-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000899749-18-000066-xbrl.zip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�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�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end